var title_f32_37_33360="Ipratropium: Drug information";
var content_f32_37_33360=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ipratropium: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12618267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12618268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?21/7/21620?source=see_link\">",
"       Ipratropium (nasal): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36469?source=see_link\">",
"       Ipratropium (oral inhalation): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8570 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33360=[""].join("\n");
var outline_f32_37_33360=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?21/7/21620?source=related_link\">",
"      Ipratropium (nasal): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/39/36469?source=related_link\">",
"      Ipratropium (oral inhalation): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_37_33361="Osgood-Schlatter PI";
var content_f32_37_33361=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F85759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F85759&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Painful and swollen area in Osgood-Schlatter disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 645px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Osgood-Schlatter disease causes pain and sometimes swelling on the front of the knee, right below the knee cap. The medical term for this spot is the tibial tuberosity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33361=[""].join("\n");
var outline_f32_37_33361=null;
var title_f32_37_33362="Removal of nasal foreign body foam rubber";
var content_f32_37_33362=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F86490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F86490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Removal of nasal foreign body - foam rubber",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 228px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Foam rubber may be grasped by alligator, Lucae (pictured here), or Gruenwald nasal dressing forceps and removed.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33362=[""].join("\n");
var outline_f32_37_33362=null;
var title_f32_37_33363="Bacitracin, neomycin, and polymyxin B: Pediatric drug information";
var content_f32_37_33363=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Bacitracin, neomycin, and polymyxin B: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18660?source=see_link\">",
"    see \"Bacitracin, neomycin, and polymyxin B: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/6/3173?source=see_link\">",
"    see \"Bacitracin, neomycin, and polymyxin B: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F138769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Neo-Polycin&trade;;",
"     </li>",
"     <li>",
"      Neosporin&reg; Neo To Go&reg; [OTC];",
"     </li>",
"     <li>",
"      Neosporin&reg; Topical [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1045504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Ophthalmic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1045500\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18660?source=see_link\">",
"      see \"Bacitracin, neomycin, and polymyxin B: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic ointment: Instill into the conjunctival sac 1 or more times daily every 3-4 hours for 7-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply 1-3 times/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F138761\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, ophthalmic: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neo-Polycin&trade;: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 10,000 units per g (3.5 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 5000 units per g (0.9 g, 15 g, 30 g, 454 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosporin&reg;: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 5000 units per g (15 g, 30 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neosporin&reg; Neo To Go&reg;: Bacitracin 400 units, neomycin 3.5 mg, and polymyxin B 5000 units per g (0.9 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F138748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1045507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Avoid contamination of the tip of the ointment tube",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Topical: Apply a thin layer to the cleansed affected area; may cover with a sterile bandage",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1045506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Help prevent infection in minor cuts, scrapes and burns; short-term treatment of superficial external ocular infections caused by susceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F138786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Allergic contact dermatitis, reddening",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Failure to heal, irritation, itching, swelling",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic: Conjunctival edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1045509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to neomycin, polymyxin B, zinc bacitracin, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1045499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prolonged use may result in overgrowth of nonsusceptible organisms",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1045498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptoms of neomycin sensitization include itching, reddening, edema, failure to heal; ophthalmic ointments may retard corneal healing",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F138756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acarbose: Neomycin may enhance the adverse/toxic effect of Acarbose. Neomycin may enhance the therapeutic effect of Acarbose. Neomycin may decrease the metabolism of Acarbose.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Aminoglycosides may enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Polymyxin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capreomycin: May enhance the neuromuscular-blocking effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CARBOplatin: Aminoglycosides may enhance the ototoxic effect of CARBOplatin. Especially with higher doses of carboplatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Aminoglycosides may decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (2nd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (3rd Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalosporins (4th Generation): May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CISplatin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Aminoglycosides may enhance the nephrotoxic effect of Colistimethate. Aminoglycosides may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colistimethate: Polymyxin B may enhance the neuromuscular-blocking effect of Colistimethate.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Aminoglycosides may enhance the nephrotoxic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gallium Nitrate: Aminoglycosides may enhance the nephrotoxic effect of Gallium Nitrate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May enhance the adverse/toxic effect of Aminoglycosides. Specifically, nephrotoxicity and ototoxicity.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Polymyxin B may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Aminoglycosides may enhance the respiratory depressant effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May decrease the excretion of Aminoglycosides. Data only in premature infants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Aminoglycosides may enhance the neuromuscular-blocking effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: May decrease the serum concentration of Aminoglycosides. Primarily associated with extended spectrum penicillins, and patients with renal dysfunction.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Amoxicillin; Ampicillin; Cloxacillin; Dicloxacillin; Nafcillin; Oxacillin; Penicillin G (Parenteral/Aqueous); Penicillin G Benzathine; Penicillin G Procaine; Penicillin V Potassium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Aminoglycosides may enhance the neuromuscular-blocking effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: Neomycin may decrease the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vancomycin: May enhance the nephrotoxic effect of Aminoglycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Neomycin may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F138757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F7413753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination. See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1045503\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/6/3173?source=see_link\">",
"      see \"Bacitracin, neomycin, and polymyxin B: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmic: May cause sensitivity to bright light; may cause temporary blurring of vision or stinging following administration",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12637 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-222.190.118.195-652B83C886-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33363=[""].join("\n");
var outline_f32_37_33363=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138769\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045504\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045500\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138761\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138748\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045507\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045506\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138786\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045509\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045499\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045498\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298809\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138756\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F138757\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7413753\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1045503\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12637\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12637|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18660?source=related_link\">",
"      Bacitracin, neomycin, and polymyxin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/6/3173?source=related_link\">",
"      Bacitracin, neomycin, and polymyxin B: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_37_33364="Urethral sphincter";
var content_f32_37_33364=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F87165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F87165&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Urethral sphincter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Urethra.",
"    <br/>",
"    (A) External urethral sphincter and compressor urethrae muscle of the male. Lateral view.",
"    <br/>",
"    (B) External urethral sphincter, compressor urethrae, and urethrovaginal sphincter muscles of the female. Lateral view.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Moore KL, Agur A. Essential Clinical Anatomy, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33364=[""].join("\n");
var outline_f32_37_33364=null;
var title_f32_37_33365="Botryomycosis";
var content_f32_37_33365=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Botryomycosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33365/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33365/contributors\">",
"     Tahaniyat Lalani, MBBS, MHS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33365/contributors\">",
"     John C Murray, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33365/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33365/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33365/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33365/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/37/33365/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botryomycosis is a chronic, suppurative infection characterized by a granulomatous inflammatory response to bacterial pathogens; it may present with cutaneous or, less commonly, visceral involvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/1\">",
"     1",
"    </a>",
"    ]. The term botryomycosis is derived from the Greek word botrys (meaning \"bunch of grapes\") and mycosis (a misnomer, due to the presumed fungal etiology in early descriptions). Other terms used to describe botryomycosis include bacterial pseudomycosis, staphylococcal actinophytosis, granular bacteriosis, and actinobacillosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botryomycosis is a relatively uncommon disease, and its description is limited to case reports in children and adults. It occurs more commonly among immunocompromised patients, although infection in immunocompetent patients has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/2\">",
"     2",
"    </a>",
"    ]. The specific role of the host immune response is not fully understood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/3-5\">",
"     3-5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Possible risk factors associated with botryomycosis include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/3,4,6-10\">",
"     3,4,6-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alcoholism",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      HIV infection",
"     </li>",
"     <li>",
"      Cystic fibrosis",
"     </li>",
"     <li>",
"      Chronic granulomatous disease",
"     </li>",
"     <li>",
"      Trauma",
"     </li>",
"     <li>",
"      Surgery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY AND PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common organism identified in botryomycosis lesions is Staphylococcus aureus. Other pathogens associated with this condition include Pseudomonas aeruginosa, Escherichia coli, Serratia, and Proteus; coagulase-negative Staphylococci, Streptococci, and Micrococci; and anaerobes such as Actinobacillus, Peptostreptococcus, and Propionibacterium acnes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/2,11\">",
"     2,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pathogenesis of botryomycosis is not fully understood; it is thought to involve a combination of potential factors including an inciting event (such as trauma), the number of organisms inoculated, the virulence of the infecting pathogen, and host susceptibility to infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/1,3,12,13\">",
"     1,3,12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Botryomycosis may present as cutaneous or visceral disease. Cutaneous botryomycosis involves the skin and subcutaneous tissue; visceral botryomycosis involves internal organs such as lungs, liver, or brain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cutaneous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cutaneous botryomycosis is the most common form of botryomycosis and usually occurs following cutaneous inoculation of bacteria due to trauma, surgery, or in conjunction with the presence of a foreign body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Lesions characteristically develop slowly and may evolve and enlarge for several months and, rarely, even years.",
"   </p>",
"   <p>",
"    Most patients present with subcutaneous nodules, but others may develop verrucous lesions or nonhealing ulcers associated with draining sinuses or fistulae (",
"    <a class=\"graphic graphic_picture graphicRef76152 \" href=\"mobipreview.htm?8/0/8196\">",
"     picture 1",
"    </a>",
"    ). Drainage from these lesions is usually purulent and may contain small yellowish \"grains\" resembling the sulfur granules seen in actinomycosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21559?source=see_link\">",
"     \"Cervicofacial actinomycosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, infection may involve contiguous soft tissues such as the subcutaneous tissue, muscles, tendons, and bone. Mucosal involvement of areas such as the tongue and nasal septum has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Disseminated infection can follow cutaneous disease in the setting of severe immunosuppression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients infected with HIV may present with atypical lesions resembling conditions such as prurigo nodularis, lichen simplex chronicus, or sporotrichosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. No correlation between CD4 count and susceptibility to botryomycosis has been described. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24538?source=see_link\">",
"     \"Fever and rash in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Visceral disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Visceral botryomycosis occurs most commonly in the lung, although involvement of other organs including liver, spleen, kidney, and brain has also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/21\">",
"     21",
"    </a>",
"    ]. Systemic symptoms such as fever, fatigue, or weight loss may or may not be present.",
"   </p>",
"   <p>",
"    Symptoms associated with pulmonary botryomycosis include chronic cough, dyspnea, hemoptysis, and chest wall pain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/11,22\">",
"     11,22",
"    </a>",
"    ]. Clinical examination may be normal or demonstrate diminished breath sounds or rhonchi over the consolidated lung. Given the prolonged duration and nature of the symptoms, pulmonary botryomycosis may be mistaken for malignancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Botryomycosis involving the liver, spleen, or kidney tends to present with chronic abdominal pain and local tenderness to palpation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/6,23\">",
"     6,23",
"    </a>",
"    ]. Ultrasonography or computerized tomography reveals a mass lesion of the abdomen suspicious for an abscess or malignancy.",
"   </p>",
"   <p>",
"    Cerebral botryomycosis has been described in association with dental caries or after oral surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Focal neurological deficits, seizures, or signs of meningitis may occur and some patients develop a fulminant course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conditions that mimic botryomycosis include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Actinomycosis",
"     </li>",
"     <li>",
"      Mycetoma",
"     </li>",
"     <li>",
"      Atypical mycobacterial infection",
"     </li>",
"     <li>",
"      Sporotrichosis",
"     </li>",
"     <li>",
"      Cutaneous leishmaniasis",
"     </li>",
"     <li>",
"      Verrucous herpes",
"     </li>",
"     <li>",
"      Simple abscess",
"     </li>",
"     <li>",
"      Malignancy",
"     </li>",
"     <li>",
"      Kaposi's sarcoma",
"     </li>",
"     <li>",
"      Nocardia",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of botryomycosis can be established in one or more of the following ways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/17\">",
"     17",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identifying nonfilamentous bacteria in granules in pus from draining sinuses",
"     </li>",
"     <li>",
"      Identifying nonfilamentous bacteria in granules in biopsy specimens",
"     </li>",
"     <li>",
"      Culturing the bacterium from ulcers or exudates in patients with clinical findings of botryomycosis",
"     </li>",
"     <li>",
"      Histopathologically after biopsy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anecdotal reports associate certain pathogens with a characteristic grain color. S. aureus is classically associated with pale yellow or white granules. Microscopic evaluation of the granules can be helpful in the diagnosis and identification of pathogens. Pus from draining sinuses should be collected on sterile gauze or aspirated and transferred to a sterile container. Granules should be picked up using a needle or forceps and crushed between two slides.",
"   </p>",
"   <p>",
"    Gram staining (using traditional methods or the Brown-Brenn stain) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    staining (using the Grocott-Gomori method) of the crushed granules is used for morphologic evaluation. Botryomycosis may be distinguished from actinomycosis and mycetoma in that botryomycosis granules are of variable size and shape up to 500 microns in diameter. Rarely, gram positive cocci &le;1 micron in diameter are present in the exudate surrounding the granule and occur singly, in pairs, or in small clumps. In contrast, actinomycetes are branching, filamentous bacteria &le;1 micron in diameter while fungi causing mycetoma have hyphae that are at least 2 microns wide. These distinctions are important for guiding clinical management.",
"   </p>",
"   <p>",
"    Microscopic evaluation of granules should be combined with routine bacterial, fungal, and mycobacterial cultures for definitive diagnosis. In addition, tissue specimens should be obtained for histopathologic diagnosis. (See",
"    <a class=\"local\" href=\"#H152581082\">",
"     'Pathology'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Radiographic studies may be useful to evaluate the size and extent of involvement. Pulmonary lesions may be present as a consolidation or mass lesion, while other forms of visceral botryomycosis usually present as a mass lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152581082\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The histopathologic appearance of botryomycosis is characterized by a central focus of necrosis surrounded by a chronic inflammatory reaction containing histiocytes, epithelioid cells, multi-nucleated giant cells, and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/23\">",
"     23",
"    </a>",
"    ]. Unlike the sulfur granules seen in actinomycosis (which contain filamentous branching organisms), the granules seen in botryomycosis (Bollinger granules) contain bacteria surrounded by an eosinophilic matrix containing club like projections. This histologic appearance is commonly referred to as the Splendore-Hoeppli phenomenon, although it may not always be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/19,26,27\">",
"     19,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gram staining (using traditional methods or the Brown-Brenn stain) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/53/42834?source=see_link\">",
"     silver nitrate",
"    </a>",
"    staining (using the Grocott-Gomori method) can be used to identify the causative pathogen(s). Botryomycosis may be distinguished from actinomycosis and mycetoma in that botryomycosis granules are of variable size and shape up to 500 microns in diameter. Rarely, gram positive cocci &le;1 micron in diameter are present in the exudate surrounding the granule and occur singly, in pairs, or in small clumps. In contrast, actinomycetes are branching, filamentous bacteria &le;1 micron in diameter while fungi causing mycetoma have hyphae that are at least 2 microns wide. This is an important distinction for guiding clinical management. (see",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below)",
"   </p>",
"   <p>",
"    The histopathologic appearance of botryomycosis is characterized by a central focus of necrosis surrounded by a chronic inflammatory reaction containing histiocytes, epithelioid cells, multi-nucleated giant cells, and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/23\">",
"     23",
"    </a>",
"    ]. Unlike the sulfur granules seen in actinomycosis (which contain filamentous branching organisms), the granules seen in botryomycosis (Bollinger granules) contain bacteria surrounded by an eosinophilic matrix containing club like projections. This histologic appearance is commonly referred to as the Splendore-Hoeppli phenomenon, although it may not always be present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/19,26,27\">",
"     19,26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiographic studies may be useful to evaluate the size and extent of involvement. Pulmonary lesions may be present as a consolidation or mass lesion, while other forms of visceral botryomycosis usually present as a mass lesion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, patients should receive antibiotic therapy until signs and symptoms of infection have resolved. A few weeks of therapy may be sufficient for those with superficial infection; patients with deep infections",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    those with underlying immunodeficiency may require months of therapy. Prolonged antibiotic therapy may be necessary in cases for which debridement is incomplete or not feasible. In such situations, antibiotic penetration to the organisms sequestered in the granules may be poor or limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Selection of antibiotics should be tailored to culture and susceptibility results. There is no conclusive evidence regarding the appropriate duration of therapy; most information on the duration of treatment of botryomycosis is anecdotal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33365/abstract/17\">",
"     17",
"    </a>",
"    ]. The duration of therapy described in case reports has ranged from weeks to months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Cutaneous disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of cutaneous disease requires antibiotic therapy and, in most cases, surgical debridement. Antibiotic therapy alone may be sufficient for patients with superficial disease if a bacterial pathogen has been identified and malignancy has been excluded. For gram-positive infections, including Staphylococcus aureus, oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    (10 to 12",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/36/26182?source=see_link\">",
"     trimethoprim",
"    </a>",
"    component) or oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/21/33104?source=see_link\">",
"     clindamycin",
"    </a>",
"    (30 to 40",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) can be used. Depending on culture and susceptibility data, other alternative agents include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    (100 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"     minocycline",
"    </a>",
"    (100 mg twice daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/29/36304?source=see_link\">",
"     erythromycin",
"    </a>",
"    (500 mg four times daily) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/37/37462?source=see_link\">",
"     cephalexin",
"    </a>",
"    (500 mg four times daily).",
"   </p>",
"   <p>",
"    For pseudomonal infections, we recommend initiating therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/0/17415?source=see_link\">",
"     ceftazidime",
"    </a>",
"    &nbsp;(2 g IV every eight hours),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    &nbsp;(400 mg IV every 12 hours),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    &nbsp;(2 g IV every eight hours), or imipenem (500 mg IV every six hours). If the isolate is fluoroquinolone sensitive, therapy may be switched to oral ciprofloxacin (750 mg twice daily).",
"   </p>",
"   <p>",
"    For infections due to other gram-negative organisms (E. coli, Serratia, Proteus),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (1 to 2 g once daily),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    &nbsp;(400 mg IV every 12 hours), or imipenem (500 mg IV every six hours) can be used initially until susceptibility data is available; oral ciprofloxacin (500 mg twice daily) can be used if the isolate is susceptible.",
"   </p>",
"   <p>",
"    In patients with superficial infection, antibiotic therapy is usually continued for one to two months until all signs of infection have resolved. Surgical debridement together with antibiotic therapy is appropriate for lesions that extend into deep tissues such as muscle or bone, for lesions that do not improve with antibiotics alone, and for immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Visceral disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of visceral disease requires a combination of surgical and antimicrobial therapy. Resection of the mass often occurs prior to diagnosis given concern for malignancy in most cases of visceral disease.",
"   </p>",
"   <p>",
"    For Staphylococcus aureus and other gram-positive infections, we recommend initiating therapy with IV",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    (15 to 20",
"    <span class=\"nowrap\">",
"     mg/kg/dose",
"    </span>",
"    every 8 to 12 hours). For S. aureus isolates sensitive to methicillin, a beta-lactam agent such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    (2 g IV every four to six hours) should be used. Patients can be switched to oral antibiotics once the infection is debrided surgically and susceptibility data are available.",
"   </p>",
"   <p>",
"    Antibiotic selection for pseudomonal and other gram-negative infections is similar to the recommendations for cutaneous infections. Therapy is usually continued for several months until all signs of infection have resolved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Botryomycosis is a chronic, suppurative infection characterized by a granulomatous inflammatory response to bacterial pathogens that is observed most commonly among immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common pathogen is Staphylococcus aureus; other pathogens have also been implicated. The pathogenesis of botryomycosis is not fully understood; it is thought to involve a combination of factors including an inciting event (such as trauma), the number of organisms inoculated, the virulence of the infecting pathogen, and host susceptibility to infection (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Microbiology and pathogenesis'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      Cutaneous botryomycosis may present with subcutaneous nodules, verrucous lesions, or non-healing ulcers associated with draining sinuses or fistulae. Drainage from the lesion is usually purulent and contains small yellowish grains resembling the sulfur granules seen in actinomycosis. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cutaneous disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Visceral botryomycosis occurs most commonly in the lung, although involvement of other organs including liver, spleen, kidney and brain has also been described. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Visceral disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Botryomycosis may be difficult to distinguish from mycetoma, actinomycosis, malignancy, and other conditions. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of botryomycosis may be established by identifying nonfilamentous bacteria in granules in pus from draining sinuses, identifying nonfilamentous bacteria in granules in biopsy specimens, or culturing bacteria from ulcers or exudates in patients with clinical findings of botryomycosis. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment of cutaneous disease requires antibiotic therapy and may also require surgical debridement, while treatment of visceral disease requires both surgical and antimicrobial therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no conclusive evidence regarding the appropriate duration of therapy. In general, patients should receive antibiotic therapy until signs and symptoms of infection have resolved. For superficial infection, a few weeks may be sufficient, while patients with deep infection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      immunodeficiency may require a prolonged course of therapy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/1\">",
"      WINSLOW DJ. Botryomycosis. Am J Pathol 1959; 35:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/2\">",
"      Williams RH, Kattih M, Boyd WP, Morgan MB. Cecal botryomycosis: case report and review. Gastrointest Endosc 2003; 57:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/3\">",
"      Brunken RC, Lichon-Chao N, van der Broek H. Immunologic abnormalities in botryomycosis. A case report with review of the literature. J Am Acad Dermatol 1983; 9:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/4\">",
"      Patterson JW, Kitces EN, Neafie RC. Cutaneous botryomycosis in a patient with acquired immunodeficiency syndrome. J Am Acad Dermatol 1987; 16:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/5\">",
"      Buescher ES, Hebert A, Rapini RP. Staphylococcal botryomycosis in a patient with the hyperimmunoglobulin E-recurrent infection syndrome. Pediatr Infect Dis J 1988; 7:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/6\">",
"      Y&ouml;r&uuml;kolu K, Ozer E, Sade M, et al. Renal botryomycosis mimicking renal cell carcinoma. J Urol 1998; 159:2076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/7\">",
"      Katapadi K, Pujol F, Vuletin JC, et al. Pulmonary botryomycosis in a patient with AIDS. Chest 1996; 109:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/8\">",
"      Paz HL, Little BJ, Ball WC Jr, Winkelstein JA. Primary pulmonary botryomycosis. A manifestation of chronic granulomatous disease. Chest 1992; 101:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/9\">",
"      Hacker P. Botryomycosis. Int J Dermatol 1983; 22:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/10\">",
"      Olmstead PM, Finn M. Botryomycosis in pierced ears. Arch Dermatol 1982; 118:925.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/11\">",
"      Hodgson R, Blackmore SA, Clarke CP. Pulmonary botryomycosis: a difficult diagnosis in the preoperative patient. J Thorac Cardiovasc Surg 2005; 130:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/12\">",
"      Magrou, J. Les formes actinomycotiques du staphylocoque. Annales de l'Institute Pasteur 1919; 33:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/13\">",
"      Shults FS, Estes PC, Franklin JA, Richter CB. Staphylococcal botryomycosis in a specific-pathogen-free mouse colony. Lab Anim Sci 1973; 23:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/14\">",
"      A diabetic man with a palpable abdominal wall mass. Clin Infect Dis 2006; 42:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/15\">",
"      Mehregan DA, Su WP, Anhalt JP. Cutaneous botryomycosis. J Am Acad Dermatol 1991; 24:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/16\">",
"      Machado CR, Schubach AO, Concei&ccedil;&atilde;o-Silva F, et al. Botryomycosis. Dermatology 2005; 211:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/17\">",
"      Neafie RC, Marty AM. Unusual infections in humans. Clin Microbiol Rev 1993; 6:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/18\">",
"      Small IA, Kobernick S. Botryomycosis of the tongue. Report of a case. Oral Surg Oral Med Oral Pathol 1967; 24:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/19\">",
"      de Vries HJ, van Noesel CJ, Hoekzema R, Hulsebosch HJ. Botryomycosis in an HIV-positive subject. J Eur Acad Dermatol Venereol 2003; 17:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/20\">",
"      Salvemini JN, Baldwin HE. Botryomycosis in a patient with acquired immunodeficiency syndrome. Cutis 1995; 56:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/21\">",
"      Bersoff-Matcha SJ, Roper CC, Liapis H, Little JR. Primary pulmonary botryomycosis: case report and review. Clin Infect Dis 1998; 26:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/22\">",
"      Kathir K, Dennis C. Primary pulmonary botryomycosis: an important differential diagnosis for lung cancer. Respirology 2001; 6:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/23\">",
"      Vasishta RK, Gupta N, Kakkar N. Botryomycosis--a series of six integumentary or visceral cases from India. Ann Trop Med Parasitol 2004; 98:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/24\">",
"      Wu WQ, Cattaneo EA, Lapi A, Halde C. Botryomycosis: first report of human brain involvement. South Med J 1978; 71:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/25\">",
"      Gillock CB, Sahni KS, Mumaw VR, Meier FA. Cerebral botryomycosis: case study. J Infect Dis 1990; 162:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/26\">",
"      Font RL, Hunts JH. Botryomycosis of limbal conjunctiva with Splendore-Hoeppli phenomenon. Arch Ophthalmol 1996; 114:1006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33365/abstract/27\">",
"      Schlossberg D, Pandey M, Reddy R. The Splendore-Hoeppli phenomenon in hepatic botryomycosis. J Clin Pathol 1998; 51:399.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7649 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33365=[""].join("\n");
var outline_f32_37_33365=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MICROBIOLOGY AND PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cutaneous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Visceral disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152581082\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Cutaneous disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Visceral disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7649\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7649|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/0/8196\" title=\"picture 1\">",
"      Botryomycosis lesion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/3/21559?source=related_link\">",
"      Cervicofacial actinomycosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/61/24538?source=related_link\">",
"      Fever and rash in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_37_33366="Placenta increta";
var content_f32_37_33366=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F73597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F73597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Placenta increta",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 299px; height: 446px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) Clusters of villi are entirely surrounded by myometrium without intervening decidua. Implantation site trophoblast can be seen scattered throughout the myometrium (arrows). Panel B) Higher power of Panel A.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Miriam D Post, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33366=[""].join("\n");
var outline_f32_37_33366=null;
var title_f32_37_33367="Losartan and hydrochlorothiazide: Drug information";
var content_f32_37_33367=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Losartan and hydrochlorothiazide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/40/31365?source=see_link\">",
"    see \"Losartan and hydrochlorothiazide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hyzaar&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Losartan/HCTZ;",
"     </li>",
"     <li>",
"      Hyzaar&reg;;",
"     </li>",
"     <li>",
"      Hyzaar&reg; DS;",
"     </li>",
"     <li>",
"      Mint-Losartan/HCTZ;",
"     </li>",
"     <li>",
"      Mint-Losartan/HCTZ DS;",
"     </li>",
"     <li>",
"      Mylan-Losartan/HCTZ;",
"     </li>",
"     <li>",
"      PMS-Losartan/HCTZ;",
"     </li>",
"     <li>",
"      Sandoz-Losartan HCT;",
"     </li>",
"     <li>",
"      Sandoz-Losartan HCT DS;",
"     </li>",
"     <li>",
"      Teva-Losartan/HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Angiotensin II Receptor Blocker;",
"     </li>",
"     <li>",
"      Diuretic, Thiazide",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190155\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Dose is individualized (combination substituted for individual components); dose may be titrated after 2-4 weeks of therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Hypertension/stroke reduction in hypertension (with LVH):",
"     </b>",
"     Usual recommended starting dose of losartan: 50 mg once daily when used as monotherapy in patients who are not volume depleted",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190156\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to dosing in individual monographs.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190157\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute: Use of combination formulation is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F190158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190141\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 50/12.5: Losartan potassium 50 mg and hydrochlorothiazide 12.5 mg; 100/12.5: Losartan potassium 100 mg and hydrochlorothiazide 12.5 mg; 100/25: Losartan potassium 100 mg and hydrochlorothiazide 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyzaar&reg; 50/12.5: Losartan potassium 50 mg and hydrochlorothiazide 12.5 mg [contains potassium 4.24 mg (0.108 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyzaar&reg; 100/12.5: Losartan potassium 100 mg and hydrochlorothiazide 12.5 mg [contains potassium 8.48 mg (0.216 mEq)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hyzaar&reg; 100/25: Losartan potassium 100 mg and hydrochlorothiazide 25 mg [contains potassium 8.48 mg (0.216 mEq)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F190130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190143\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension; stroke risk reduction in patients with HTN and left ventricular hypertrophy (LVH)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F190175\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Hyzaar&reg; may be confused with Cozaar&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Based on clinical trials of the combination product in patients with essential hypertension. Also see individual agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular:  Edema (1%), palpitation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Dizziness (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Skin rash (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Abdominal pain (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Upper respiratory infection (6%), cough (3%), sinusitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening) or  frequency not defined (some reactions attributed to single component): Bilirubin increased (serum), BUN increased, hematocrit decreased, hemoglobin decreased, hyper-/hypotension, hyponatremia, liver enzymes increased, rhabdomyolysis, serum creatinine increased, thrombocytopenia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190146\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypersensitivity to losartan, hydrochlorothiazide, or any component of the formulation; sulfonamide-derived drugs; concomitant use with aliskiren in patients with diabetes mellitus; anuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F190133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Electrolyte disturbances: Hyperkalemia may occur with angiotensin II receptor antagonists; risk factors include renal dysfunction, diabetes mellitus, and concomitant use of potassium-sparing diuretics, potassium supplements, and/or potassium-containing salts. Use cautiously, if at all, with these agents and monitor potassium closely. Thiazide diuretics may cause hypokalemia, hypochloremic alkalosis, hypomagnesemia, and hyponatremia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypersensitivity reactions: Hypersensitivity reactions may occur with hydrochlorothiazide. Risk is increased in patients with a history of allergy or bronchial asthma.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: Symptomatic hypotension may occur upon initiation in patients who are salt- or volume-depleted (eg, those treated with high-dose diuretics); correct volume depletion prior to administration. This transient hypotensive response is not a contraindication to further treatment with losartan/hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ocular effects: Hydrochlorothiazide may cause acute transient myopia and acute angle-closure glaucoma, typically occurring within hours to weeks following initiation; discontinue therapy immediately in patients with acute decreases in visual acuity or ocular pain. Risk factors may include a history of sulfonamide or penicillin allergy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Photosensitivity: Photosensitization may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal function deterioration: May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in patients with low renal blood flow (eg, renal artery stenosis, heart failure) whose glomerular filtration rate (GFR) is dependent on efferent arteriolar vasoconstriction by angiotensin II; deterioration may result in oliguria, acute renal failure, and progressive azotemia. Small increases in serum creatinine may occur following initiation; consider discontinuation only in patients with progressive and/or significant deterioration in renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfa allergy: Chemical similarities are present among sulfonamides, sulfonylureas, carbonic anhydrase inhibitors, thiazides, and loop diuretics (except ethacrynic acid). Use in patients with sulfonamide allergy is specifically contraindicated in product labeling, however, a risk of cross-reaction exists in patients with allergy to any of these compounds; avoid use when previous reaction has been severe. Discontinue if signs of hypersensitivity are noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Aortic/mitral stenosis: Use with caution in patients with significant aortic/mitral stenosis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use hydrochlorothiazide with caution in patients with prediabetes or diabetes mellitus; may see a change in glucose control.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gout: In certain patients with a history of gout, a familial predisposition to gout, or chronic renal failure, gout can be precipitated by hydrochlorothiazide.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use caution in patients with severe hepatic impairment; in cirrhosis, avoid electrolyte and acid/base imbalances that might lead to hepatic encephalopathy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Hypercalcemia: Thiazide diuretics may decrease renal calcium excretion; consider avoiding use in patients with hypercalcemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypercholesterolemia: Use with caution in patients with moderate or high cholesterol concentrations; increased cholesterol and triglyceride levels have been reported with thiazides.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Parathyroid disease: Thiazide diuretics reduce calcium excretion; pathologic changes in the parathyroid glands with hypercalcemia and hypophosphatemia have been observed with prolonged use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal artery stenosis: Use losartan with caution in patients with unstented unilateral/bilateral renal artery stenosis. When unstented bilateral renal artery stenosis is present, use is generally avoided due to the elevated risk of deterioration in renal function unless possible benefits outweigh risks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use losartan with caution with pre-existing renal insufficiency and severe renal impairment. Avoid hydrochlorothiazide in severe renal disease (ineffective); may precipitate azotemia; discontinue or consider withholding if renal impairment occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic lupus erythematosus (SLE): Hydrochlorothiazide can cause SLE exacerbation or activation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Angiotensin-converting enzyme (ACE) inhibitors and renin inhibitors: Concomitant use of an ACE-inhibitor or renin inhibitor (eg, aliskiren) is associated with an increased risk of hypotension, hyperkalemia, and renal dysfunction. Concomitant use with aliskiren should be avoided in patients with GFR &lt;60 mL/minute and is contraindicated in patients with diabetes mellitus (regardless of GFR).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; African-American patients: When used to reduce the risk of stroke in patients with HTN and LVH, may not be effective in the African-American population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy:",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F190164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F190137\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Thiazide Diuretics may enhance the hypotensive effect of ACE Inhibitors. Specifically, postural hypotension which can accompany ACE Inhibitor initiation. Thiazide Diuretics may enhance the nephrotoxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the hypotensive effect of Angiotensin II Receptor Blockers. Aliskiren may enhance the nephrotoxic effect of Angiotensin II Receptor Blockers. Management: Avoid aliskiren use with ACEIs or ARBs in patients with diabetes or estimated glomerular filtration rate below 60 mL/min. In other patients receiving these combinations, monitor serum potassium, serum creatinine, and blood pressure periodically.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Allopurinol: Thiazide Diuretics may enhance the potential for allergic or hypersensitivity reactions to Allopurinol. Thiazide Diuretics may increase the serum concentration of Allopurinol. Specifically, Thiazide Diuretics may increase the concentration of Oxypurinol, an active metabolite of Allopurinol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Analgesics (Opioid): May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antidiabetic Agents: Thiazide Diuretics may diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May enhance the orthostatic hypotensive effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benazepril: Hydrochlorothiazide may enhance the hypotensive effect of Benazepril. Hydrochlorothiazide may enhance the nephrotoxic effect of Benazepril. Benazepril may decrease the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta2-Agonists: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Thiazide Diuretics. The diuretic response is likewise decreased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: Thiazide Diuretics may decrease the excretion of Calcium Salts. Continued concomitant use can also result in metabolic alkalosis.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Canagliflozin: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. Canagliflozin may enhance the hypotensive effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Thiazide Diuretics may enhance the adverse/toxic effect of CarBAMazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carvedilol: CYP2C9 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. Specifically, concentrations of the S-carvedilol enantiomer may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of CycloSPORINE (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inducers (Strong): May increase the metabolism of CYP2C9 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Moderate): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Inhibitors (Strong): May decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C9 Substrates: CYP2C9 Inhibitors (Moderate) may decrease the metabolism of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Thiazide Diuretics may enhance the QTc-prolonging effect of Dofetilide. Thiazide Diuretics may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Licorice: May enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Thiazide Diuretics may decrease the excretion of Lithium.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Angiotensin II Receptor Blockers may increase the serum concentration of Lithium.  Management: Lithium dosage reductions will likely be needed following the addition of an angiotensin II receptor antagonist.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the orthostatic hypotensive effect of Orthostatic Hypotension Producing Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C9 Substrates. Management: Use CYP2C9 substrates at the lowest recommended dose, and monitor closely for adverse effects, during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Milk Thistle: May increase the serum concentration of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): Thiazide Diuretics may enhance the hypercalcemic effect of Multivitamins/Minerals (with ADEK, Folate, Iron).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May diminish the therapeutic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: Angiotensin II Receptor Blockers may enhance the adverse/toxic effect of Nonsteroidal Anti-Inflammatory Agents. Specifically, the combination may result in a significant decrease in renal function. Nonsteroidal Anti-Inflammatory Agents may diminish the therapeutic effect of Angiotensin II Receptor Blockers. The combination of these two agents may also significantly decrease glomerular filtration and renal function.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OXcarbazepine: Thiazide Diuretics may enhance the adverse/toxic effect of OXcarbazepine. Specifically, there may be an increased risk for hyponatremia.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2C9 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Salts: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Angiotensin II Receptor Blockers may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Angiotensin II Receptor Blockers may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with ARBs, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, maintain adequate hydration and monitor renal function closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Phosphates: Diuretics may enhance the nephrotoxic effect of Sodium Phosphates. Specifically, the risk of acute phosphate nephropathy may be enhanced.  Management: Consider avoiding this combination by temporarily suspending treatment with diuretics, or seeking alternatives to oral sodium phosphate bowel preparation. If the combination cannot be avoided, hydrate adequately and monitor fluid and renal status.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Thiazide Diuretics may enhance the hypokalemic effect of Topiramate. Thiazide Diuretics may increase the serum concentration of Topiramate.  Management: Monitor for increased topiramate levels/adverse effects (e.g., hypokalemia) with initiation/dose increase of a thiazide diuretic. Closely monitor serum potassium concentrations with concomitant therapy. Topiramate dose reductions may be necessary.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: Thiazide Diuretics may enhance the hypercalcemic effect of Toremifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valsartan: Hydrochlorothiazide may enhance the hypotensive effect of Valsartan. Valsartan may increase the serum concentration of Hydrochlorothiazide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin D Analogs: Thiazide Diuretics may enhance the hypercalcemic effect of Vitamin D Analogs.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F190138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C/D (2nd and 3rd trimesters) (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F190149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      [U.S. Boxed Warning]: Drugs that act on the renin-angiotensin system can cause injury and death to the developing fetus. Discontinue as soon as possible once pregnancy is detected.",
"     </b>",
"     Also see individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F190160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F9843044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products may contain potassium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F190148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hyzaar Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-12.5 mg (90): $305.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-12.5 mg (100): $436.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-25 mg (100): $461.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Losartan Potassium-HCTZ Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-12.5 mg (90): $225.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-12.5 mg (90): $306.70",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100-25 mg (90): $306.70",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F190150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      2Zaris (PH);",
"     </li>",
"     <li>",
"      Angioretic (EC);",
"     </li>",
"     <li>",
"      Anzaplus (PH);",
"     </li>",
"     <li>",
"      Cardiovasc (EC);",
"     </li>",
"     <li>",
"      Co-Normoten (PH);",
"     </li>",
"     <li>",
"      Combetzar (PH);",
"     </li>",
"     <li>",
"      Convertal D (UY);",
"     </li>",
"     <li>",
"      Corodin-D (CN, PY);",
"     </li>",
"     <li>",
"      Corus-H (BR);",
"     </li>",
"     <li>",
"      Cosaar Plus (AT, CH);",
"     </li>",
"     <li>",
"      Cosca Plus (KP);",
"     </li>",
"     <li>",
"      Cosca Plus-F (KP);",
"     </li>",
"     <li>",
"      Cozaar Plus (DK, ES, KP, PT);",
"     </li>",
"     <li>",
"      Cozaar-Comp (FI, GB, IE, NO);",
"     </li>",
"     <li>",
"      Cozaarex D (AR);",
"     </li>",
"     <li>",
"      Ecozar Plus (PH);",
"     </li>",
"     <li>",
"      Fortzaar (FR, IT, MY, PT, SE, TH);",
"     </li>",
"     <li>",
"      Hipress (BR);",
"     </li>",
"     <li>",
"      Hisart (TW);",
"     </li>",
"     <li>",
"      Hyzaar (BB, BM, BS, BZ, CL, CN, CR, CZ, FR, GR, GY, HK, ID, JM, MX, MY, NL, NZ, PA, PE, PH, PK, PL, SG, SR, TH, TR, TT, TW, VE);",
"     </li>",
"     <li>",
"      Hyzaar DS (PH);",
"     </li>",
"     <li>",
"      Hyzaar Forte (HK, SG, TW);",
"     </li>",
"     <li>",
"      Hyzaar Plus (HK, SG);",
"     </li>",
"     <li>",
"      Kenzar Plus (PH);",
"     </li>",
"     <li>",
"      Lorzaar Plus (DE);",
"     </li>",
"     <li>",
"      Losacor D (AR, PE);",
"     </li>",
"     <li>",
"      Losacor HCT (HK);",
"     </li>",
"     <li>",
"      Losardex PLus (IL);",
"     </li>",
"     <li>",
"      Losargard Plus (PH);",
"     </li>",
"     <li>",
"      Losart-H (PH);",
"     </li>",
"     <li>",
"      Losartan Plus (IL);",
"     </li>",
"     <li>",
"      Lotan Plus (IL);",
"     </li>",
"     <li>",
"      Lozap H (BG, EE);",
"     </li>",
"     <li>",
"      Lozarkan Plus (KP);",
"     </li>",
"     <li>",
"      Lozarsin (KP);",
"     </li>",
"     <li>",
"      Lozetin Plus (KP);",
"     </li>",
"     <li>",
"      Nefrotal Plus (DO);",
"     </li>",
"     <li>",
"      Nor-Sartan H (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Ocsaar Plus (IL);",
"     </li>",
"     <li>",
"      Osartan Plus (KP);",
"     </li>",
"     <li>",
"      Rozataplus (KP);",
"     </li>",
"     <li>",
"      Sarlotan Plus (KP);",
"     </li>",
"     <li>",
"      Satoren H (CO);",
"     </li>",
"     <li>",
"      Synzar (TW);",
"     </li>",
"     <li>",
"      Tensarten-HCT (CO);",
"     </li>",
"     <li>",
"      Vivasartan Plus (PH);",
"     </li>",
"     <li>",
"      Wilopres Plus (PH);",
"     </li>",
"     <li>",
"      Zaart-H (IN)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohn JN and Tognoni G, &ldquo;Valsartan Heart Failure Trial Investigators. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2001, 345(23):1667-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/11759645/pubmed\" id=\"11759645\" target=\"_blank\">",
"        11759645",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dahlof B, Devereux RB, Kjeldsen SE, et al, &ldquo;Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE): A Randomised Trial Against Atenolol,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 359(9311):995-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/11937178/pubmed\" id=\"11937178\" target=\"_blank\">",
"        11937178",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Dickstein K, Kjekshus J, et al, \"Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients After Acute Myocardial Infarction: The OPTIMAAL Randomised Trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2002, 360(9335):752-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/12241832/pubmed\" id=\"12241832\" target=\"_blank\">",
"        12241832",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Epstein BJ and Gums JG, \"Angiotensin Receptor Blockers Versus ACE Inhibitors: Prevention of Death and Myocardial Infarction in High-Risk Populations,\"",
"      <i>",
"       Ann Pharmacother",
"      </i>",
"      , 2005, 39(3):470-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/15701766/pubmed\" id=\"15701766\" target=\"_blank\">",
"        15701766",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Granger CB, McMurray JJ, Yusuf S, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Intolerant to Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Alternative Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):772-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/13678870/pubmed\" id=\"13678870\" target=\"_blank\">",
"        13678870",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan NM and Sever PS, &ldquo;Combination Therapy: A Key to Comprehensive Patient Care,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1997, 10(7 Pt 2):127S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/9231887/pubmed\" id=\"9231887\" target=\"_blank\">",
"        9231887",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McMurray JJ, Ostergren J, Swedberg K, et al, \"Effects of Candesartan in Patients With Chronic Heart Failure and Reduced Left-Ventricular Systolic Function Taking Angiotensin-Converting-Enzyme Inhibitors: The CHARM-Added Trial,\"",
"      <i>",
"       Lancet",
"      </i>",
"      , 2003, 362(9386):767-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/13678869/pubmed\" id=\"13678869\" target=\"_blank\">",
"        13678869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Moser M and Black HR, &ldquo;The Role of Combination Therapy in the Treatment of Hypertension,&rdquo;",
"      <i>",
"       Am J Hypertens",
"      </i>",
"      , 1998, 11(6 Pt 2):73S-8S, 95S-100S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/9655566/pubmed\" id=\"9655566\" target=\"_blank\">",
"        9655566",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pfeffer MA, McMurray JJ, Velazquez EJ, et al, \"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(2):203.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pitt B, Poole-Wilson PA, Segal R, et al, \"Effect of Losartan Compared With Captopril on Mortality in Patients With Symptomatic Heart Failure: Randomised Trial - The Losartan Heart Failure Survival Study ELITE II,\"",
"      <i>",
"       Lancet",
"      </i>",
"      ,  2000, 355(9215):1582-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/10821361/pubmed\" id=\"10821361\" target=\"_blank\">",
"        10821361",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sipahi I, Debanne SM, Rowland DY, et al, &ldquo;Angiotensin-Receptor Blockade and Risk of Cancer: Meta-Analysis of Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet Oncol",
"      </i>",
"      , 2010, 11(7):627-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?32/37/33367/abstract-text/20542468/pubmed\" id=\"20542468\" target=\"_blank\">",
"        20542468",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10247 Version 46.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33367=[""].join("\n");
var outline_f32_37_33367=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709021\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190152\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190153\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190170\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190155\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190156\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190157\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190158\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190141\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190130\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190143\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190175\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190168\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190146\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190133\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190164\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190137\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190138\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190149\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190160\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9843044\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190148\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190150\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190145\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10247\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10247|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?30/40/31365?source=related_link\">",
"      Losartan and hydrochlorothiazide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_37_33368="Management of recurrent or metastatic cervical cancer";
var content_f32_37_33368=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of recurrent or metastatic cervical cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33368/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33368/contributors\">",
"     Jason D Wright, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33368/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33368/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33368/contributors\">",
"     Arno J Mundt, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33368/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33368/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/37/33368/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 19, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although uncommon at initial diagnosis, metastatic disease will develop in 15 to 61 percent women with cervical cancer, usually within the first two years of completing treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the majority of cases, metastatic cervical cancer is not curable. However, for some patients who present with recurrent disease in the pelvis (locoregional recurrence) or with limited distant metastatic disease, surgical treatment is potentially curative.",
"   </p>",
"   <p>",
"    Histologically, squamous cell carcinoma (SCC), adenocarcinoma, and adenosquamous carcinomas account for approximately 70, 25, and 3 to 5 percent of all cervical cancers, respectively (",
"    <a class=\"graphic graphic_table graphicRef65824 \" href=\"mobipreview.htm?2/38/2668\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/2\">",
"     2",
"    </a>",
"    ]. Rarer histologies include neuroendocrine or small cell carcinomas.",
"   </p>",
"   <p>",
"    The management of recurrent or metastatic cervical cancer will be discussed here. Specific issues regarding patterns of relapse after treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/42/17064?source=see_link\">",
"     \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186822333\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recurrent cervical cancer can present as a local recurrence or as metastatic disease. &nbsp;",
"   </p>",
"   <p>",
"    Locally recurrent cervical cancer usually presents with vaginal symptoms (ie, discharge, bleeding, dyspareunia, or pain). On pelvic exam, a mass or nodularity at the vaginal cuff, which may extend to the side wall, may be visualized or palpated. Disease within the vaginal pelvis (or vaginal vault) can be tender to palpation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prone to bleeding easily.",
"   </p>",
"   <p>",
"    By comparison, patients with metastatic cervical cancer usually present with either no symptoms or non-specific complaints (ie, fatigue, nausea, or weight loss); however, they may have symptoms related to the site of metastases. As an example, patients with bone metastases present with a chronic pain, not alleviated with rest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H172229098\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with findings suspicious for recurrence on pelvic exam should undergo a biopsy.",
"   </p>",
"   <p>",
"    Women who present with signs (ie, weight loss, palpable abdominal lesions) or symptoms (ie, pain, nausea, or weight loss) should undergo radiologic imaging to evaluate for metastatic disease. In addition, imaging is essential for women who present with a mass on pelvic exam, because the extent of disease will influence the treatment plan.",
"   </p>",
"   <p>",
"    Metastatic cervical cancer may present as nodal disease involving the para-aortic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supraclavicular nodes, limited disease involving one organ site, or widely metastatic disease. In one study of over 200 patients, distant metastases, disease limited to the para-aortic nodes, and disease in the supraclavicular nodes (with or without para-aortic node involvement) was found in 65, 22, and 14 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/3\">",
"     3",
"    </a>",
"    ]. In another review of the literature, the estimated prevalence of organ site involvement by metastatic cervical cancer was [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Pelvic or para-aortic nodes (75 and 62 percent, respectively)",
"     </li>",
"     <li>",
"      Lung (33 to 38 percent)",
"     </li>",
"     <li>",
"      Liver (33 percent)",
"     </li>",
"     <li>",
"      Peritoneum (5 to 27 percent)",
"     </li>",
"     <li>",
"      Adrenal gland (14 to 16 percent)",
"     </li>",
"     <li>",
"      Intestines (12 percent)",
"     </li>",
"     <li>",
"      Skin (10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The most commonly used imaging modalities include computed tomography (CT) and positron emission tomography (PET) with or without CT. Of these, we suggest",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    for evaluation of local and distant disease. It has a sensitivity of 93 to 96 percent and specificity of 93 to 95 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, the results from a",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan often lead to changes to the therapeutic plan for women with recurrent disease by sparing women from an extensive surgical approach in the setting of widely metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients presenting with isolated metastatic findings on imaging should undergo a biopsy to prove metastatic disease, as there is a risk that these findings may represent a second primary malignancy or a benign process. As an example, in one series of 23 women with cervical cancer who presented with pulmonary lesions and underwent resection, seven (29 percent) were diagnosed with primary lung cancer at final pathologic analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H104508737\">",
"     'Limited metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104509800\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF LOCAL RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who present with a local relapse, treatment directed to the site of recurrence can be performed with curative intent. Options include hysterectomy, pelvic exenteration, or radiation therapy; the choice depends on the patient&rsquo;s prior treatment.",
"   </p>",
"   <p>",
"    Patients who have previously been treated with radiation therapy (RT) and those who are not candidates for surgical resection should be offered chemotherapy. The approach to these patients is identical to the treatment of women with metastatic disease. (See",
"    <a class=\"local\" href=\"#H104509204\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8642804\">",
"    <span class=\"h2\">",
"     Candidates for surgical resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who experience a local recurrence should be offered surgical resection with curative intent. Commonly employed criteria to identify those women most likely to benefit from surgery include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/10\">",
"     10",
"    </a>",
"    ] (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/42/17064?source=see_link&amp;anchor=H2#H2\">",
"     \"Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance\", section on 'Disease recurrence'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A central pelvic recurrence without side wall fixation or associated hydronephrosis",
"     </li>",
"     <li>",
"      A long disease-free interval",
"     </li>",
"     <li>",
"      Tumor size of the recurrence less than 3 cm in diameter",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8642880\">",
"    <span class=\"h3\">",
"     Surgical procedure",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343518599\">",
"    <span class=\"h4\">",
"     Following RT with uterine conservation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who underwent primary RT, radical hysterectomy for management of local recurrence is the preferred approach and is associated with five-year survival rates ranging between 30 and 40 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, surgical complications are more common in this setting. In one study, 15 of 34 patients who underwent surgery for persistent of recurrent disease following RT experienced major postoperative complications, including fistula formation (in five women).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343518606\">",
"    <span class=\"h4\">",
"     Following hysterectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have undergone hysterectomy (with or without adjuvant RT or chemoradiation), pelvic exenteration represents the only potentially curative option for local recurrence or persistent disease. Careful patient selection is required given the perioperative and postoperative morbidity associated with this extensive surgical approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31689?source=see_link\">",
"     \"Exenteration for gynecologic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H343518613\">",
"    <span class=\"h2\">",
"     Non-surgical options",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8642945\">",
"    <span class=\"h3\">",
"     Candidates for radiation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;RT is a reasonable option for the following patients:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Women who have not been previously treated with RT",
"     </li>",
"     <li>",
"      Women with operable disease who opt not to proceed with pelvic exenteration",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The benefit of RT was demonstrated in a single institution experience of 35 women who were treated with high-dose RT following a pelvic recurrence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/13\">",
"     13",
"    </a>",
"    ]. The 5- and 10-year survival rate was 43 and 33 percent, respectively, and pelvic control rates were 69 and 62 percent, respectively. The use of brachytherapy and a long treatment-free interval between primary surgery and diagnosis of recurrence were positive predictors of a good outcome.",
"   </p>",
"   <p>",
"    Given the superiority of concomitant chemotherapy with RT (chemoradiation) over RT alone as primary treatment, most experts prefer chemoradiation for these patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=see_link&amp;anchor=H3#H3\">",
"     \"Management of locally advanced cervical cancer\", section on 'Primary chemoradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8642960\">",
"    <span class=\"h3\">",
"     Candidates for chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who are not candidates for surgical resection or primary RT, chemotherapy is the only option. Chemotherapy has activity for the treatment of cervical cancer, although treatment is less successful if the recurrence is in an area that was previously irradiated. (See",
"    <a class=\"local\" href=\"#H2177909474\">",
"     'First-line treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1205655\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF METASTATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of metastatic cervical cancer depends on the extent of disease at presentation. For patients with limited metastatic disease (ie, disease in the para-aortic nodes or solitary lung metastasis), treatment can be directed towards the area of recurrence using radiation therapy (RT) or a surgical approach. However, for women with more extensive disease, chemotherapy is the only treatment option.",
"   </p>",
"   <p>",
"    The treatment approach to women with metastatic disease is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104509153\">",
"    <span class=\"h2\">",
"     Disease isolated to the lymph nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women presenting with disease limited to the nodes (para-aortic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    supraclavicular nodes), the prognosis is poor. This was illustrated in a retrospective study of 375 patients with recurrent cervical cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/3\">",
"     3",
"    </a>",
"    ]. The rate of overall survival at five years was 27 and 0 percent for women with limited metastatic disease involving the para-aortic nodes (n=60) or the supraclavicular nodes (n=26) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are limited data to help guide treatment of women with metastatic disease limited to the lymph nodes. Some experts prefer systemic chemotherapy, while others prefer RT (with or without chemotherapy). A choice between them depends on institutional practice and patient preference. (See",
"    <a class=\"local\" href=\"#H2177909474\">",
"     'First-line treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104508737\">",
"    <span class=\"h2\">",
"     Limited metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who present with isolated or limited metastatic disease, usually involving the lung, surgical resection is a reasonable option that can result in a sustained clinical remission. As an example, in one series of 15 women who underwent resection of pulmonary metastases for cervical cancer, 13 were alive with a median follow-up of 18 months (range, 4 to 68 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/9\">",
"     9",
"    </a>",
"    ]. The short interval follow-up and lack of historical controls (that received chemotherapy, for example) limits interpretation of this approach. Given the potential morbidity associated with resection, careful selection of patients is required. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=see_link&amp;anchor=H8#H8\">",
"     \"Surgical resection of pulmonary metastases: Outcomes by histology\", section on 'Gynecologic cancers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=see_link\">",
"     \"Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H104509204\">",
"    <span class=\"h2\">",
"     Metastatic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with metastatic disease and those who are not candidates for a local treatment approach, we suggest chemotherapy. There are several agents with activity in cervical cancer, which can be used as part of a combination regimen or as single agent therapy.",
"   </p>",
"   <p>",
"    Treatment for metastatic cervical cancer can be stratified on whether or not prior chemotherapy was administered. This stratification is based on a retrospective evaluation by the Gynecologic Oncology Group (GOG) that included 428 patients treated on first-line chemotherapy trials [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/14\">",
"     14",
"    </a>",
"    ]. The following factors were associated with a higher likelihood of a poor response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Black race (versus non-black) &mdash; odds ratio [OR] for poor response 0.49 (95% CI 0.28-0.83)",
"     </li>",
"     <li>",
"      Performance status 1 or 2 (versus 0) &mdash; OR 0.60 (95% CI 0.38-0.94)",
"     </li>",
"     <li>",
"      Pelvic disease (versus non-pelvic location) &mdash; OR 0.58 (95% CI 0.38-0.90)",
"     </li>",
"     <li>",
"      Prior treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      as part of chemoradiation (versus none) &mdash; OR 0.52 (95% CI 0.32-0.85)",
"     </li>",
"     <li>",
"      Recurrence within one year of diagnosis (versus longer) &mdash; OR 0.61 (95% CI 0.39-0.95)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data were used to construct a prognostic model to predict a poor treatment response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based chemotherapy by identifying three risk groups: high risk (four to five factors present), mid risk (two to three factors present), and low risk (zero to one factor present). This model was externally validated in a separate group of patients treated on a separate GOG trial with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/14\">",
"     14",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-risk group &mdash; The overall response rate (ORR) was 14 percent, median progression-free survival (PFS) was 3 months, and median overall survival (OS) was 5.6 months",
"     </li>",
"     <li>",
"      Mid-risk group &mdash; ORR 29 percent, PFS 4 months, OS 7.6 months",
"     </li>",
"     <li>",
"      Low-risk group &mdash; ORR 43 percent, PFS 7 months, OS 12 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This model suggests that chemotherapy-naive patients have a higher response rate than women who received prior chemotherapy, including as part of chemoradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with metastatic, advanced, or recurrent cervical cancer who are candidates for chemotherapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    is the most widely used agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/17\">",
"     17",
"    </a>",
"    ]. However, there are no randomized trials comparing single agent cisplatin to other single agents (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    ). The approach to chemotherapy in the first- and later line treatment setting is reviewed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2177909474\">",
"    <span class=\"h3\">",
"     First-line treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with recurrent, metastatic, or advanced cervical cancer should receive treatment consisting of a platinum-based combination plus the angiogenesis inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    . This recommendation is based on the results of GOG 240, in which over 400 women with primary stage IVB, recurrent, persistent cervical squamous cell cancer or adenocarcinoma were randomly assigned to chemotherapy (either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    or paclitaxel plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ) with or without bevacizumab (15",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 21 days). Although the final data have yet to be reported, results from the second interim analysis showed the addition of bevacizumab to chemotherapy improved overall survival by four months compared to chemotherapy alone (17 versus 13 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While we await the final analysis of GOG 240 to better evaluate the toxicity profile of treatment and whether the specific chemotherapy regimen had an impact on survival,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    should be incorporated into the first-line treatment of metastatic or recurrent cervical cancer. Although the preferred chemotherapy combination to use with bevacizumab has not been established, the choice of chemotherapy should mirror the approach to selection of agents for patients who do not receive bevacizumab. (See",
"    <a class=\"local\" href=\"#H1225233361\">",
"     'Combination chemotherapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1225233361\">",
"    <span class=\"h4\">",
"     Combination chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the first-line setting we suggest a platinum-based combination, regardless of whether",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is also administered. There are limited data on the use of a non-platinum based regimen in this setting, although the limited data suggest that non-platinum based combinations are not more effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, data support the use of a platinum-based combination rather than single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H1639879582\">",
"     'Combination versus single agent therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We await the results of GOG 240 which compared the administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    to paclitaxel plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    in two treatment arms. (See",
"    <a class=\"local\" href=\"#H2177909474\">",
"     'First-line treatment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Our preferred combination is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    rather than other cisplatin-based regimens. This is based on the results of GOG 204, in which 434 patients with metastatic or advanced cervical cancer were randomly assigned treatment with cisplatin plus paclitaxel (the reference control arm) or one of three experimental regimens (cisplatin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"     vinorelbine",
"    </a>",
"    , cisplatin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , or cisplatin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    ) with the following results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference in response rates &mdash; For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , the overall response rate (ORR) was 29 percent. The ORR was 26, 22, and 23 percent, for cisplatin administered with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      , respectively.",
"     </li>",
"     <li>",
"      There was no difference in the risk of death, although the study was underpowered for this endpoint. Compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      , the hazard ratio (HR) for death with each regimen was:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      &mdash; HR 1.15 (95% CI 0.79-1.67)",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      &mdash; HR 1.32 (95% CI 0.91-1.92)",
"     </li>",
"     <li>",
"      For",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      &mdash; HR 1.26 (95% CI 0.86-1.82)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       Cisplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      resulted in much less serious febrile neutropenia compared to cisplatin in combination with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       vinorelbine",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       topotecan",
"      </a>",
"      (6 versus 13, 14, and 10 percent), respectively. However, cisplatin plus paclitaxel resulted in less serious thrombocytopenia compared to the other arms (7 versus 8, 28, and 35 percent for cisplatin plus vinorelbine, gemcitabine, or topotecan, respectively). &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1639880214\">",
"    <span class=\"h4\">",
"     Alternate use of carboplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the toxicity seen with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based combination chemotherapy,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    is a reasonable substitute for cisplatin, particularly for patients with medical comorbidities (eg, pre-existing renal failure) and those patients previously treated with cisplatin-based chemoradiation. This is based on the preliminary results of the Japanese Clinical Oncology Group 0505 trial (JCOG 0505) presented at the 2012 American Society of Clinical Oncology Meeting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/21\">",
"     21",
"    </a>",
"    ]. In JCOG 0505, 253 women with stage IVB, persistent or recurrent cervical cancer were randomly assigned treatment with cisplatin (50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (135",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    or carboplatin (area under curve [AUC] 5) plus paclitaxel (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ),",
"    </span>",
"    administered every three weeks for six cycles. Prior cisplatin therapy (primarily with chemoradiation) was noted in 43 and 50 percent of each group, respectively. Compared to cisplatin plus paclitaxel, treatment with carboplatin and paclitaxel resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar overall response rate (63 versus 60 percent).",
"     </li>",
"     <li>",
"      No difference in OS (HR for mortality 0.99, 90% CI, 0.79-1.25), although a difference was noted among the following subgroups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Among women not previously treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (n=117),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      resulted in a lower median OS compared to cisplatin plus paclitaxel (13 versus 23 months, HR 1.57, 95% CI 1.06-2.32).",
"     </li>",
"     <li>",
"      Among women previously treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (n=127),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      resulted in a higher OS (19 versus 16 months, HR 0.69, 95% CI 0.47-1.02).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Significantly less serious (grade 4) neutropenic events (45 versus 75 percent, p&lt;.0001). There were also less serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      incidences of renal insufficiency (0 versus 2.4 percent), nausea, and vomiting (3 versus 7 percent). However,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      resulted in more neuropathic events (7 versus 1 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The results of JCOG 0505 establish",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    as a reasonable alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus paclitaxel in the treatment of women with metastatic cervical cancer, particularly in those who are not candidates for cisplatin",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    were previously treated with cisplatin-based chemoradiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1639879582\">",
"    <span class=\"h4\">",
"     Combination versus single agent therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The evidence to support the use of a platinum-based combination rather than single agent therapy is limited. However, combination therapy was compared against single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    in a 2012 meta-analysis that included five randomized trials (n= 1114) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/22\">",
"     22",
"    </a>",
"    ]. Compared to combination platinum-based therapy, single agent cisplatin resulted in a lower response rate (relative risk [RR] 0.60, 95% CI 0.44-0.81) but was associated with far less toxicity, including less serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    neutropenia (RR 0.04, 95% CI 0.02-0.12), and thrombocytopenia (RR 0.16, 95% CI 0.05-0.48).",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    in two trials and resulted in overall survival (OS) ranging from 13 to 15 months and progression free survival (PFS) from 6 to 8 months. In contrast, OS ranged from 7 to 9 months and PFS was approximately three months with cisplatin alone (&gt;11 trials). &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85099849\">",
"    <span class=\"h3\">",
"     Second-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who have progressed after first-line treatment and those patients who are not candidates for combination chemotherapy, we suggest single agent chemotherapy. However, there is no evidence that treatment in the second or later line setting improves overall survival compared to best supportive care in this population.",
"   </p>",
"   <p>",
"    A choice among active agents must be tailored to the individual patient, with consideration to prior therapies received, residual toxicity, and performance status. Given the limited activity of currently available agents, we encourage participation in well-designed clinical trials exploring alternative approaches to metastatic cervical cancer.",
"   </p>",
"   <p>",
"    The most active single agents are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      &mdash; ORR 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/23\">",
"       23",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Nanoparticle, albumin-bound",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (125",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      on days 1, 8, and 15 every 28 days) &mdash; ORR 29 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/24\">",
"       24",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/59/953?source=see_link\">",
"       Vinorelbine",
"      </a>",
"      (30",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV push weekly for two weeks every 21 days) &mdash; ORR 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       Paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV every three weeks with dose reduction to 135",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      if patients received prior RT) &mdash; ORR 20 to 25 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/28-30\">",
"       28-30",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/27/36279?source=see_link\">",
"       Pemetrexed",
"      </a>",
"      (900",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV every three weeks) &mdash; ORR 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/25/38297?source=see_link\">",
"       Ifosfamide",
"      </a>",
"      (1.2",
"      <span class=\"nowrap\">",
"       g/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV daily for five days every 28 days) &mdash; ORR 22 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/33,34\">",
"       33,34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"       Topotecan",
"      </a>",
"      (1.5",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV daily for five days every 21 days) &mdash; ORR 19 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/33,35-37\">",
"       33,35-37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       Irinotecan",
"      </a>",
"      (125",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      IV every three weeks) &mdash; ORR 15 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/38,39\">",
"       38,39",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF ACUTELY SYMPTOMATIC PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with pelvic pain or bleeding from locally advanced disease, and for patients with symptomatic metastatic disease, single-dose or short-course external beam radiation therapy (RT) may be useful. However, treatment planning is critical for women who have previously been treated with RT due to the risks of excessive toxicity to normal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. For women with symptoms from a vaginal or pelvic recurrence, the optimal regimen has not been established. A typical regimen consists of twice daily fractionations of external beam RT (3.7 Gy per fraction) for two consecutive days repeated at four-week intervals for three courses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33368/abstract/40,43\">",
"     40,43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the treatment of visceral or distant metastases, large fractions of RT administered in a short treatment course may also be used for local treatment of symptoms related to metastatic disease, such as alleviation of pain from skeletal metastases, or symptoms associated with brain lesions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=see_link\">",
"     \"Radiation therapy for the management of painful bone metastases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=see_link\">",
"     \"Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Following treatment of early stage cervical cancer, distant metastases or multiple recurrence sites develop in 15 to 61 percent of cases, usually within the first two years of completing treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recurrent cervical cancer presents as disease isolated to the pelvis (locoregional recurrence) or with disease involving other organs or outside the pelvis. If a vaginal recurrence is suspected, the area of concern should be biopsied to prove recurrent disease. (See",
"      <a class=\"local\" href=\"#H186822333\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients suspected of recurrent disease should undergo positron emission tomography",
"      <span class=\"nowrap\">",
"       (PET)/computed",
"      </span>",
"      tomography (CT) for evaluation of local and distant disease. (See",
"      <a class=\"local\" href=\"#H186822333\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with a local recurrence, we suggest surgical resection if they are appropriate surgical candidates based on tumor recurrence, age, and comorbidities (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). In select patients, surgical resection may present a curative option. Patients who are not surgical candidates should receive chemoradiation, if they have not been previously undergone pelvic or intravaginal radiation. (See",
"      <a class=\"local\" href=\"#H104509800\">",
"       'Management of local recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women presenting with disease limited to the nodes (ie, para-aortic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      supraclavicular nodes), some experts prefer to treat with systemic chemotherapy. Others prefer to administer radiation therapy (RT) (with or without chemotherapy). A choice between them depends on institutional practice and patient preferences.",
"     </li>",
"     <li>",
"      For women presenting with isolated metastatic disease (ie, to the lung or liver), we suggest surgical resection if they are appropriate candidates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). These patients may achieve a sustained clinical remission following resection of disease.",
"     </li>",
"     <li>",
"      For women with recurrent cervical cancer, those who are not surgical candidates, and those who present with metastatic disease, we suggest first-line treatment with chemotherapy plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      rather than chemotherapy alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2177909474\">",
"       'First-line treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are candidates for first-line chemotherapy, we suggest a platinum-based combination rather than a non-platinum based regimen (with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We also suggest a combination platinum-based regimen rather than single agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest cisplatin plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      rather than other platinum-based regimens (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/61/38873?source=see_link\">",
"       Carboplatin",
"      </a>",
"      plus paclitaxel is a reasonable alternative, particularly for patients who are poor candidates for cisplatin (eg, due to pre-existing renal failure) and patients previously treated with cisplatin-based chemoradiation. (See",
"      <a class=\"local\" href=\"#H2177909474\">",
"       'First-line treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who progress following first-line chemotherapy and those who are not candidates for combination therapy, we suggest single agent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A choice among active agents must be tailored to the individual patient, with consideration to prior therapies received, residual toxicity, and performance status. (See",
"      <a class=\"local\" href=\"#H85099849\">",
"       'Second-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are symptomatic due to vaginal metastases or other lesions, we suggest radiation therapy for palliation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Management of acutely symptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975 to 2003. National Cancer Institute, Bethesda, MD 2006.",
"    </li>",
"    <li>",
"     SEER data for 2000-2004 file://seer.cancer.gov/ (Accessed on April 25, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/3\">",
"      Hong JH, Tsai CS, Lai CH, et al. Recurrent squamous cell carcinoma of cervix after definitive radiotherapy. Int J Radiat Oncol Biol Phys 2004; 60:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/4\">",
"      Fulcher AS, O'Sullivan SG, Segreti EM, Kavanagh BD. Recurrent cervical carcinoma: typical and atypical manifestations. Radiographics 1999; 19 Spec No:S103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/5\">",
"      Patel CN, Nazir SA, Khan Z, et al. 18F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol 2011; 196:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/6\">",
"      Chung HH, Jo H, Kang WJ, et al. Clinical impact of integrated PET/CT on the management of suspected cervical cancer recurrence. Gynecol Oncol 2007; 104:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/7\">",
"      Pallardy A, Bodet-Milin C, Oudoux A, et al. Clinical and survival impact of FDG PET in patients with suspicion of recurrent cervical carcinoma. Eur J Nucl Med Mol Imaging 2010; 37:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/8\">",
"      van der Veldt AA, Buist MR, van Baal MW, et al. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET. J Nucl Med 2008; 49:1936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/9\">",
"      Lim MC, Lee HS, Seo SS, et al. Pathologic diagnosis and resection of suspicious thoracic metastases in patients with cervical cancer through thoracotomy or video-assisted thoracic surgery. Gynecol Oncol 2010; 116:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/10\">",
"      Friedlander M, Grogan M, U.S. Preventative Services Task Force. Guidelines for the treatment of recurrent and metastatic cervical cancer. Oncologist 2002; 7:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/11\">",
"      Rutledge S, Carey MS, Prichard H, et al. Conservative surgery for recurrent or persistent carcinoma of the cervix following irradiation: is exenteration always necessary? Gynecol Oncol 1994; 52:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/12\">",
"      Maneo A, Landoni F, Cormio G, et al. Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. Int J Gynecol Cancer 1999; 9:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/13\">",
"      Haasbeek CJ, Uitterhoeve AL, van der Velden J, et al. Long-term results of salvage radiotherapy for the treatment of recurrent cervical carcinoma after prior surgery. Radiother Oncol 2008; 89:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/14\">",
"      Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010; 116:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/15\">",
"      Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J Clin Oncol 2007; 25:2966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/16\">",
"      Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer 2009; 115:3166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/17\">",
"      Gadducci A, Tana R, Cosio S, Cionini L. Treatment options in recurrent cervical cancer (Review). Oncol Lett 2010; 1:3.",
"     </a>",
"    </li>",
"    <li>",
"     NCI Press Release: Bevacizumab significantly improves survival for patients with recurrent and metastatic cervical cancer. file://cancer.gov/newscenter/newsfromnci/2013/GOG240 (Accessed on February 19, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/19\">",
"      Symonds RP, Davidson SE, Chan S, et al. SCOTCERV: a phase II trial of docetaxel and gemcitabine as second line chemotherapy in cervical cancer. Gynecol Oncol 2011; 123:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/20\">",
"      Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27:4649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/21\">",
"      Kitagawa R, Katsumata N, Shibata T, et al. A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505). J Clin Oncol 2012; 30:Abstr 5006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/22\">",
"      Scatchard K, Forrest JL, Flubacher M, et al. Chemotherapy for metastatic and recurrent cervical cancer. Cochrane Database Syst Rev 2012; 10:CD006469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/23\">",
"      Weiss GR, Green S, Hannigan EV, et al. A phase II trial of carboplatin for recurrent or metastatic squamous carcinoma of the uterine cervix: a Southwest Oncology Group study. Gynecol Oncol 1990; 39:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/24\">",
"      Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: A gynecologic oncology group study. Gynecol Oncol 2012; 127:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/25\">",
"      Morris M, Brader KR, Levenback C, et al. Phase II study of vinorelbine in advanced and recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1998; 16:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/26\">",
"      Lacava JA, Leone BA, Machiavelli M, et al. Vinorelbine as neoadjuvant chemotherapy in advanced cervical carcinoma. J Clin Oncol 1997; 15:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/27\">",
"      Muggia FM, Blessing JA, Method M, et al. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/28\">",
"      McGuire WP, Blessing JA, Moore D, et al. Paclitaxel has moderate activity in squamous cervix cancer. A Gynecologic Oncology Group study. J Clin Oncol 1996; 14:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/29\">",
"      Curtin JP, Blessing JA, Webster KD, et al. Paclitaxel, an active agent in nonsquamous carcinomas of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol 2001; 19:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/30\">",
"      Kudelka AP, Winn R, Edwards CL, et al. An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix. Anticancer Drugs 1997; 8:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/31\">",
"      Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2008; 110:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/32\">",
"      Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group. Ann Oncol 2010; 21:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/33\">",
"      Thigpen T. The role of chemotherapy in the management of carcinoma of the cervix. Cancer J 2003; 9:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/34\">",
"      Sutton GP, Blessing JA, DeMars LR, et al. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996; 63:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/35\">",
"      Bookman MA, Blessing JA, Hanjani P, et al. Topotecan in squamous cell carcinoma of the cervix: A Phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2000; 77:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/36\">",
"      Muderspach LI, Blessing JA, Levenback C, Moore JL Jr. A Phase II study of topotecan in patients with squamous cell carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 2001; 81:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/37\">",
"      Abu-Rustum NR, Lee S, Massad LS. Topotecan for recurrent cervical cancer after platinum-based therapy. Int J Gynecol Cancer 2000; 10:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/38\">",
"      Lhomm&eacute; C, Fumoleau P, Fargeot P, et al. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix. J Clin Oncol 1999; 17:3136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/39\">",
"      Look KY, Blessing JA, Levenback C, et al. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Gynecol Oncol 1998; 70:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/40\">",
"      Spanos W Jr, Guse C, Perez C, et al. Phase II study of multiple daily fractionations in the palliation of advanced pelvic malignancies: preliminary report of RTOG 8502. Int J Radiat Oncol Biol Phys 1989; 17:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/41\">",
"      Onsrud M, Hagen B, Strickert T. 10-Gy single-fraction pelvic irradiation for palliation and life prolongation in patients with cancer of the cervix and corpus uteri. Gynecol Oncol 2001; 82:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/42\">",
"      Halle JS, Rosenman JG, Varia MA, et al. 1000 cGy single dose palliation for advanced carcinoma of the cervix or endometrium. Int J Radiat Oncol Biol Phys 1986; 12:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33368/abstract/43\">",
"      van Lonkhuijzen L, Thomas G. Palliative radiotherapy for cervical carcinoma, a systematic review. Radiother Oncol 2011; 98:287.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3185 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-18C9BB78CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33368=[""].join("\n");
var outline_f32_37_33368=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186822333\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H172229098\">",
"      DIAGNOSTIC EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H104509800\">",
"      MANAGEMENT OF LOCAL RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8642804\">",
"      Candidates for surgical resection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8642880\">",
"      - Surgical procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H343518599\">",
"      Following RT with uterine conservation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H343518606\">",
"      Following hysterectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H343518613\">",
"      Non-surgical options",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8642945\">",
"      - Candidates for radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8642960\">",
"      - Candidates for chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1205655\">",
"      MANAGEMENT OF METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104509153\">",
"      Disease isolated to the lymph nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104508737\">",
"      Limited metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H104509204\">",
"      Metastatic disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2177909474\">",
"      - First-line treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1225233361\">",
"      Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1639880214\">",
"      Alternate use of carboplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H1639879582\">",
"      Combination versus single agent therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85099849\">",
"      - Second-line therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MANAGEMENT OF ACUTELY SYMPTOMATIC PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3185\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3185|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?2/38/2668\" title=\"table 1\">",
"      Histopathology cervical cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31689?source=related_link\">",
"      Exenteration for gynecologic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/42/17064?source=related_link\">",
"      Invasive cervical cancer: Patterns of recurrence and posttreatment surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/50/7976?source=related_link\">",
"      Management of locally advanced cervical cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/58/6057?source=related_link\">",
"      Overview of the clinical manifestations, diagnosis, and management of patients with brain metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/8/33924?source=related_link\">",
"      Radiation therapy for the management of painful bone metastases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/32/13834?source=related_link\">",
"      Surgical resection of pulmonary metastases: Benefits; indications; preoperative evaluation and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/15/13560?source=related_link\">",
"      Surgical resection of pulmonary metastases: Outcomes by histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_37_33369="Operating room safety";
var content_f32_37_33369=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Operating room safety",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Bradford D Winters, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Peter J Pronovost, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Ayse P Gurses, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Hilary Sanfey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33369/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/37/33369/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H10760466\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical and anesthetic safety has improved significantly in the last few decades. Examples of important safety advances include improved surgical techniques, technology for patient monitoring such as pulse oximetry to prevent hypoxemia, and fail-safe systems such as pin-indexing systems for gas cylinders and lines to prevent delivery of hypoxic gas mixtures. Teamwork between anesthesiologists, surgeons, and nurses also improves operating room safety. However, the operating room (OR) environment continues to have significant safety risks for patients as well as the health care providers who work there.",
"   </p>",
"   <p>",
"    This topic focuses on the science of safety principles and efforts to improve safety in the OR. Related quality and safety topics that address the details of informed consent, perioperative medication management, and hospital discharge are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link\">",
"     \"Perioperative medication management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12330?source=see_link\">",
"     \"Hospital discharge\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30334885\">",
"    <span class=\"h1\">",
"     SCIENCE OF SAFETY TOOLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of applying scientific principles to health care practice is to reduce adverse events and improve patient safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19874305\">",
"    <span class=\"h2\">",
"     Systems Engineering Initiative for Patient Safety (SEIPS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;One model of work system design for patient safety is the Systems Engineering Initiative for Patient Safety (SEIPS) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This model is anchored in the discipline of human factors engineering and describes the five major components of a health care system:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tasks",
"     </li>",
"     <li>",
"      Personnel",
"     </li>",
"     <li>",
"      Tools and technologies",
"     </li>",
"     <li>",
"      Physical environment",
"     </li>",
"     <li>",
"      Organization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the Systems Engineering Initiative for Patient Safety model, the interactions of these five components drive the performance of care processes and safety and quality practices that determine patient, staff, and organizational outcomes. When one component of a care system is changed, it can have a positive or negative effect upon the other components, processes, and outcomes of the system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10760474\">",
"    <span class=\"h2\">",
"     Safe system design",
"    </span>",
"    &nbsp;&mdash;&nbsp;The science of safety requires recognition that everyone makes mistakes. Well-designed systems must be in place to prevent mistakes, make them visible, and reduce harm should the mistake occur. As an example, it is important to document allergies to antibiotics before administering prophylactic antibiotics to a surgical patient. A well-designed system for allergy documentation incorporates two drug allergy checks by two different people, independent of each other.",
"   </p>",
"   <p>",
"    Safe system design is based upon three main principles that apply to both technical work and teamwork:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903550\">",
"    <span class=\"h3\">",
"     Standardization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standardization reduces variability, and in turn reduces errors. As an example, all medical gas equipment manufacturers have standardized their equipment with unique connectors for oxygen lines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/29/11732?source=see_link\">",
"     nitrous oxide",
"    </a>",
"    lines. This system adds reliability and safety through standardization and is one of the best safe design examples of technical work in the OR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30336110\">",
"    <span class=\"h3\">",
"     Checklists",
"    </span>",
"    &nbsp;&mdash;&nbsp;A checklist creates independent verification for critical steps in the work process [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of checklists are for the placement and care of central lines and for preoperative briefing. (See",
"    <a class=\"local\" href=\"#H10760516\">",
"     'Central line infection'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H697945\">",
"     'Using a checklist for preoperative briefing'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30336121\">",
"    <span class=\"h3\">",
"     Learning from errors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians often engage in &ldquo;first order&rdquo; problem solving by applying a temporary fix or work-around to solve a pressing clinical problem. While a temporary fix may solve the problem for one patient, clinicians must employ &ldquo;second order&rdquo; problem solving processes in order to reduce harm to future patients. Second order problem solving requires examination and analysis of the event to identify problems and design systems that defend against future harm [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When things go wrong, the following questions should be asked:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      What happened?",
"     </li>",
"     <li>",
"      Why did it happen?",
"     </li>",
"     <li>",
"      What can we do to reduce the risk?",
"     </li>",
"     <li>",
"      How do we prove that we reduced this risk?",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The science of safety is grounded in the understanding that teams make wiser decisions when there is diverse and independent input. This means that input from all team members is considered, including patients, parents, and all clinicians involved in a patient&rsquo;s care. Patients and their families add experiential knowledge, while clinicians offer discipline-specific knowledge.",
"   </p>",
"   <p>",
"    A culture of safety allows all team members to feel comfortable and encouraged to voice their concerns without fear of retribution or criticism, regardless of their position on the team [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10760481\">",
"    <span class=\"h2\">",
"     Comprehensive unit-based safety program (CUSP)",
"    </span>",
"    &nbsp;&mdash;&nbsp;A comprehensive unit-based safety program (CUSP) makes safety and quality a permanent part of a clinical group&rsquo;s mission by fostering active communication, teamwork, and collaboration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/7\">",
"     7",
"    </a>",
"    ]. Because culture varies widely among units within a hospital, CUSP is implemented at the unit or clinical area level with a multidisciplinary team composed of physicians, nurses, administrators, and other staff.",
"   </p>",
"   <p>",
"    CUSP not only identifies problems and works toward solutions, it taps into the wisdom of many people and can be a major force for cultural change that sustains and reinforces patient safety initiatives. This program has been effective in high-risk environments, such as the ICU [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/8\">",
"     8",
"    </a>",
"    ], and is now being widely used in many different clinical areas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/9\">",
"     9",
"    </a>",
"    ], including the OR.",
"   </p>",
"   <p>",
"    A CUSP program involves five components:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903564\">",
"    <span class=\"h3\">",
"     Education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staff is educated on the science of safety.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903591\">",
"    <span class=\"h3\">",
"     Identify hazards",
"    </span>",
"    &nbsp;&mdash;&nbsp;Staff members are asked to identify defects in their clinical area. CUSP encourages staff to proactively ask &ldquo;How will we harm the next patient?&rdquo; This strategy uncovers hazards that are unique to a care area and empowers staff in that area to mitigate them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903599\">",
"    <span class=\"h3\">",
"     Administrative support",
"    </span>",
"    &nbsp;&mdash;&nbsp;A senior executive is partnered with a unit to actively support local efforts. This bridges the division between administrators and frontline staff (nurses, doctors, pharmacists, and others), and provides a mechanism to voice safety concerns directly to hospital administration. Moreover, a senior executive on the local CUSP team ensures there are requisite resources for the work, holds the team accountable for reducing risks, and informs senior leadership of safety hazards to patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903606\">",
"    <span class=\"h3\">",
"     Regular meetings",
"    </span>",
"    &nbsp;&mdash;&nbsp;CUSP teams meet regularly to review safety issues, investigate and identify defects, and design safer systems of care. To be effective, defects are prioritized to determine which ones will have the greatest impact on safety and quality and be the most feasible to implement. As part of this process, factors contributing to and mitigating defects are analyzed and rated for their importance. A one-page summary report from this learning from defect process is generated and shared broadly throughout the organization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30336166\">",
"    <span class=\"h3\">",
"     Implementation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tools such as briefings and debriefings are implemented to facilitate communication and teamwork and establish a culture of safety in the operating room [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. While operating room briefing formats vary, the essential components include an introduction of names and roles, a review of key checklist items (eg, giving antibiotics), any safety concerns of team members, and a contingency plan for risks during the operation. Another useful tool is shadowing, in which one type of clinician (eg, resident) follows another (eg, nurse) for several hours, then discusses how they will work differently now that they have walked in another&rsquo;s professional shoes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30335848\">",
"    <span class=\"h1\">",
"     TEAMWORK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Team training is a useful method of improving communication. As an example, a teamwork training program, TeamSTEPPS (Team Strategies and Tools to Enhance Performance and Patient Safety), has been implemented at many hospitals around the world [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In the United States, the Agency for Healthcare Research and Quality is currently implementing TeamSTEPPS training nationwide (",
"    <a class=\"external\" href=\"file://teamstepps.ahrq.gov/\">",
"     file://teamstepps.ahrq.gov",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    An observational study of TeamSTEPPS training on trauma resuscitation team performance demonstrated meaningful improvement in efficacy of care for patients in a Level 1 trauma center. Compared with pretraining performance (convenience sample of 33 patients), the teams&rsquo; post-training performance (40 patients) showed significant decreases in the time from arrival to the CT scanner (26 to 22 minutes), the time to intubation (10 to 6.6 minutes) and the time to the OR (130 to 94 minutes) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/16\">",
"     16",
"    </a>",
"    ]. Additional information about team training for the care of obstetrical patients is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=see_link&amp;anchor=H2#H2\">",
"     \"Reducing adverse obstetrical outcomes through safety sciences\", section on 'Teamwork training'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698006\">",
"    <span class=\"h1\">",
"     INFORMED SURGICAL CONSENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physicians have a legal and ethical responsibility to provide adequate information to the patient so the patient is able to process the information and make appropriate decisions. The five components of informed consent according to the Systems Engineering Initiative for Patient Safety (SEIPS) model are listed here.",
"   </p>",
"   <p>",
"    Review of the surgical consent before surgery is a critical part of the preoperative briefing because it entails re-identification of the patient identity, confirmation of, the surgery or procedure to be performed, and the site, side or level of the planned procedure. (See",
"    <a class=\"local\" href=\"#H697945\">",
"     'Using a checklist for preoperative briefing'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The details of obtaining proper informed consent are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43094?source=see_link\">",
"     \"Informed consent\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Task",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The task of securing an informed consent from the patient must be done before any invasive procedures are started or any blood or blood products administered.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; The surgeon or surgical resident performing the procedure should carry out this task, which involves more than just getting a patient&rsquo;s signature. It involves explaining the risks, benefits, and alternatives to the procedure using language that is clearly understood by the patient, so that he or she can make an &ldquo;informed&rdquo; decision before signing and giving consent.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Tools such as fully vetted consent forms that use clear and unambiguous language could ensure a true informed patient consent. Informed consent has medico-legal and ethical ramifications. In addition, this document is equally important for the care team because it provides a road map of actions the patient expects, assuming that the patient understands the risks, benefits, and alternatives.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      The environment may adversely affect this process. Sometimes informed consent is performed immediately before surgery in a public area (eg, outside the OR), in which the surrounding distractions may coerce a patient to consent without fully comprehending the information described. Unfortunately, the anesthesiologist&rsquo;s and sometimes the surgeon&rsquo;s initial introduction to the patient often happens shortly before going to the OR.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      An organizational culture that clearly understands the informed consent process, the value this document brings to the care team, and the protection it provides for the patient, will ensure that this task achieves its goal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697945\">",
"    <span class=\"h1\">",
"     USING A CHECKLIST FOR PREOPERATIVE BRIEFING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A preoperative briefing should be performed with the entire OR team including the surgeon, anesthesiologist, circulating nurse, and scrub technician. Briefings standardize teamwork, can lower staff anxiety over the unknown, and improve organizational culture. The briefing process anticipates risks, which helps staff perform better and recover from a situation should it occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incorporation of a checklist, as shown in the table, helps ensure safety measures are followed, which is associated with decreases in morbidity and mortality (",
"    <a class=\"graphic graphic_table graphicRef52392 \" href=\"mobipreview.htm?42/19/43325\">",
"     table 1",
"    </a>",
"    ). &nbsp;An observational study of a 19 item surgical safety checklist in 1750 patients undergoing urgent surgery showed a significant decrease in death rates (1.4 versus 3.7 percent) and complication rates (11.7 versus 18.4 percent) after implementation of the checklist [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/4\">",
"     4",
"    </a>",
"    ]. In addition, implementation of the checklist significantly increased adherence to six selected safety measures from 18.6 to 50.7 percent (",
"    <a class=\"graphic graphic_figure graphicRef66168 \" href=\"mobipreview.htm?30/11/30910\">",
"     figure 1",
"    </a>",
"    ). The use of such a checklist has been adopted by the World Health Organization (WHO). More information is available at the WHO site Safe Surgery Saves Lives:",
"    <a class=\"external\" href=\"file://www.who.int/patientsafety/safesurgery/en/index.html\">",
"     www.who.int/patientsafety/safesurgery/en/index.html",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    The preoperative briefing is standardized and should include the following elements:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Team introductions and roles.",
"     </li>",
"     <li>",
"      Re-identification of the patient identity and consent, the surgery or procedure to be performed, and the site, side or level as indicated (",
"      <a class=\"graphic graphic_table graphicRef59666 \" href=\"mobipreview.htm?39/28/40395\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Identification of the patient&rsquo;s medical status (",
"      <a class=\"graphic graphic_table graphicRef78084 \" href=\"mobipreview.htm?9/5/9307\">",
"       table 3",
"      </a>",
"      ) and recent",
"      <span class=\"nowrap\">",
"       laboratory/radiology",
"      </span>",
"      results, with a management plan for glycemic control and appropriateness of beta blockers during surgery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H19#H19\">",
"       \"Perioperative medication management\", section on 'Diabetic medications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=see_link&amp;anchor=H4#H4\">",
"       \"Perioperative medication management\", section on 'Beta blockers'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Antibiotic",
"      <span class=\"nowrap\">",
"       administration/re-dosing",
"      </span>",
"      needs. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H11#H11\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Repeat dosing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Deep venous thrombosis prophylaxis (",
"      <a class=\"graphic graphic_table graphicRef50947 \" href=\"mobipreview.htm?34/54/35693\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=see_link\">",
"       \"Prevention of venous thromboembolic disease in surgical patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patient positioning, padding, and skin preparation.",
"     </li>",
"     <li>",
"      Equipment, instrument, or implant concerns. The team should verify that the necessary equipment is present and working.",
"     </li>",
"     <li>",
"      Appropriate monitoring strategies.",
"     </li>",
"     <li>",
"      Goals and critical steps of the procedure, with contingency plans.",
"     </li>",
"     <li>",
"      Blood product availability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=see_link\">",
"       \"Use of blood products in the critically ill\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Identification of likely pathology specimens.",
"     </li>",
"     <li>",
"      Post-operative disposition (post anesthesia care unit versus intensive care unit).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698033\">",
"    <span class=\"h1\">",
"     CORRECT PATIENT, SITE, AND PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Practicing safe, high-quality OR care begins with accurately identifying the patient, surgical site, and procedure (",
"    <a class=\"graphic graphic_table graphicRef59666 \" href=\"mobipreview.htm?39/28/40395\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/18-20\">",
"     18-20",
"    </a>",
"    ]. The United States Joint Commission sentinel event statistics database reported that wrong site surgery was the most frequently reported serious adverse event from 1995 to 2010, accounting for 666 of 4850 sentinel events (13.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/21\">",
"     21",
"    </a>",
"    ]. However, reporting of sentinel events to the Joint Commission is voluntary and may represent only a portion of actual events. A systematic review found that the rate of wrong site surgery varied from 0.09 to 4.5 per 10,000 surgeries performed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/19\">",
"     19",
"    </a>",
"    ]. Factors that contribute to wrong site surgery include incorrect patient positioning, poor communication, incorrect or lack of patient consent, failure to use site markings, surgeon fatigue, multiple surgeons, multiple procedures on same patient, unusual time pressures, emergent operations, and unusual patient anatomy.",
"   </p>",
"   <p>",
"    The five components of verifying the correct patient, site, and procedure according to the Systems Engineering Initiative for Patient Safety model are listed here.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tasks",
"      </strong>",
"      &ndash; Accurate identification of the patient, surgical site, and procedure. In cases where an anesthesia block precedes the surgical intervention, the identification of the surgical site and procedure must be done by both the anesthesia team and the surgical team.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      &ldquo;Dual identifiers&rdquo; or two different providers (usually a nurse and physician) must independently confirm they have the correct patient, site, and procedure. To be effective, however, the checks must be truly independent. Two clinicians verifying identifiers or other information together is not an independent check because individuals commonly encode each other&rsquo;s errors.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; Hospitals typically use technical tools such as plastic wrist bands or stamp cards to identify patients, but these may be accidentally removed or lost. The most common method of identifying the correct operative site is to mark it with an indelible marker or dye when the correct patient is being verified. If the site is not marked at that time, it should be done using the independent check process to ensure the correct site is marked.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash;",
"      <strong>",
"      </strong>",
"      Sometimes, the physical environment obscures the wristband (eg, arms tucked under the patient on the OR table). In this setting, a second band could be placed on a more visible part of the body.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; An organizational culture that supports independent checks will reduce errors. The correct procedure is confirmed in the OR at the start of a briefing or &ldquo;time-out&rdquo; by asking the patient what he or she is expecting to have done.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697912\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a significant risk for surgical site and central line associated infections associated with the operating room.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10760509\">",
"    <span class=\"h2\">",
"     Surgical site infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical site infections (SSI) are common complications of operating room procedures. SSIs are more common in contaminated or dirty wounds than in clean or clean-contaminated wounds. Other risk factors such as diabetes, obesity, and smoking also contribute to SSIs. Risk factors for SSIs have been combined into a predictive model called the National Healthcare Safety Network risk index. Wound classification and other risk factors for SSI are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=see_link\">",
"     \"Epidemiology and pathogenesis of and risk factors for surgical site infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    On average, an SSI doubles the cost of a patient&rsquo;s healthcare, mainly by increasing the length of the patient&rsquo;s hospital stay [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/22\">",
"     22",
"    </a>",
"    ]. Several interventions such as appropriate antibiotic prophylaxis and maintenance of normothermia can reduce the risk of an SSI [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/23\">",
"     23",
"    </a>",
"    ]. The five components of preventing surgical site infection according to the Systems Engineering Initiative for Patient Safety model are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tasks",
"      </strong>",
"      &ndash; Antibiotic prophylaxis is a recommended preoperative practice, and appropriate antibiotics and timing of administration for different surgical procedures are described in evidence-based guidelines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/24\">",
"       24",
"      </a>",
"      ]. This task involves administering the first dose at least 10 minutes, but less than 60 minutes, before incision to obtain adequate tissue levels of antibiotics (",
"      <a class=\"graphic graphic_table graphicRef79097 \" href=\"mobipreview.htm?22/46/23275\">",
"       table 5",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Avoiding hypothermia reduces SSI rates [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. In addition, impaired thermoregulation can affect drug metabolism and impair platelet function. The importance of maintaining normothermia during recovery has led to the mandate from the Joint Commission and the Surgical Care Improvement Project (SCIP) to warm patients to 36&deg;C within fifteen minutes of their arrival in the post-anesthesia care unit (PACU) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/27\">",
"       27",
"      </a>",
"      ]. Warming in the operating room and the PACU can be achieved using circulating water garments or forced air warming devices [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/28\">",
"       28",
"      </a>",
"      ]. &nbsp;",
"      <br/>",
"      <br/>",
"      Although elevating the temperature of the operating room can reduce the temperature gradient and reduce heat loss from the patient, there is no standard target thermostat setting in the operating room. The temperature of pediatric operating rooms is usually maintained at a higher setting compared with operating rooms for adult surgery, since children can lose heat faster due to the larger surface-to-volume ratio in children. However, the need to maintain normothermia in the patient must be balanced by the ability of operating room personnel to function given that heavy impervious surgical gowns may result in profuse sweating that can lead to dehydration or inadvertent wound contamination.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; The anesthesiologist is responsible for administering the antibiotics and managing normothermia. However, these tasks require effective communication among team members. For maintaining normothermia, the anesthesiologist should balance the need to maintain normothermia in the patient with the comfort of the operating room staff. Modern forced-air systems to warm the patient allow for this balance to be maintained fairly easily.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; Preprinted schedules help to ensure repeated dosing of antibiotics when necessary. Warming blankets and fluid and blood warming devices should be readily available. Modern forced warm air devices are very effective at maintaining the patient's temperature while allowing the operating room team to maintain a comfortable working environment.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; The OR environment, including cold OR tables, cold air convection currents in the theater, and cold intravenous fluids,",
"      <strong>",
"      </strong>",
"      increases a patient&rsquo;s risk of hypothermia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33834?source=see_link&amp;anchor=H1324457038#H1324457038\">",
"       \"Overview of complications occurring in the post-anesthesia care unit\", section on 'Hypothermia or hyperthermia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; The organization must support the",
"      <strong>",
"      </strong>",
"      teamwork necessary for the",
"      <strong>",
"      </strong>",
"      timely administration of antibiotics and maintenance of normothermia as well as providing the appropriate tools and technologies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10760516\">",
"    <span class=\"h2\">",
"     Central line infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central lines are often placed in the OR and are a potential source of postoperative infection. The five components of preventing central line infections according to the Systems Engineering Initiative for Patient Safety model are listed here. The prevention of central line infections is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H30#H30\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Catheter teams and use of checklist'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Tasks",
"      </strong>",
"      &ndash; There is clear evidence demonstrating that most central line-associated infections are preventable if the following checklist is used to ensure that these behaviors are completed (",
"      <a class=\"graphic graphic_table graphicRef75251 \" href=\"mobipreview.htm?32/35/33340\">",
"       table 6",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Wash hands prior to the procedure",
"     </li>",
"     <li>",
"      Use full barrier protection (sterile gowns, glove, hats, and full body drapes)",
"     </li>",
"     <li>",
"      Use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      to prepare the skin site",
"     </li>",
"     <li>",
"      Avoid use of the femoral site for central line placement",
"     </li>",
"     <li>",
"      Remove catheters when no longer indicated",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; The anesthesiologist inserting the central line in the OR must adhere to the behaviors on the checklist.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; A central line insertion checklist should be used as a guide.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; The anesthesiologist must be provided with the appropriate equipment, enough space and time to insert central lines safely and appropriately.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; Effective teamwork and an organizational culture that supports infection reduction are both vital. The OR staff should be empowered to alert the anesthesiologist or surgeon if they forget to wash their hands or if a guidewire accidentally touches the anesthesia circuit and becomes contaminated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39731065\">",
"    <span class=\"h1\">",
"     NEEDLESTICK INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Needlestick injuries and injuries from other sharp objects are common throughout the hospital setting and are a constant risk in the operating room. Although the incidence of needlestick injuries has been reduced by advances in education, needle disposal, engineering changes (eg, needleless devices, safety needles) and worker protection, institutions and healthcare professionals must continue to assume responsibility in further lowering the risk.",
"   </p>",
"   <p>",
"    The epidemiology of bloodborne exposures in healthcare workers, United States Occupational Safety and Health Administration (OSHA) requirements regarding infection control procedures and training, the management of potential exposure to bloodborne pathogens including human immunodeficiency virus (HIV-1), hepatitis B virus (HBV) and hepatitis C virus (HCV) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7930?source=see_link\">",
"     \"Management of healthcare personnel exposed to HIV\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23416?source=see_link\">",
"     \"Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/31/18931?source=see_link\">",
"     \"Patient information: Blood or body fluid exposure (The Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10760523\">",
"    <span class=\"h1\">",
"     ANESTHESIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Improvements in the safety of anesthesia administration have decreased the incidence of perioperative myocardial infarction, neurological injuries, and mortality. Much of this improvement is attributed to better medications, equipment, and monitoring tools and other technology.",
"   </p>",
"   <p>",
"    International standards for the safe practice of anesthesia have been established by the World Health Organization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These comprehensive standards detail recommendations for training and accreditation, record keeping, equipment, patient evaluation, intraoperative monitoring and postoperative care. The five components of safe anesthesia administration according to the Systems Engineering Initiative for Patient Safety model are listed here. The details of anesthesia administration and management of anesthetic complications are discussed elsewhere. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=see_link\">",
"     \"Overview of anesthesia and anesthetic choices\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33834?source=see_link\">",
"     \"Overview of complications occurring in the post-anesthesia care unit\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Task",
"      </strong>",
"      &ndash; Safe administration of anesthesia in accordance with international standards of care.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; Anesthesiologist, nurse anesthetist, anesthesia assistants.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; Monitoring tools such as pulse oximetry and capnography are widely credited with improved OR safety. Improved monitoring provides early warning of adverse events and allows prevention of patient harm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Pulse oximetry monitors the blood for adequate oxygen delivery. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9736?source=see_link\">",
"       \"Pulse oximetry\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Capnography shows whether alveolar ventilation is established, which reduces the chance of an unrecognized esophageal intubation. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=see_link\">",
"       \"Carbon dioxide monitoring (capnography)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; Adequate and appropriate equipment and facilities, should be present wherever anesthesia and recovery is provided. Anesthesia equipment should conform to relevant national and international standards [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; The organization must support the",
"      <strong>",
"      </strong>",
"      anesthesiologists and the anesthesia care team, by providing proper equipment and a culture of teamwork within the anesthesia team as well as with the surgeons and nursing staff.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697964\">",
"    <span class=\"h1\">",
"     PROTECTING PATIENTS FROM INJURY IN THE OR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients must be transferred and positioned properly in the OR. In addition, patients and OR personnel must be protected from electrical, thermal, or radiologic injury in the OR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H480550\">",
"    <span class=\"h2\">",
"     Proper positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proper positioning of the patient is required to avoid pressure sores, nerve compression, deep vein thrombosis, and compartment syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=see_link\">",
"     \"Prevention of pressure ulcers\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=see_link\">",
"     \"Nerve injury associated with pelvic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=see_link&amp;anchor=H25#H25\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Surgery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=see_link\">",
"     \"Acute compartment syndrome of the extremities\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Task",
"      </strong>",
"      &ndash; Prevent injury to patients by providing proper positioning during surgery.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; Nursing staff, surgeons, and anesthesia personnel must work together to ensure proper positioning of patients for surgery.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; Equipment to prevent injury such as gel pad, pillows, or axillary or chest rolls must be available.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; The correct OR table with appropriate attachments should be available and in good working order. Moving the patient should be done in a coordinated fashion and sliding boards or roll boards should be used for patients who cannot move themselves. Restraints should be secure but",
"      <strong>",
"       not",
"      </strong>",
"      too tight and should",
"      <strong>",
"       not",
"      </strong>",
"      be placed over superficial nerves or bony prominences.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; The OR staff must be educated about the correct equipment and procedures to optimize patient positioning and avoid injuries during surgery.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20903643\">",
"    <span class=\"h2\">",
"     Electrical injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrical injury can lead to muscle contraction, respiratory paralysis, seizures, or lead to ventricular fibrillation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/36\">",
"     36",
"    </a>",
"    ]. Electricity also dissipates energy throughout the tissues and increases the temperature of the tissue, which can produce burns or cause cellular death. Grounding of power supplies is necessary to prevent electrical injury. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=see_link\">",
"     \"Environmental electrical injuries\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An ungrounded or &ldquo;floating&rdquo; power supply must be monitored with a line isolation monitor (LIM). A LIM monitors the integrity of a power supply and alarms when it is not grounded properly. The five components of preventing electrical injury in the operating room according to the Systems Engineering Initiative for Patient Safety model are listed here.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Task",
"      </strong>",
"      &ndash; Prevent electrical injury to patients and personnel in the operating room by using a LIM.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; All OR personnel are responsible for knowing how the LIM works and what to do if the alarm sounds.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies &ndash;",
"      </strong>",
"      A line isolation monitor (LIM) should be used to quickly recognize and prevent an electrical injury.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; The OR is purposefully isolated from the ground unit and the OR equipment is ungrounded to add protection against an electrical shock. With this configuration, two faults must exist before a patient is shocked. If one fault occurs, the electrical current can leak to the ground, thereby removing one layer of protection. Thus, the LIM monitors the flow of electricity from the OR to the ground and sounds an alarm when it detects a leak.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; The team must quickly work together to unplug the most recently connected equipment and work backwards until the alarm terminates, then remove that item for inspection by Clinical Engineering.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697755\">",
"    <span class=\"h2\">",
"     Thermal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 100 OR fires occur per year in the United States, resulting in 1 to 2 deaths per year though the numbers may be higher due to under-reporting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/37\">",
"     37",
"    </a>",
"    ]. Skin preparation and antiseptic solutions and anesthetic gases can cause fires in the OR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/34\">",
"     34",
"    </a>",
"    ]. Most surgical fires occur in the airway (34 percent) and head or face (28 percent). An oxygen enriched environment is a contributing factor in most (74 percent) surgical fires. The five components of preventing thermal injury in the operating room according to the Systems Engineering Initiative for Patient Safety model are listed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=see_link\">",
"     \"Classification of burns\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=see_link\">",
"     \"Emergency care of moderate and severe thermal burns in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Task",
"      </strong>",
"      &ndash; Prevent thermal injury to patients and staff in the operating room.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; All OR personnel are responsible for preventing a fire.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; Water based skin preparations exist but are less commonly used because they take up to 15 minutes to dry and must be fully dry to be effective. The faster drying alcohol based preparations, take only 3 minutes to dry on bare skin. However, if applied to hair bearing areas, alcohol based skin preparations may take as much as 1 hour to dry, resulting in a prolonged period of flammability. Thus alcohol based skin preparations should be avoided for hair bearing areas and when an oxygen-enriched environment is required, as in head and neck surgery. Briefings and checklists can define whether adequate drying time has occurred.",
"      <br/>",
"      <br/>",
"      The oxygen should be set at a safe minimum (usually 30 percent FIO2), and fire retardant technologies should be used if possible. As an example, endotracheal tubes made of less flammable materials or metal reduce the risk of fire during an airway surgery and should be considered in high risk cases. Briefings and checklists can define whether it is appropriate to minimize oxygen, ensure appropriate equipment is used, and define the risk environment for the case.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; Thermal injury from an OR fire is always a concern when local concentrations of oxygen are high, when flammable materials and gases are used, and when ignition source (eg, cautery) are used. For cases where flammable gastrointestinal gases may cause a hazard, use of cautery should be avoided [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/34\">",
"       34",
"      </a>",
"      ]. For example, to avoid an explosion during gastrointestinal surgery, the bowel opening should be made with a scissors or scalpel. Once the gas is released, it will be safe to use cautery to extend the incision.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; The organization must educate staff and establish policies to prevent thermal injuries or mitigate harm in case of fire. Simulation exercises can effectively prepare personnel to control a fire, protect the patient, and reduce the panic that OR fires can engender should they occur despite robust prevention strategies. Fire suppression systems must also be in place but sprinklers can contaminate the surgical field and halon-type systems are not feasible with personnel in the room.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697762\">",
"    <span class=\"h2\">",
"     Radiation injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation injury is rarely immediate like a burn or shock and because of this is often under-rated. In fact, this adverse outcome most often manifests after long periods of time. Even very low levels of radiation exposure have stochastic (random) biologic effects that are cumulative and permanent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/38-40\">",
"     38-40",
"    </a>",
"    ]. The probability of radiation injury increases with increasing cumulative exposure to radiation. The five components of preventing radiation injury in the OR according to the Systems Engineering Initiative for Patient Safety model are listed here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=see_link\">",
"     \"Biology and clinical features of radiation injury in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Task",
"      </strong>",
"      &ndash; Prevent radiation injury to patients and personnel in the OR.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; Staff must adhere to the principles of keeping the radiation dose as low as reasonably allowable, minimizing radiation exposure, and meeting regulatory guidelines.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; Radiation barriers should be provided for all OR personnel. In addition, OR personnel should wear radiation dosimeters (tools) to track exposures.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; The U.S. Regulatory Commission limits a person&rsquo;s radiation exposure to 5000",
"      <span class=\"nowrap\">",
"       mrems/year,",
"      </span>",
"      and the Centers for Disease Control and Prevention limits fetal exposures to 500 mrems during an entire pregnancy. To ensure guidelines are met, the United States Health and Human Services&rsquo; Office of Health and Safety investigates radiation doses that exceed 125 mrems to the whole body or &gt;1875 mrems to the extremities in a given quarter year. Moreover, corrective action is required if radiation exposures exceed &gt;375",
"      <span class=\"nowrap\">",
"       mrem/quarter",
"      </span>",
"      to the whole body or &gt;5625",
"      <span class=\"nowrap\">",
"       mrem/quarter",
"      </span>",
"      to the extremities.",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; Minimizing or preventing exposure relies heavily upon education, teamwork, and an organizational culture that consistently uses radiation barriers and dosimeters.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H698070\">",
"    <span class=\"h1\">",
"     CONNECTION ERRORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Connection errors or misconnections and wrong infusions are infusions of the wrong medication or gas into the wrong place [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/41\">",
"     41",
"    </a>",
"    ]. For example, intravenous medications have been injected into the epidural space and gas has been infused into the bloodstream. This is a result of Luer-lock fittings, connectors and locks that make different brands of tubing compatible. While Luer-locks are convenient and crease a microbiologically closed system [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/42\">",
"     42",
"    </a>",
"    ], they can contribute to inadvertent connection errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No amount of vigilance or local safety culture can prevent all medication errors or connection errors. However, education about Luer-lock misconnections along with increasing standardization in the types of infusion devices, the drug names, concentrations and dosing limits can decrease errors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Task",
"      </strong>",
"      &ndash; Ensure proper infusion of medications and gases.",
"     </li>",
"     <li>",
"      <strong>",
"       Personnel",
"      </strong>",
"      &ndash; Anesthesia and nursing staff.",
"     </li>",
"     <li>",
"      <strong>",
"       Tools and technologies",
"      </strong>",
"      &ndash; The tasks of preparing, labeling, administering, documenting, and disposing of drugs should be streamlined to help OR personnel avoid errors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/44\">",
"       44",
"      </a>",
"      ]. Rapid and reliable access to drugs, supplies and equipment should be provided. Intravenous drugs should be provided in clearly identified, ready to administer packaging at the point of care. Infusion devices and drug choices should be limited and standardized.",
"     </li>",
"     <li>",
"      <strong>",
"       Physical environment",
"      </strong>",
"      &ndash; The dynamics in the OR environment place tremendous stress on its staff, making mistakes inevitable [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/45\">",
"       45",
"      </a>",
"      ]. Distractions, fatigue, multi-tasking, and time pressures deplete a person&rsquo;s ability to remain vigilant and consistently defend against poorly-designed systems that can lead to mistakes. An observational study of stressors in the OR demonstrated that technical problems, patient and equipment problems, and teamwork problems were the most stressful factors for surgeons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Organization",
"      </strong>",
"      &ndash; Minimizing medication errors and connection errors requires a multidisciplinary approach and organizational support for standardization of infusion devices and drug choices. The Joint Commission has issued recommendations to reduce tubing misconnection errors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697785\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE DEBRIEFING",
"    </span>",
"    &nbsp;&mdash;&nbsp;A postoperative debriefing is used to identify and learn from",
"    <span class=\"nowrap\">",
"     mistakes/defects",
"    </span>",
"    that occurred during the procedure with the purpose of improving care and preventing the next patient from being harmed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33369/abstract/47\">",
"     47",
"    </a>",
"    ]. While it is relatively easy to identify hazards in debriefings, it is more difficult to ensure the risks are reduced.",
"   </p>",
"   <p>",
"    It is essential that the OR team creates an organizational system and process to collect issues identified in debriefings, prioritize them, and implement interventions to reduce these risks. The debriefing checklist should include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ensure all paperwork is properly labeled with the patient&rsquo;s name and medical record number.",
"     </li>",
"     <li>",
"      Complete specimen forms for pathology.",
"     </li>",
"     <li>",
"      Did any equipment problems occur that need to be investigated?",
"     </li>",
"     <li>",
"      What could we have done to make the procedure safer or more efficient?",
"     </li>",
"     <li>",
"      Discuss the transition of the patient from the OR to the post-operative care unit (PACU) or the intensive care unit (ICU), in terms of fluid management, antibiotics,",
"      <span class=\"nowrap\">",
"       tests/x-rays,",
"      </span>",
"      pain control, medications, blood glucose control, and ongoing DVT prophylaxis. Instructions for patients going home on the day of surgery should be provided. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12330?source=see_link&amp;anchor=H12#H12\">",
"       \"Hospital discharge\", section on 'Patient instructions'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H697905\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The operating room (OR) poses significant safety risks to patients as well as the health care providers who work there. &nbsp;(See",
"      <a class=\"local\" href=\"#H10760466\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Systems Engineering Initiative for Patient Safety model describes the five major components of a health care as tasks, personnel, tools and technologies, physical environment and organization. The interactions of these five components drive the performance of care processes and safety and quality practices that determine patient, staff, and organizational outcomes. (See",
"      <a class=\"local\" href=\"#H19874305\">",
"       'Systems Engineering Initiative for Patient Safety (SEIPS)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patient safety can be improved by bringing scientific principles to health care practice. Safe system design is built upon the principles of standardization, checklists, and learning from errors. (See",
"      <a class=\"local\" href=\"#H10760474\">",
"       'Safe system design'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A comprehensive unit-based safety program (CUSP) makes safety and quality a permanent part of a clinical group&rsquo;s mission by fostering active communication, teamwork, and collaboration. A CUSP program involves education, identification of hazards, administrative support, regular meetings and implementation. (See",
"      <a class=\"local\" href=\"#H10760481\">",
"       'Comprehensive unit-based safety program (CUSP)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physicians have a legal and ethical responsibility to provide adequate information to the patient so the patient is able to process the information and make appropriate decisions. (See",
"      <a class=\"local\" href=\"#H698006\">",
"       'Informed surgical consent'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43094?source=see_link\">",
"       \"Informed consent\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend that a preoperative briefing with a checklist be performed with the entire OR team including the surgeon, anesthesiologist, circulating nurse, and scrub technician before proceeding with surgery (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H697945\">",
"       'Using a checklist for preoperative briefing'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend using dual identifiers to identify the patient, surgical site, and procedure before proceeding with surgery (",
"      <a class=\"graphic graphic_table graphicRef59666 \" href=\"mobipreview.htm?39/28/40395\">",
"       table 2",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H698033\">",
"       'Correct patient, site, and procedure'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is a significant risk for surgical site and central line associated infections associated with the operating room. (See",
"      <a class=\"local\" href=\"#H697912\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Surgical site infection rates are reduced with appropriate antibiotic prophylaxis and maintenance of normothermia. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=see_link&amp;anchor=H10#H10\">",
"       \"Overview of control measures to prevent surgical site infection\", section on 'Timing of prophylaxis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=see_link\">",
"       \"Controversies in control measures to prevent surgical site infection\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Central line infection rates can be reduced with handwashing, full barrier protection, proper skin preparation, avoidance of the femoral site, and removal of catheters when they are no longer indicated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link\">",
"       \"Prevention of intravascular catheter-related infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients must be transferred and positioned properly in the OR. &nbsp;In addition, patients and OR personnel must be protected from electrical, thermal, or radiologic injury in the OR. (See",
"      <a class=\"local\" href=\"#H697964\">",
"       'Protecting patients from injury in the OR'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      A line isolation monitor (LIM) should be used to ensure quick recognition and prevention of electrical injury.",
"     </li>",
"     <li>",
"      Alcohol based skin preparations should be avoided for hair bearing areas and when an oxygen-enriched environment is required, as in head and neck surgery.",
"     </li>",
"     <li>",
"      Oxygen should be set at a safe minimum (usually 30 percent FIO2), and fire retardant technologies should be used if possible.",
"     </li>",
"     <li>",
"      Radiation doses should be kept as low as reasonably allowable to minimize radiation exposure and meet regulatory guidelines.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Connection errors and infusions of the wrong medication or gas into the wrong place can be decreased by standardizing the types of infusion devices, the drug names, concentrations and dosing limits. (See",
"      <a class=\"local\" href=\"#H698070\">",
"       'Connection errors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A postoperative debriefing is used to identify and learn from",
"      <span class=\"nowrap\">",
"       mistakes/defects",
"      </span>",
"      that occurred during the procedure with the purpose of improving care and preventing the next patient from being harmed. (See",
"      <a class=\"local\" href=\"#H697785\">",
"       'Postoperative debriefing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/1\">",
"      Carayon P, Schoofs Hundt A, Karsh BT, et al. Work system design for patient safety: the SEIPS model. Qual Saf Health Care 2006; 15 Suppl 1:i50.",
"     </a>",
"    </li>",
"    <li>",
"     Carayon P, Hundt AS, Alvarado CJ, et al. Implementing a Systems Engineering Intervention for Improving Safety in Outpatient Surgeries. In: Advances in Patient Safety: From Research to Implementation, Henriksen K, Battles JB, Marks ES, Lewin DI.  (Eds), Agency for Healthcare Research and Quality (US), Rockville, MD 2005. Vol 3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/3\">",
"      Haynes AB, Weiser TG, Berry WR, et al. Changes in safety attitude and relationship to decreased postoperative morbidity and mortality following implementation of a checklist-based surgical safety intervention. BMJ Qual Saf 2011; 20:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/4\">",
"      Weiser TG, Haynes AB, Dziekan G, et al. Effect of a 19-item surgical safety checklist during urgent operations in a global patient population. Ann Surg 2010; 251:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/5\">",
"      Pronovost PJ, Holzmueller CG, Martinez E, et al. A practical tool to learn from defects in patient care. Jt Comm J Qual Patient Saf 2006; 32:102.",
"     </a>",
"    </li>",
"    <li>",
"     Surowiecki, J. The Wisdom of Crowds: Why the Many are Smarter than the Few and How Collective Wisdom Shapes Business, Economics, Societies and Nations, 1st edition, Random House, New York 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/7\">",
"      Timmel J, Kent PS, Holzmueller CG, et al. Impact of the Comprehensive Unit-based Safety Program (CUSP) on safety culture in a surgical inpatient unit. Jt Comm J Qual Patient Saf 2010; 36:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/8\">",
"      Pronovost, P, Weast, et al. Implementing and validating a comprehensive unit-based safety program. J Pat Saf 2005; 1:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/9\">",
"      Holzmueller CG, Timmel J, Kent PS, et al. Implementing a team-based daily goals sheet in a non-ICU setting. Jt Comm J Qual Patient Saf 2009; 35:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/10\">",
"      Makary MA, Holzmueller CG, Thompson D, et al. Operating room briefings: working on the same page. Jt Comm J Qual Patient Saf 2006; 32:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/11\">",
"      Makary MA, Holzmueller CG, Sexton JB, et al. Operating room debriefings. Jt Comm J Qual Patient Saf 2006; 32:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/12\">",
"      Thompson DA, Holzmueller CG, Lubomski L, Pronovost PJ. View the world through a different lens: shadowing another provider. Jt Comm J Qual Patient Saf 2008; 34:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/13\">",
"      Alonso, A, Baker, DP, Holtzman, A, et al. Reducing medical error in the Military Health System: How can team training help?. Human Resource Management Review 2006; 16:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/14\">",
"      Weaver SJ, Rosen MA, DiazGranados D, et al. Does teamwork improve performance in the operating room? A multilevel evaluation. Jt Comm J Qual Patient Saf 2010; 36:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/15\">",
"      Stead K, Kumar S, Schultz TJ, et al. Teams communicating through STEPPS. Med J Aust 2009; 190:S128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/16\">",
"      Capella J, Smith S, Philp A, et al. Teamwork training improves the clinical care of trauma patients. J Surg Educ 2010; 67:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/17\">",
"      Smith HM, Jacob AK, Segura LG, et al. Simulation education in anesthesia training: a case report of successful resuscitation of bupivacaine-induced cardiac arrest linked to recent simulation training. Anesth Analg 2008; 106:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/18\">",
"      Guglielmi C, Canacari E, Moorman D, et al. Strategies for preventing wrong site, wrong procedure, wrong patient surgery. AORN J 2010; 92:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/19\">",
"      Devine J, Chutkan N, Norvell DC, Dettori JR. Avoiding wrong site surgery: a systematic review. Spine (Phila Pa 1976) 2010; 35:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/20\">",
"      Neily J, Mills PD, Eldridge N, et al. Incorrect surgical procedures within and outside of the operating room. Arch Surg 2009; 144:1028.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.jointcommission.org/sentinel_event_statistics_quarterly/ (Accessed on March 21, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/22\">",
"      Broex EC, van Asselt AD, Bruggeman CA, van Tiel FH. Surgical site infections: how high are the costs? J Hosp Infect 2009; 72:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/23\">",
"      Gagliardi AR, Eskicioglu C, McKenzie M, et al. Identifying opportunities for quality improvement in surgical site infection prevention. Am J Infect Control 2009; 37:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/24\">",
"      Casey AL, Elliott TS. Progress in the prevention of surgical site infection. Curr Opin Infect Dis 2009; 22:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/25\">",
"      Sessler DI. New surgical thermal management guidelines. Lancet 2009; 374:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/26\">",
"      Mauermann WJ, Nemergut EC. The anesthesiologist's role in the prevention of surgical site infections. Anesthesiology 2006; 105:413.",
"     </a>",
"    </li>",
"    <li>",
"     SCIP-Inf-7 www.qualitynet.org (Accessed on March 02, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/28\">",
"      Galv&atilde;o CM, Liang Y, Clark AM. Effectiveness of cutaneous warming systems on temperature control: meta-analysis. J Adv Nurs 2010; 66:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/29\">",
"      Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational study. BMJ 2010; 340:c309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/30\">",
"      Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/31\">",
"      Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med 2004; 32:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/32\">",
"      Merry AF, Cooper JB, Soyannwo O, et al. An iterative process of global quality improvement: the International Standards for a Safe Practice of Anesthesia 2010. Can J Anaesth 2010; 57:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/33\">",
"      Merry AF, Cooper JB, Soyannwo O, et al. International Standards for a Safe Practice of Anesthesia 2010. Can J Anaesth 2010; 57:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/34\">",
"      Nishiyama K, Komori M, Kodaka M, Tomizawa Y. Crisis in the operating room: fires, explosions and electrical accidents. J Artif Organs 2010; 13:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/35\">",
"      Adedeji R, Oragui E, Khan W, Maruthainar N. The importance of correct patient positioning in theatres and implications of mal-positioning. J Perioper Pract 2010; 20:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/36\">",
"      Barker SJ, Doyle DJ. Electrical safety in the operating room: dry versus wet. Anesth Analg 2010; 110:1517.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.jointcommission.org/assets/1/18/SEA_29.PDF (Accessed on April 28, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/38\">",
"      Le Heron J, Padovani R, Smith I, Czarwinski R. Radiation protection of medical staff. Eur J Radiol 2010; 76:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/39\">",
"      Chaffins JA. Radiation protection and procedures in the OR. Radiol Technol 2008; 79:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/40\">",
"      Sheyn DD, Racadio JM, Ying J, et al. Efficacy of a radiation safety education initiative in reducing radiation exposure in the pediatric IR suite. Pediatr Radiol 2008; 38:669.",
"     </a>",
"    </li>",
"    <li>",
"     Joint Commission on Accreditation of Healthcare Organizations, USA. Tubing misconnections-a persistent and potentially deadly occurrence. Sentinel Event Alert, Issue 36, April 3, 2006. www.jointcommission.org/sentinel_event_alert_issue_36_tubing_misconnections&mdash;a_persistent_and_potentially_deadly_occurrence/ (Accessed on August 11, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/42\">",
"      McAfee N, Seidel K, Watkins S, Flynn JT. A continuous quality improvement project to decrease hemodialysis catheter infections in pediatric patients: use of a closed luer-lock access cap. Nephrol Nurs J 2010; 37:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/43\">",
"      Simmons D, Phillips MS, Grissinger M, et al. Error-avoidance recommendations for tubing misconnections when using Luer-tip connectors: a statement by the USP Safe Medication Use Expert Committee. Jt Comm J Qual Patient Saf 2008; 34:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/44\">",
"      Fraind DB, Slagle JM, Tubbesing VA, et al. Reengineering intravenous drug and fluid administration processes in the operating room: step one: task analysis of existing processes. Anesthesiology 2002; 97:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/45\">",
"      Arora S, Hull L, Sevdalis N, et al. Factors compromising safety in surgery: stressful events in the operating room. Am J Surg 2010; 199:60.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.jointcommission.org/assets/1/18/SEA_36.PDF.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33369/abstract/47\">",
"      Papaspyros SC, Javangula KC, Adluri RK, O'Regan DJ. Briefing and debriefing in the cardiac operating room. Analysis of impact on theatre team attitude and patient safety. Interact Cardiovasc Thorac Surg 2010; 10:43.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15077 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-512E5AB897-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33369=[""].join("\n");
var outline_f32_37_33369=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H697905\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10760466\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30334885\">",
"      SCIENCE OF SAFETY TOOLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19874305\">",
"      Systems Engineering Initiative for Patient Safety (SEIPS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10760474\">",
"      Safe system design",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20903550\">",
"      - Standardization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30336110\">",
"      - Checklists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30336121\">",
"      - Learning from errors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10760481\">",
"      Comprehensive unit-based safety program (CUSP)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20903564\">",
"      - Education",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20903591\">",
"      - Identify hazards",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20903599\">",
"      - Administrative support",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20903606\">",
"      - Regular meetings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30336166\">",
"      - Implementation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30335848\">",
"      TEAMWORK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698006\">",
"      INFORMED SURGICAL CONSENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H697945\">",
"      USING A CHECKLIST FOR PREOPERATIVE BRIEFING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698033\">",
"      CORRECT PATIENT, SITE, AND PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H697912\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10760509\">",
"      Surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10760516\">",
"      Central line infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39731065\">",
"      NEEDLESTICK INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10760523\">",
"      ANESTHESIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H697964\">",
"      PROTECTING PATIENTS FROM INJURY IN THE OR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H480550\">",
"      Proper positioning",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20903643\">",
"      Electrical injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H697755\">",
"      Thermal injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H697762\">",
"      Radiation injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H698070\">",
"      CONNECTION ERRORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H697785\">",
"      POSTOPERATIVE DEBRIEFING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H697905\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15077\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15077|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/11/30910\" title=\"figure 1\">",
"      Adherence to safety measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15077|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/19/43325\" title=\"table 1\">",
"      World Health Organization surgical safety checklist",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?39/28/40395\" title=\"table 2\">",
"      JCAHO protocol for surgical timeout",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?9/5/9307\" title=\"table 3\">",
"      ASA physical status scale",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/54/35693\" title=\"table 4\">",
"      Perioperative VTE prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/46/23275\" title=\"table 5\">",
"      Timing of surgical prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/35/33340\" title=\"table 6\">",
"      Line infection prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/57/8090?source=related_link\">",
"      Acute compartment syndrome of the extremities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/0/4106?source=related_link\">",
"      Biology and clinical features of radiation injury in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/18/44328?source=related_link\">",
"      Carbon dioxide monitoring (capnography)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/14/4326?source=related_link\">",
"      Classification of burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17242?source=related_link\">",
"      Emergency care of moderate and severe thermal burns in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4410?source=related_link\">",
"      Environmental electrical injuries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/35/36406?source=related_link\">",
"      Epidemiology and pathogenesis of and risk factors for surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/2/12330?source=related_link\">",
"      Hospital discharge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43094?source=related_link\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/47/7930?source=related_link\">",
"      Management of healthcare personnel exposed to HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/55/23416?source=related_link\">",
"      Management of healthcare workers exposed to hepatitis B virus or hepatitis C virus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/3/3129?source=related_link\">",
"      Nerve injury associated with pelvic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/22/19817?source=related_link\">",
"      Overview of anesthesia and anesthetic choices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/2/33834?source=related_link\">",
"      Overview of complications occurring in the post-anesthesia care unit",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/35/31290?source=related_link\">",
"      Overview of control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?18/31/18931?source=related_link\">",
"      Patient information: Blood or body fluid exposure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/45/40666?source=related_link\">",
"      Perioperative medication management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/1/1049?source=related_link\">",
"      Prevention of pressure ulcers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/32/9736?source=related_link\">",
"      Pulse oximetry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/56/1930?source=related_link\">",
"      Reducing adverse obstetrical outcomes through safety sciences",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/49/793?source=related_link\">",
"      Use of blood products in the critically ill",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_37_33370="Management of locally advanced and borderline resectable exocrine pancreatic cancer";
var content_f32_37_33370=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Management of locally advanced and borderline resectable exocrine pancreatic cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     Harvey Mamon, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?32/37/33370/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?32/37/33370/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 10, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;About 45,220 people develop cancer of the exocrine pancreas each year in the United States, and almost all are expected to die from the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/1\">",
"     1",
"    </a>",
"    ]. The majority of these tumors (85 percent) are adenocarcinomas arising from the ductal epithelium. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=see_link\">",
"     \"Pathology of exocrine pancreatic neoplasms\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgical resection offers the only chance of cure. However, only 15 to 20 percent of patients have resectable disease at diagnosis; approximately 40 percent have metastatic disease, and another 30 to 40 percent have locally advanced unresectable tumors. Typically these patients have tumor adherence or invasion into adjacent structures, particularly the celiac and superior mesenteric vasculature (T4 or stage III disease, (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"mobipreview.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    )). Median survival is 8 to 12 months for patients with locally advanced disease and less for those with metastatic disease at presentation.",
"   </p>",
"   <p>",
"    Optimal treatment for locally advanced unresectable pancreatic cancer is controversial. This topic review will focus on the therapeutic options, which include radiation therapy (RT) alone, chemotherapy alone, and combined chemoradiotherapy with or without surgery. Surgical management of potentially resectable disease, the use of adjuvant chemotherapy and RT, systemic chemotherapy for patients with metastatic disease, and a compilation of chemotherapy regimens used for treatment of pancreatic cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link\">",
"     \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=see_link\">",
"     \"Treatment protocols for pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CRITERIA FOR UNRESECTABILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;An assessment of resectability is usually made based upon a preoperative staging contrast-enhanced computed tomography (CT) scan and less commonly at the time of laparotomy. A variety of other imaging modalities, including MRI, endoscopic ultrasound (EUS), as well as staging laparoscopy, may be needed in some circumstances. This topic is addressed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Consensus-based guidelines from the National Comprehensive Cancer Network define the following characteristics as indicating unresectability [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Head of pancreas lesions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Greater than 180 degrees SMA encasement, any celiac abutment",
"     </li>",
"     <li>",
"      Unreconstructable",
"      <span class=\"nowrap\">",
"       SMV/portal",
"      </span>",
"      vein occlusion",
"     </li>",
"     <li>",
"      Aortic invasion or encasement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Body",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      SMA or celiac encasement greater than 180 degrees",
"     </li>",
"     <li>",
"      Unreconstructable",
"      <span class=\"nowrap\">",
"       SMV/portal",
"      </span>",
"      vein occlusion",
"     </li>",
"     <li>",
"      Aortic invasion",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tail",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      SMA or celiac encasement greater than 180 degrees",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all sites",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Distant metastases",
"     </li>",
"     <li>",
"      Metastases to lymph nodes beyond the field of resection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Borderline resectable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases are considered \"borderline\" resectable, although the definition is variable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H26\">",
"     'Role of surgery and management of borderline resectable disease'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Some reserve the term \"borderline resectable\" for cases where there is focal (less than one-half of the circumference) tumor abutment of the visceral arteries or short-segment occlusion of the SMV or",
"    <span class=\"nowrap\">",
"     SMV/portal",
"    </span>",
"    vein confluence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Others suggest that venous narrowing without occlusion be included in the definition of borderline resectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Encasement (more than one-half of the vessel circumference) or occlusion of the superior mesenteric vein (SMV) or the SMV-portal vein confluence used to be considered a criterion for unresectability. However, many centers have demonstrated the feasibility of SMV reconstruction, and this is now considered by many to represent borderline resectable disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20569101\">",
"    <span class=\"h3\">",
"     Recommendations from expert groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;A consensus statement from a conference sponsored by the American Hepato-Pancreato-Biliary Association, and cosponsored by the Society of Surgical Oncology and the Society for Surgery of the Alimentary tract recommended that tumors considered borderline resectable include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      No distant metastases.",
"     </li>",
"     <li>",
"      Venous involvement of the",
"      <span class=\"nowrap\">",
"       SMV/portal",
"      </span>",
"      vein demonstrating tumor abutment with or without impingement and narrowing of the lumen, encasement of the",
"      <span class=\"nowrap\">",
"       SMV/portal",
"      </span>",
"      vein but without encasement of the nearby arteries, or short segment venous occlusion resulting from either tumor thrombus or encasement, but with suitable vessel proximal and distal to the area of vessel involvement, allowing for safe resection and reconstruction.",
"     </li>",
"     <li>",
"      Gastroduodenal artery encasement up to the hepatic artery with either short segment encasement or direct tumor abutment of the hepatic artery, without extension to the celiac axis.",
"     </li>",
"     <li>",
"      Tumor abutment of the SMA not to exceed &gt;180 degrees of the circumference of the vessel wall.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These criteria have also been adopted as definitions of borderline resectable disease in the consensus-based guidelines of the National Comprehensive Cancer Network (NCCN) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EXTERNAL BEAM RT ALONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Locally advanced pancreatic tumors can usually be encompassed in a conventional external beam RT (EBRT) portal. However, in most settings, EBRT alone does not provide optimal tumor control; local failure rates are as high as 72 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/9\">",
"     9",
"    </a>",
"    ]. These dismal results have spawned efforts to improve outcomes by the concurrent administration of drugs that act as radiation sensitizers, including 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , and most recently,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Radiation as a single modality may be considered in the setting of palliation of pain&nbsp;for a patient who is not considered a candidate for combined chemoradiotherapy due to medical comorbidities and whose pain is not adequately controlled with narcotic analgesics. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H8#H8\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Pain'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CONCOMITANT CHEMORADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;As has been seen in a variety of tumors arising in the gastrointestinal tract, the addition of concurrent chemotherapy to EBRT improves outcomes compared to EBRT alone in patients with locally advanced pancreatic cancer. From the standpoint of symptom palliation, cancer-related pain is diminished in 35 to 65 percent of patients, and cachexia and obstructive symptoms may also improve. However, the survival benefit from chemoradiotherapy relative to EBRT alone is modest, and local control remains problematic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     5-FU-based approaches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have evaluated combined 5-FU and EBRT, which are synergistic in other gastrointestinal malignancies. While the majority have compared chemoradiotherapy to EBRT alone, the control arm in a few studies was supportive care only or chemotherapy alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Early trials versus RT alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two early randomized trials directly comparing EBRT with and without concomitant 5-FU-based chemotherapy came to opposite conclusions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A Gastrointestinal Tumor Study Group (GITSG) trial randomly assigned 106 patients with locally advanced pancreatic adenocarcinoma to EBRT (60 Gy) alone or concurrent EBRT (either 40 or 60 Gy) plus bolus 5-FU [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Enrollment to the EBRT alone arm was discontinued when interim analysis demonstrated clearly superior median time to progression (TTP) and overall survival in both combined modality groups. The one-year survival was 11 percent with EBRT alone, compared with 38 and 36 percent with 40 Gy and 60 Gy EBRT plus 5-FU, respectively. After an additional 88 patients were enrolled in the combined modality arms, there was a trend toward improved survival with 60 Gy EBRT plus 5-FU, but the difference in TTP and overall survival was not statistically significant when compared to the 40 Gy arm.",
"     </li>",
"     <li>",
"      Largely based upon the experience in other gastrointestinal malignancies such as rectal cancer, infusional rather than bolus 5-FU has become the most commonly used approach for radiation sensitization. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=see_link&amp;anchor=H9#H9\">",
"       \"Adjuvant therapy for resected rectal cancer\", section on 'Infusional versus bolus 5-FU'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link\">",
"       \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Infusional 5-FU was used in a trial from the Eastern Cooperative Oncology Group (ECOG) which randomly assigned 114 patients to RT (59.4 Gy) alone or with concurrent infusional 5-FU (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily on days 2 through 5 and 28 to 31) plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      on day 2) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/12\">",
"       12",
"      </a>",
"      ]. In contrast to the GITSG trial, the addition of chemotherapy to RT increased toxicity without providing any benefit in terms of response rate (9 versus 6 percent), median disease-free survival (5 versus 5.1 months) or overall survival (7.1 versus 8.4 months, respectively). The method of 5-FU administration (intermittent high-dose rather than the more contemporary method of continuous infusions of lower doses such as 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily during EBRT) as well as the inclusion of mitomycin C might have contributed to the relatively poor outcomes in the experimental group. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Versus supportive care alone'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A pooled analysis of these two trials concluded that the length of survival with chemoradiotherapy was significantly increased relative to radiotherapy alone (HR for death 0.69, 95% CI 0.51 to 0.94) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Medicare/SEER report",
"    </span>",
"    &nbsp;&mdash;&nbsp;A benefit for chemoradiotherapy as compared to RT alone was further supported by a retrospective but large series of 1700 elderly patients with locally advanced pancreatic cancer derived from a linked",
"    <span class=\"nowrap\">",
"     Medicare/SEER",
"    </span>",
"    database [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/14\">",
"     14",
"    </a>",
"    ]. Forty-four percent of patients received some form of therapy, and the adjusted mean survival durations for patients undergoing chemoradiotherapy, RT alone, chemotherapy alone, and no therapy were 47, 29, 27, and 15 weeks, respectively. Although not derived from a randomized trial, these data support the view that chemoradiotherapy provides benefit over either modality alone and that treatment appears to be better than supportive care.",
"   </p>",
"   <p>",
"    The authors performed a sophisticated statistical analysis using propensity score methods to minimize the impact of selection bias. However, the possibility that patients who are considered good candidates for chemoradiotherapy may survive longer due to other unmeasurable factors can only be excluded in a randomized trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Versus supportive care alone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relatively modest benefits of treatment also raise the question of whether combined chemotherapy and EBRT are better than supportive care alone. In order to address this issue, Japanese investigators conducted a small study in which 31 patients with locally unresectable pancreatic cancer were randomly assigned to EBRT (50.4 Gy in 28 fractions) with concurrent 5-FU or no chemoradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/15\">",
"     15",
"    </a>",
"    ]. Despite the small number of patients, treatment was associated with statistically significant improvements in median survival (13.2 versus 6.4 months), one-year survival (53 versus 0 percent), average monthly Karnofsky score (77.1 versus 65.5), and the number of days spent in the hospital per month of survival (12.3 versus 19.0 days). The treatment arm in this trial reflects the most frequently used method of concurrent 5-FU administration, at least in the United States.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Oral fluoropyrimidines as a substitute for infusional 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, largely based upon the experience in other gastrointestinal malignancies such as rectal cancer, infusional rather than bolus 5-FU has become the most commonly used approach for radiation sensitization. Accumulating data support the view that oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    can safely replace continuous infusional 5-FU as a radiation sensitizer in patients treated for locally advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/16-18\">",
"     16-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon the results of phase III studies comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    versus infusional FU during chemoradiotherapy for rectal cancer, many investigators feel that substituting capecitabine for infusional FU as a radiation sensitizer is reasonable for other gastrointestinal malignancies and that the question is not worthy of phase III studies in each tumor type. In our view, the use of capecitabine as a radiation sensitizer in patients undergoing fluoropyrimidine-based chemoradiotherapy for pancreatic cancer is reasonable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=see_link&amp;anchor=H19#H19\">",
"     \"Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer\", section on 'Oral fluoropyrimidines versus infusional 5-FU'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    S-1 is an oral fluoropyrimidine that includes three different agents: ftorafur, chlorohydroxy dihydropyridine (a potent DPD inhibitor), and oxonic acid (which inhibits phosphorylation of intestinal 5-FU, which is thought responsible for treatment-related diarrhea). S-1 is approved in Japan for adjuvant therapy of gastric cancer and in Europe for treatment of advanced gastric cancer; it is not available in the US.",
"   </p>",
"   <p>",
"    Although fewer data are published with S-1 than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , S-1 also appears to be a safe and effective substitute for infusional FU, where available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Gemcitabine-based chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    has potent radiation sensitizing effects in conjunction with its demonstrated clinical benefit in metastatic pancreatic cancer provided the rationale for investigating its use in patients with locally advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    treatment schedules and doses have been studied, limiting the ability to compare outcomes among published studies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In early reports, the combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      plus EBRT was unexpectedly toxic at relatively low dose levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. This was thought attributable, at least in part, to relatively large RT fields.",
"      <br/>",
"      <br/>",
"      On the basis of these results, the Cancer and Leukemia Group B conducted a phase II trial of low-dose twice weekly gemcitabine (40",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice weekly) plus concurrent RT (50.4 Gy) in 43 patients with locally unresectable nonmetastatic pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/24\">",
"       24",
"      </a>",
"      ]. Treatment was still relatively toxic: grade 3 or 4 hematologic toxicity in 60 percent, grade 3 or 4 gastrointestinal toxicity in 42 percent, and one treatment-related death attributed to sepsis. Although median overall survival was a disappointing 8.2 months, two patients were still alive at 35 and 41 months of posttreatment follow-up.",
"     </li>",
"     <li>",
"      More favorable toxicity profiles have been noted in other phase II trials using higher doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      administered once or twice weekly with more tailored RT fields [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/25-28\">",
"       25-28",
"      </a>",
"      ]. As an example, a prospective phase II study conducted in Italy tested weekly gemcitabine (100",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      over 24 hours) plus concurrent three-dimensional conformal RT (50.4 Gy), followed by five cycles of standard-dose gemcitabine alone in 40 patients with locally advanced pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/28\">",
"       28",
"      </a>",
"      ]. Grade 3 to 4 acute toxicity was observed in 21 (53 percent), but the median survival was 15.5 months, and 25 percent were still alive at two years.",
"     </li>",
"     <li>",
"      An alternative strategy is being pursued by other investigators using standard doses of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (1000",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly) plus small field RT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/29-31\">",
"       29-31",
"      </a>",
"      ]. Early results are encouraging, particularly in the setting of locally advanced but potentially resectable disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link&amp;anchor=H18#H18\">",
"       \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\", section on 'Gemcitabine-based chemoradiotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Gemcitabine versus fluoropyrimidines",
"    </span>",
"    &nbsp;&mdash;&nbsp;These small trials have not addressed which agent (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    versus a fluoropyrimidine) is optimal for use with concurrent RT in patients with locally advanced disease.",
"   </p>",
"   <p>",
"    Three very small randomized trials have directly compared both approaches:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One trial randomly assigned 34 patients with locally advanced disease to chemoradiotherapy with either concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (gemcitabine 600",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for six weeks plus three dimensional conformal EBRT 50.4 to 61.2 Gy) or bolus 5-FU (5-FU 500",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for three days every two weeks for six weeks plus the same EBRT regimen) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/32\">",
"       32",
"      </a>",
"      ]. There were no significant differences in the toxicity profile between the two groups. Patients receiving gemcitabine were significantly more likely to have their pain controlled (39 versus 6 percent), and they also lived significantly longer median survival (14.5 versus 6.7 months). The small size of this study and the unconventional schedule of 5-FU administration make it difficult to interpret the differences in outcome.",
"     </li>",
"     <li>",
"      In a second trial from Lithuania, 19 patients with locally advanced pancreatic cancer were randomly assigned to chemoradiotherapy (50 Gy EBRT) using concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      (250 to 300",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      weekly) or FU (either",
"      <span class=\"nowrap\">",
"       350mg/m2",
"      </span>",
"      per day on days 1 to 5 and 31 to 35, or 500",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      per day on days 1 to 3 and 31 to 33 of EBRT) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/33\">",
"       33",
"      </a>",
"      ]. There were no significant differences between the groups in terms of overall survival or time to disease progression.",
"     </li>",
"     <li>",
"      Concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      -based chemoradiotherapy (gemcitabine 300",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      once per week) was directly compared to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      -based chemoradiotherapy (capecitabine 830",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily Monday through Friday), both with 50.4 Gy external beam RT, in a small trial of 74 patients with locally advanced nonmetastatic pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/18\">",
"       18",
"      </a>",
"      ]. All patients in both arms initiated therapy with 12 weeks of induction chemotherapy with gemcitabine plus capecitabine, and only those with stable or responding disease were randomly assigned to one of the two chemoradiotherapy arms. Although there were slight differences in median overall (15.2 versus 13.4 months) and progression-free survival (12 versus 10.4 months) that favored the capecitabine arm, they were not statistically significant. More patients in the gemcitabine group had nonhematologic toxic effects during chemoradiotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the small size of these trials limit the confidence with which conclusions can be drawn, there is little evidence to support better outcomes in patients undergoing chemoradiotherapy for locally advanced pancreatic cancer with concomitant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    as compared to concurrent daily infusional 5-FU (the usual regimen) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    . A 2009 qualitative systematic review concluded that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    is still the reference chemotherapy for use with concurrent radiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Combining gemcitabine and 5-FU",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ECOG attempted a trial in which 5-FU,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    , and RT were combined in the treatment of locally unresectable pancreatic cancer; however, excess toxicity forced early closure after only seven patients were treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/35\">",
"     35",
"    </a>",
"    ]. On the other hand, a subsequent phase II trial of this approach conducted by the CALGB suggested acceptable toxicity and a median survival of 12.2 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/36\">",
"     36",
"    </a>",
"    ]. Further experience with this approach is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Paclitaxel plus EBRT",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     Paclitaxel",
"    </a>",
"    is a potent radiation sensitizer and may be particularly beneficial for the many pancreatic cancers that harbor p53 mutations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=see_link\">",
"     \"Epidemiology and risk factors for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Experience with this approach is limited but promising:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an initial report, 11 of 42 assessable patients with locally advanced disease who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      50",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      per week and concurrent EBRT (50.4 Gy) obtained a partial response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/37\">",
"       37",
"      </a>",
"      ]. Fourteen patients with initially unresectable disease then underwent surgical reexploration, and four could be completely resected.",
"     </li>",
"     <li>",
"      A subsequent RTOG study applied this same regimen to 122 patients with locally advanced unresectable disease, 109 of whom were assessable for response [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/39\">",
"       39",
"      </a>",
"      ]. There were seven clinically complete and 28 partial responses (overall response rate 32 percent), median survival was 11.2 months. Chemoradiotherapy was complicated by a grade 3 or 4 hypersensitivity reaction in seven, myelosuppression in 16, and one patient had a fatal neutropenic infection. A subsequent RTOG trial using",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      and EBRT combined with concurrent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      is now under way.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Role of surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery in patients treated initially with chemoradiotherapy for borderline resectable pancreatic cancer is discussed below. (See",
"    <a class=\"local\" href=\"#H26\">",
"     'Role of surgery and management of borderline resectable disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY ALONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemotherapy alone is an increasingly utilized treatment option for patients with locally advanced disease. The data to support the use of chemotherapy in this setting come mainly from two sources: chemotherapy trials conducted in mixed populations of patients with both locally advanced and metastatic disease, and the few trials that have directly compared 5-FU-based chemoradiotherapy versus 5-FU or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    chemotherapy alone.",
"   </p>",
"   <p>",
"    Contemporary trials evaluating different chemotherapy combinations in mixed populations of patients with locally advanced and metastatic pancreatic cancer suggest that the impact of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -based chemotherapy on survival among patients with locally advanced disease may be of approximately the same magnitude as that achieved by chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a global phase III trial comparing",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with and without tipifarnib in 688 patients with locally advanced (n = 164) or metastatic pancreatic cancer, the median survival of patients with locally advanced disease in both groups was 10.5 months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A randomized comparison between",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"       irinotecan",
"      </a>",
"      in 360 patients (51 with locally advanced disease) reported a median survival duration of 11.7 and 9.8 months in the patients with locally advanced disease in the gemcitabine alone and",
"      <span class=\"nowrap\">",
"       gemcitabine/irinotecan",
"      </span>",
"      arms, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/42\">",
"       42",
"      </a>",
"      ]. A longer median survival duration (15 months) was reported in a Japanese phase II trial of single agent gemcitabine that was limited to 50 patients with locally advanced nonmetastatic pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is inherently hazardous to perform cross-study comparisons, these median survival values are similar or better than those reported in series of patients treated with chemoradiotherapy. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Concomitant chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Whether better outcomes could be achieved with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    combinations is unclear. One phase II trial evaluating neoadjuvant gemcitabine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    in patients with initially unresectable or borderline resectable nonmetastatic pancreatic cancer showed that 40 percent had sufficient tumor regression to undergo operative resection, which was complete (R0) in 69 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/44\">",
"     44",
"    </a>",
"    ]. However, there are no randomized trials comparing this approach (or any other gemcitabine combination such as gemcitabine plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    or gemcitabine plus nanoparticle albumin-bound",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) to gemcitabine alone. As a result, at many institutions, gemcitabine alone is considered the standard approach for locally advanced nonmetastatic disease when chemotherapy alone is indicated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the metastatic setting, many clinicians are now using short-term infusional FU plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    (FOLFIRINOX, (",
"    <a class=\"graphic graphic_table graphicRef79571 \" href=\"mobipreview.htm?43/3/44094\">",
"     table 2",
"    </a>",
"    )) based on the improved activity and survival when compared with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    . While some clinicians are using upfront FOLFIRINOX for patients with locally advanced pancreatic cancer, the available data on the safety and efficacy of this approach are scant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/45\">",
"     45",
"    </a>",
"    ]. Although it appears that objective response rates in the primary tumor are approximately the same as they are in metastatic disease, there are few data on rates of resectability, perioperative morbidity, and mortality in patients who undergo surgery after receiving FOLFIRINOX, and no data on long-term outcomes. Thus, the safety and efficacy of this approach is not yet established for patients with locally advanced disease. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link&amp;anchor=H84834598#H84834598\">",
"     \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'FOLFIRINOX'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=see_link&amp;anchor=H8525617#H8525617\">",
"     \"Treatment protocols for pancreatic cancer\", section on 'FOLFIRINOX (fluorouracil plus leucovorin, irinotecan, and oxaliplatin)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Trials comparing chemotherapy and chemoradiotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few trials have directly compared chemoradiotherapy to chemotherapy alone (either 5-FU-based or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    ), none of which provide a definitive answer as to which approach is better.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     5-FU-based chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three early trials comparing chemoradiotherapy to 5-FU-based chemotherapy conducted in the 1980s came to opposite conclusions (",
"    <a class=\"graphic graphic_table graphicRef53139 \" href=\"mobipreview.htm?40/38/41580\">",
"     table 3",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early ECOG study, 5-FU-based chemoradiotherapy was of similar efficacy to 5-FU alone for patients with locally advanced pancreatic cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/46\">",
"       46",
"      </a>",
"      ]. This study was criticized for using a suboptimal RT dose (40 Gy).",
"     </li>",
"     <li>",
"      Similarly, a small trial of 5-FU-based chemoradiotherapy (RT dose 46 Gy) followed by 5-FU plus methyl CCNU versus 5-FU and methyl CCNU alone which enrolled 15 patients per arm failed to show a survival benefit from the addition of chemoradiotherapy to chemotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A survival benefit for combined modality therapy compared to 5-FU-based chemotherapy alone was shown in a GITSG trial in which 43 patients with locally advanced pancreatic cancer were randomly assigned to EBRT with concurrent bolus 5-FU followed by SMF chemotherapy (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"       streptozocin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/16/38144?source=see_link\">",
"       mitomycin",
"      </a>",
"      , and 5-FU) versus SMF chemotherapy alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/48\">",
"       48",
"      </a>",
"      ]. The survival benefit (median 42 versus 32 weeks) was modest but statistically significant. The SMF regimen has fallen out of favor for the treatment of advanced disease. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link&amp;anchor=H11#H11\">",
"       \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'Streptozocin and ifosfamide'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Gemcitabine-based chemotherapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to these results, a survival benefit for chemoradiotherapy followed by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    could not be shown compared to gemcitabine alone in the French FFCD-SFRO trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/49\">",
"     49",
"    </a>",
"    ]. The chemoradiotherapy arm consisted of EBRT (60 Gy in 30 fractions) plus concomitant 5-FU (300",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over 24 hours five days per week) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    (20",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on days 1 through 5 during weeks 1 and 5) followed by gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for three of every four weeks) until progression. The chemotherapy alone group received gemcitabine (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    weekly for seven of the first eight weeks, then for three of every four weeks), also until progression.",
"   </p>",
"   <p>",
"    The trial was halted because of poor accrual after 109 of the planned 176 patients were enrolled. At a median 31-month follow-up, the group receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone had significantly better one-year (53 versus 32 percent) and median survival (13 versus 8.6 months), as well as significantly less treatment-related (particularly hematologic) toxicity.",
"   </p>",
"   <p>",
"    Interpretation of these results is limited by the relatively high dose of RT (60 Gy compared to the more usual 54 Gy in the setting of locally advanced disease) and the likely contribution of concurrent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    to the toxicity profile. Thus, this trial should be interpreted as showing that RT to 60 Gy with concurrent 5-FU and cisplatin appears to be inferior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    alone; it does not demonstrate that gemcitabine alone is superior to all types of conventional 5-FU-based or gemcitabine-based chemoradiotherapy.",
"   </p>",
"   <p>",
"    A randomized ECOG trial (ECOG 4201) of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    with or without RT (50.4 Gy in 28 fractions) in patients with localized unresectable pancreatic cancer was prematurely terminated (with only 74 of 316 patients enrolled) due to poor accrual [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/50\">",
"     50",
"    </a>",
"    ]. In the final publication, while there was a statistically significant improvement in median overall survival with chemoradiotherapy (11.1 versus 9.2 months), there was also a significantly higher rate of grade 4 and 5 (fatal) toxicity (41 versus 9 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Meta-analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two separate meta-analyses of trials comparing chemoradiotherapy (with or without subsequent chemotherapy) versus chemotherapy alone concluded that there was no survival benefit (and greater toxicity) for chemoradiotherapy as compared to chemotherapy alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/13,34\">",
"     13,34",
"    </a>",
"    ]. However, the obvious heterogeneity in the trials in terms of chemotherapy regimen and RT dose, as well as their small size, limits the confidence in this conclusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     CHEMOTHERAPY FOLLOWED BY CHEMORADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A strategy for limiting the use of chemoradiotherapy to those who are most likely to benefit involves initial",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -based chemotherapy, followed by chemoradiotherapy for those without evidence of disease progression. Randomized trials have not been performed to compare this approach to that of chemoradiotherapy or chemotherapy alone, but data from at least three retrospective series suggest that a period of initial chemotherapy can permit the selection of those patients who derive optimal benefit from chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. The two largest series are described below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     GERCOR series",
"    </span>",
"    &nbsp;&mdash;&nbsp;This strategy was evaluated in a retrospective series of 181 patients with locally advanced, unresectable but nonmetastatic pancreatic cancer who had been treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    -based chemotherapy alone as part of phase II and III trials conducted by the European Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/51\">",
"     51",
"    </a>",
"    ]. In each protocol, chemotherapy was initially given for three months, and the decision to continue it or administer chemoradiotherapy (55 Gy external beam RT with concurrent infusional 5-FU) was left to the discretion of the investigator.",
"   </p>",
"   <p>",
"    Among the 128 patients who did not progress after three months of chemotherapy and who retained an adequate performance status, 72 received chemoradiotherapy while 56 continued with chemotherapy. When the two groups were compared, chemoradiotherapy was associated with significant improvement in median progression-free survival (10.8 versus 7.4 months with chemotherapy) and overall survival (15 versus 11.7 months).",
"   </p>",
"   <p>",
"    These data support the view that chemoradiotherapy improves survival relative to continued chemotherapy alone after a period of initial disease control with chemotherapy. Another interpretation is that early chemotherapy allows the selection of patients who do not have occult micrometastatic disease, thus limiting RT to those who might benefit from improved local control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     MD Anderson report",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar results were noted in an analysis of 323 consecutive patients with locally advanced pancreatic cancer treated at MD Anderson, 76 of whom received a median of 2.5 months of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    prior to chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/52\">",
"     52",
"    </a>",
"    ]. Median overall survival was significantly longer in those who underwent an initial period of chemotherapy prior to chemoradiotherapy (11.9 versus 8.5 months), as was progression-free survival (6.4 versus 4.2 months) and the median time to both local and distant disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Taken together, these data support the use of an initial period of chemotherapy prior to embarking on a course of chemoradiotherapy in patients with locally advanced pancreatic cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/34\">",
"     34",
"    </a>",
"    ]. Prospective evaluation of this treatment strategy is needed to validate the benefit of this approach; such a phase III trial is underway in Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     STEREOTACTIC BODY RADIOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stereotactic body radiotherapy (SBRT) is capable of precisely delivering high doses of radiation to small tumor volumes. Cyber Knife is an example of SBRT technology that uses real-time tracking of implanted fiducials to potentially integrate organ motion into real-time therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=see_link&amp;anchor=H3#H3\">",
"     \"Stereotactic body radiation therapy: Rationale and clinical experience\", section on 'Technological advances'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SBRT has been explored in a limited number of clinical studies as an alternative approach to conventional fractional external beam RT with concurrent chemotherapy for the management of locally advanced disease. However, the benefit of SBRT remains uncertain, since it is not clear that median survival is better than would be expected with other forms of therapy, and toxicity may be worse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/54-59\">",
"     54-59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A single institution trial included 22 patients with locally advanced, unresectable pancreatic cancer who were treated with SBRT (45 Gy divided into three doses of 15 Gy over five to ten days) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/55\">",
"       55",
"      </a>",
"      ]. Acute toxicity was pronounced, with deterioration of performance status, nausea, and increased pain seen at 14 days. Four patients developed severe gastric mucositis or ulceration, and one patient had a nonfatal stomach perforation. Six patients developed local tumor progression, and median survival was only six months.",
"     </li>",
"     <li>",
"      Another study treated 77 patients (81 percent locally advanced, including eight recurrent tumors, 19 percent metastatic disease) with Cyber Knife (single fraction of 25 Gy) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/56\">",
"       56",
"      </a>",
"      ]. Some patients had received prior radiation or chemotherapy. The overall survival rates at 6 and 12 months were 56 and 21 percent. The 12-month rate of late toxicity (mostly ulceration of the GI tract) was 25 percent.",
"     </li>",
"     <li>",
"      The crude rate of late mucosal toxicity was even higher (44 percent) in a second prospective trial from this same institution of 16 patients who were treated with single fraction SBRT (25 Gy) using Cyberknife in between cycle 1 and 2 of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       gemcitabine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The substantial local toxicity seen in these initial reports was not counterbalanced by any suggestion of improved survival. The median survival durations reported in these three studies (six to seven months) do not compare favorably with median survivals seen in modern phase II studies of chemotherapy alone or conventional fractionation chemoradiation in patients with locally advanced disease (10 months or higher) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A tolerance-based hypofractionated strategy for SBRT may result in a more favorable toxicity profile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, until randomized trials comparing this approach versus conventional fluoropyrimidine-based chemoradiotherapy are completed, the place of SBRT in the therapeutic armamentarium for locally advanced pancreatic cancer will remain undefined. As a result of these issues, the use of SBRT cannot be recommended at this time unless in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     ROLE OF SURGERY AND MANAGEMENT OF BORDERLINE RESECTABLE DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median survival of patients with locally advanced unresectable pancreatic cancer is about 10 to 12 months. Interest in applying the principles of neoadjuvant or induction therapy to such patients comes from their poor prognosis and the potential for longer-term survival if disease can be resected. Two independent systematic reviews concluded that approximately one-third of initially",
"    <span class=\"nowrap\">",
"     unresectable/borderline",
"    </span>",
"    resectable pancreatic tumors could be rendered resectable through the use of neoadjuvant therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. However, these data must be interpreted cautiously given the heterogeneous nature of this group of patients, and the treatments given to them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606636893\">",
"    <span class=\"h2\">",
"     Initially unresectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;At most institutions, encasement (more than 180 degree involvement of the vessel circumference) of the superior mesenteric artery or celiac axis or unreconstructable occlusion of the portal vein or SMV represent indicators of unresectability. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Criteria for unresectability'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Such patients are generally approached with initial chemotherapy followed by chemoradiotherapy, if there is no evidence of disease progression. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Chemotherapy followed by chemoradiotherapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The best way to define a response to upfront chemotherapy or chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/63\">",
"     63",
"    </a>",
"    ] and the role of surgery following a &ldquo;good&rdquo; response to initial chemotherapy",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chemoradiotherapy are unclear. While it is reasonable to evaluate responding patients for potential resectability after chemoradiotherapy, the frequency with which this results in a dramatic response and culminates in a complete resection is low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/4,25,64-70\">",
"     4,25,64-70",
"    </a>",
"    ]. In addition, long-term survival appears to be exceedingly rare in this circumstance, largely due to the development of metastatic disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, induction therapy is not yet a standard approach for patients with locally advanced, categorically unresectable disease. Whenever possible, such patients should be offered treatment in the context of a clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H606636900\">",
"    <span class=\"h2\">",
"     Borderline resectable disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, neoadjuvant therapy is a reasonable option for patients who have borderline resectable tumors, the definition of which is variable (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Criteria for unresectability'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    At some institutions, these patients are treated with upfront surgical exploration and resection, if technically feasible. However, at other centers, in an attempt to increase the likelihood of a margin-negative resection, such patients are treated initially with chemotherapy, chemoradiotherapy or both followed by restaging and surgical reevaluation. There are no randomized trials; the available data utilizing neoadjuvant therapy in patients with borderline resectable disease consist mainly of small single institution series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/3-5,17,25,64-66,68,70,72-77\">",
"     3-5,17,25,64-66,68,70,72-77",
"    </a>",
"    ] and small phase II (uncontrolled) trials in which a mixture of patients with initially resectable, unresectable, and borderline resectable disease were enrolled [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/78-83\">",
"     78-83",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The largest single institution series of patients with borderline resectable disease from MD Anderson included 160 patients who were classified as borderline resectable because of tumor abutment of the visceral arteries or short segment occlusion of the SMV, findings suggestive but not diagnostic of metastatic disease or a marginal performance status [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/3\">",
"     3",
"    </a>",
"    ]. Of these, 125 completed neoadjuvant therapy (induction chemotherapy in 82; chemoradiotherapy in 117) and were restaged. Eighty-two had potentially operative tumors, of whom 79 underwent an operation; 66 were resected, 62 with microscopically negative margins (38 percent of the original cohort). At a median follow-up of 27 months, the median survival for the unresectable and resectable cohorts were 13 and 40 months, respectively. Among the 66 patients who completed all therapy, the five-year survival was 36 percent, and 27 patients remained free of disease progression at last follow-up.",
"   </p>",
"   <p>",
"    A meta-analysis of phase II trials testing a variety of neoadjuvant strategies concluded that, among patients with",
"    <span class=\"nowrap\">",
"     borderline/unresectable",
"    </span>",
"    pancreatic cancer, 32 percent were able to undergo potentially curative resection after neoadjuvant therapy, and the median survival in this group was 22.3 months (range 18 to 26 months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/84\">",
"     84",
"    </a>",
"    ]. Whether this represents an actual benefit of preoperative chemoradiation or an overestimate of unresectability by imaging remains unclear; however, it does emphasize the need to surgically document the resectability or unresectability of patients with borderline-unresectable pancreatic cancer.&nbsp;",
"   </p>",
"   <p>",
"    These results suggest that in some cases where resectability is borderline on the basis of vascular involvement, induction chemotherapy, chemoradiotherapy, or a combined approach is feasible and may contribute to complete resection and long-term survival. However, whether this approach is superior to upfront surgery followed by adjuvant therapy is not established. Furthermore, the best regimen to use for neoadjuvant therapy in this setting is not established. Neoadjuvant approaches in patients with potentially resectable pancreatic cancer are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=see_link\">",
"     \"Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Role of intraoperative RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative RT (IORT) permits the delivery of high dose RT directly to areas of tumor involvement without the morbidity associated with irradiation of adjacent normal tissues, particularly small bowel. A number of reports from both single institutions and cooperative groups have explored IORT, usually in conjunction with preoperative chemoradiotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/4,85-89\">",
"     4,85-89",
"    </a>",
"    ]. Taken together, the available data suggest that while local control rates may be higher with IORT compared to EBRT alone, this benefit is offset by the rapid development of metastatic disease in most reports, and it is not clear that IORT contributes to higher survival rates. The benefits of IORT have been marginal or absent in other reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of IORT for treatment of pancreatic cancer included 14 reports published between 1995 and 2007 (the majority case series, no randomized trials) involving patients with either localized resectable or locally advanced disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/90\">",
"     90",
"    </a>",
"    ]. The authors concluded that, while the use of IORT may be associated with a slight (and statistically nonsignificant) improvement in median survival among patients with localized, potentially resectable pancreatic cancer, no benefit could be shown in the setting of locally advanced disease. No published studies addressed quality of life issues.",
"   </p>",
"   <p>",
"    At present, in the absence of randomized trials demonstrating benefit, IORT cannot be considered a standard approach, and it should be reserved for patients who are enrolled in clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SYMPTOM PALLIATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although chemoradiotherapy can frequently relieve pain and may successfully palliate obstructive symptoms, specific treatment may be needed to provide relief of obstructive jaundice, gastric outlet obstruction, and unrelieved pain. Here we will provide a brief overview of palliation for specific symptoms. A complete discussion of this topic is presented elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Obstructive jaundice",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized trials and a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/91\">",
"     91",
"    </a>",
"    ] demonstrate that endoscopically placed stents are as successful as surgical bypass procedures in relieving the obstructive jaundice caused by pancreatic cancer, but with lower morbidity and procedure-related mortality rates. Most jaundiced patients can be successfully managed using stents, and relatively few require surgical biliary-enteric bypass as a planned palliative procedure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H2#H2\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Jaundice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718238237\">",
"    <span class=\"h3\">",
"     Percutaneous versus endoscopic stenting",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stenting can be performed either percutaneously or endoscopically. In a randomized trial comparing these two approaches in 75 patients with malignant bile duct obstruction, patients treated endoscopically had a higher success rate for relief of jaundice (81 versus 61 percent) and a significantly lower 30-day mortality rate (15 versus 33 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/92\">",
"     92",
"    </a>",
"    ]. Thus, most patients are approached endoscopically, at least initially. However, for some patients, especially those who have undergone prior pancreaticoduodenectomy, endoscopic stent placement may not be feasible, and percutaneous approaches are needed for adequate palliation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37491?source=see_link\">",
"     \"Percutaneous transhepatic cholangiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718238244\">",
"    <span class=\"h3\">",
"     Plastic versus metal stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of plastic and metal stents, both covered and uncovered, are available for endoscopic deployment. A systematic review and meta-analysis concluded that compared with plastic stents, metal stents had a lower risk of recurrent obstruction but were not superior with regard to technical success, therapeutic success, mortality, or complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/91,93\">",
"     91,93",
"    </a>",
"    ]. As a result, the decision to use one versus another should be guided by expected length of survival, quality of life, costs, and physician expertise. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H1135516949#H1135516949\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Types of stents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The placement of a plastic stent is inexpensive and effective, and the stent can be easily removed or exchanged. Plastic stents, however, eventually develop occlusion by sludge",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bacterial biofilm, and maintaining biliary drainage with plastic stents usually requires repeated endoscopic retrograde cholangiopancreatographies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H17011418#H17011418\">",
"       \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Patency of plastic stents'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Metal stents extend the duration of stent patency (approximately 8 to 12 versus 2 to 5 months). However, metal stents have significantly higher costs and may not be removable. Thus, the diagnosis of malignant disease must be firmly established before a metal stent is deployed. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H17011425#H17011425\">",
"       \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Plastic versus metal stents'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      A patient&rsquo;s treatment plan may not be known during the initial endoscopic retrograde cholangiopancreatography (eg, if biliary drainage is required before staging can be completed). Options in this setting include placing a plastic (and thus easily removed) stent or a self-expanding metal stent (which provides longer-term patency). A Monte Carlo decision analysis compared several strategies in patients with obstructive jaundice from pancreatic cancer with an undetermined surgical plan, and the results suggested that a short-length self-expanding metal stent is the preferred initial treatment for overall cost minimization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/94\">",
"       94",
"      </a>",
"      ]. In general, the placement of metal stents could be considered in patients with potentially resectable pancreatic cancer, especially if surgery is likely to be delayed (eg, if neoadjuvant therapy is planned); even metal stents can be removed if and when the patient undergoes resection without additional morbidity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/95\">",
"       95",
"      </a>",
"      ]. However, ideally, the use of a metal stent in a patient who is a candidate for resection should be reviewed with the surgeon prior to placement. If a stent is placed preoperatively, the proximal end should be kept at or below the level of the cystic duct takeoff. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=see_link&amp;anchor=H5#H5\">",
"       \"Surgery in the treatment of exocrine pancreatic cancer and prognosis\", section on 'Role of biliary drainage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H718238153\">",
"    <span class=\"h3\">",
"     Covered versus uncovered stents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several trials have evaluated differences in stent patency rates between covered and uncovered metal stents for the treatment of distal malignant biliary disease; despite showing significantly less tumor ingrowth, long-term patency rates (six months and beyond) are not higher for covered stents. This can likely be explained by the many other etiologies of stent occlusion other than tumor ingrowth, including tumor overgrowth and stent obstruction by debris and biliary sludge.",
"   </p>",
"   <p>",
"    One potential benefit of covered metal stents is that they are more easily removable at the time of surgery than are uncovered metal stents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?32/37/33370/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Many endoscopists avoid the use of covered metal stents in a patient with an intact gallbladder because of the potential to block the cystic duct, but this is a theoretical concern, and has not been borne out in clinical studies. As noted above, the use of a metal stent in a patient who is a candidate for resection should be reviewed with the surgeon prior to placement. This subject is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H1135517058#H1135517058\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Complications'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=see_link&amp;anchor=H7922550#H7922550\">",
"     \"Endoscopic stenting for malignant pancreaticobiliary obstruction\", section on 'Covered versus uncovered metal stents'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Gastric outlet obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastroduodenal obstruction caused by pancreatic cancer can be managed by gastrojejunostomy, although experience is increasing with endoscopically placed expandable metal stents. Patients who have both gastric outlet obstruction and obstructive jaundice may be best served by surgical",
"    <span class=\"nowrap\">",
"     gastric/biliary",
"    </span>",
"    bypass. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H5#H5\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Duodenal obstruction'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37895?source=see_link\">",
"     \"Enteral stents for the palliation of malignant gastroduodenal obstruction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Palliation of pain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palliation of pain caused by pancreatic adenocarcinoma can usually be successfully achieved by drug treatment alone. Celiac plexus block may be required for pain control in selected patients and may be achieved by a surgical, radiographically guided percutaneous or endosonographically guided approach. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=see_link&amp;anchor=H8#H8\">",
"     \"Exocrine pancreatic cancer: Palliation of symptoms\", section on 'Pain'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30088?source=see_link\">",
"     \"Endoscopic ultrasound-guided celiac plexus and ganglia interventions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=see_link\">",
"     \"Cancer pain management: Interventional therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=see_link\">",
"       \"Patient information: Pancreatic cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=see_link\">",
"       \"Patient information: Pancreatic cancer (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8145733\">",
"    <span class=\"h2\">",
"     Locally advanced, unresectable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 40 percent of patients with pancreatic cancer present with locally advanced, unresectable nonmetastatic disease, typically a T4 lesion (",
"    <a class=\"graphic graphic_table graphicRef62155 \" href=\"mobipreview.htm?42/32/43532\">",
"     table 1",
"    </a>",
"    ). The optimal management of these patients is controversial. Therapeutic options include radiation therapy (RT) alone, chemoradiotherapy, and chemotherapy alone. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients, we suggest an initial period of chemotherapy rather than chemoradiotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This approach has the advantage of sparing those patients who have rapidly progressive disease in the liver or peritoneum from undergoing RT. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Chemotherapy followed by chemoradiotherapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Concomitant chemoradiotherapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"       Gemcitabine",
"      </a>",
"      monotherapy (",
"      <a class=\"graphic graphic_table graphicRef60330 \" href=\"mobipreview.htm?35/56/36749\">",
"       table 4",
"      </a>",
"      ) represents a standard approach. For patients with an excellent performance status, and a total bilirubin level that is below 1.5 times the upper limit of normal, combination chemotherapy with FOLFIRINOX (",
"      <a class=\"graphic graphic_table graphicRef79571 \" href=\"mobipreview.htm?43/3/44094\">",
"       table 2",
"      </a>",
"      ) is an option. However, clinicians should be cautioned that until prospective trials and larger retrospective experiences with FOLFIRINOX in this setting are published, toxicity remains an extremely important consideration and largely unknown although it is assumed to be the same as in the metastatic setting. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=see_link&amp;anchor=H84834598#H84834598\">",
"       \"Chemotherapy for advanced exocrine pancreatic cancer\", section on 'FOLFIRINOX'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients who do not progress, we suggest combined treatment with external beam RT (EBRT) plus concomitant low-dose infusional 5-FU (eg, 200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily) rather than RT alone (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest the substitution of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (or, where available, S-1) for infusional 5-FU in patients for whom ambulatory infusional therapy using a pump is not considered feasible (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Oral fluoropyrimidines as a substitute for infusional 5-FU'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative, increasingly used approach to 5-FU-based chemoradiotherapy is continued chemotherapy alone. However, because no trial has shown that chemotherapy alone is superior to conventionally dosed radiotherapy using concomitant infusional 5-FU in patients with locally advanced unresectable disease, we prefer 5-FU-based concurrent chemoradiotherapy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chemotherapy alone'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=see_link\">",
"       \"Treatment protocols for pancreatic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      While it is reasonable to restage and reevaluate the potential for resectability after chemoradiotherapy, the frequency of a complete resection and long-term survival is low for patients who initially have categorically unresectable tumors. (See",
"      <a class=\"local\" href=\"#H606636893\">",
"       'Initially unresectable disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8145744\">",
"    <span class=\"h2\">",
"     Borderline resectable",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some cases are considered \"borderline\" resectable, mostly based upon vascular involvement, although the definition is variable. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Borderline resectable'",
"    </a>",
"    above.)",
"    <br/>",
"    <br/>",
"    Although some of these patients will prove to be resectable with initial surgery, the likelihood of an incomplete resection is high. An initial attempt at downstaging with chemotherapy, chemoradiotherapy, or a combination followed by restaging and surgical exploration in responders is a reasonable approach for fit patients who are willing to accept the uncertainty of clinical benefit from this approach. The best form of induction therapy to use in this setting is unclear. Whenever possible, such patients should be encouraged to enroll on clinical trials testing new approaches. (See",
"    <a class=\"local\" href=\"#H606636900\">",
"     'Borderline resectable disease'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines. Available at: www.nccn.org (Accessed on May 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/3\">",
"      Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 2008; 206:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/4\">",
"      Greer SE, Pipas JM, Sutton JE, et al. Effect of neoadjuvant therapy on local recurrence after resection of pancreatic adenocarcinoma. J Am Coll Surg 2008; 206:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/5\">",
"      Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 2006; 13:1035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/6\">",
"      Chun YS, Milestone BN, Watson JC, et al. Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010; 17:2832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/7\">",
"      Bold RJ, Charnsangavej C, Cleary KR, et al. Major vascular resection as part of pancreaticoduodenectomy for cancer: radiologic, intraoperative, and pathologic analysis. J Gastrointest Surg 1999; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/8\">",
"      Callery MP, Chang KJ, Fishman EK, et al. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 2009; 16:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/9\">",
"      Roldan GE, Gunderson LL, Nagorney DM, et al. External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer. Cancer 1988; 61:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/10\">",
"      A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 1979; 189:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/11\">",
"      Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 1981; 48:1705.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/12\">",
"      Cohen SJ, Dobelbower R Jr, Lipsitz S, et al. A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282. Int J Radiat Oncol Biol Phys 2005; 62:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/13\">",
"      Sultana A, Tudur Smith C, Cunningham D, et al. Systematic review, including meta-analyses, on the management of locally advanced pancreatic cancer using radiation/combined modality therapy. Br J Cancer 2007; 96:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/14\">",
"      Krzyzanowska MK, Weeks JC, Earle CC. Treatment of locally advanced pancreatic cancer in the real world: population-based practices and effectiveness. J Clin Oncol 2003; 21:3409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/15\">",
"      Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2002; 53:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/16\">",
"      Schneider BJ, Ben-Josef E, McGinn CJ, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005; 63:1325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/17\">",
"      Stokes JB, Nolan NJ, Stelow EB, et al. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer. Ann Surg Oncol 2011; 18:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/18\">",
"      Mukherjee S, Hurt CN, Bridgewater J, et al. Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial. Lancet Oncol 2013; 14:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/19\">",
"      Ikeda M, Ioka T, Ito Y, et al. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2013; 85:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/20\">",
"      Lawrence TS, Eisbruch A, Shewach DS. Gemcitabine-mediated radiosensitization. Semin Oncol 1997; 24:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/21\">",
"      Wolff RA, Evans DB, Gravel DM, et al. Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma. Clin Cancer Res 2001; 7:2246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/22\">",
"      Blackstock AW, Bernard SA, Richards F, et al. Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer. J Clin Oncol 1999; 17:2208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/23\">",
"      Joensuu TK, Kiviluoto T, K&auml;rkk&auml;inen P, et al. Phase I-II trial of twice-weekly gemcitabine and concomitant irradiation in patients undergoing pancreaticoduodenectomy with extended lymphadenectomy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2004; 60:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/24\">",
"      Blackstock AW, Tepper JE, Niedwiecki D, et al. Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas. Int J Gastrointest Cancer 2003; 34:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/25\">",
"      Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 2003; 7:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/26\">",
"      Moore AM, Cardenes H, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study (abstract). Proc Am Soc Clin Oncol 2004; 22:339s.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/27\">",
"      Epelbaum R, Rosenblatt E, Nasrallah S, et al. Phase II study of gemcitabine combined with radiation therapy in patients with localized, unresectable pancreatic cancer. J Surg Oncol 2002; 81:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/28\">",
"      Mattiucci GC, Morganti AG, Valentini V, et al. External beam radiotherapy plus 24-hour continuous infusion of gemcitabine in unresectable pancreatic carcinoma: long-term results of a phase II study. Int J Radiat Oncol Biol Phys 2010; 76:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/29\">",
"      Murphy JD, Adusumilli S, Griffith KA, et al. Full-dose gemcitabine and concurrent radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 2007; 68:801.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/30\">",
"      Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006; 13:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/31\">",
"      Cardenes HR, Moore AM, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol 2011; 34:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/32\">",
"      Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys 2003; 57:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/33\">",
"      Brasiniene B, Juozaityte E. The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. Medicina (Kaunas) 2007; 43:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/34\">",
"      Huguet F, Girard N, Guerche CS, et al. Chemoradiotherapy in the management of locally advanced pancreatic carcinoma: a qualitative systematic review. J Clin Oncol 2009; 27:2269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/35\">",
"      Talamonti MS, Catalano PJ, Vaughn DJ, et al. Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. J Clin Oncol 2000; 18:3384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/36\">",
"      Mamon HJ, Niedzwiecki D, Hollis D, et al. A phase 2 trial of gemcitabine, 5-fluorouracil, and radiation therapy in locally advanced nonmetastatic pancreatic adenocarcinoma : cancer and Leukemia Group B (CALGB) 80003. Cancer 2011; 117:2620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/37\">",
"      Safran H, Moore T, Iannitti D, et al. Paclitaxel and concurrent radiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2001; 49:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/38\">",
"      King TC, Estalilla OC, Safran H. Role of p53 and p16 gene alterations in determining response to concurrent paclitaxel and radiation in solid tumor. Semin Radiat Oncol 1999; 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/39\">",
"      Rich T, Harris J, Abrams R, et al. Phase II study of external irradiation and weekly paclitaxel for nonmetastatic, unresectable pancreatic cancer: RTOG-98-12. Am J Clin Oncol 2004; 27:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/40\">",
"      Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005; 23:3509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/41\">",
"      Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004; 22:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/42\">",
"      Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004; 22:3776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/43\">",
"      Ishii H, Furuse J, Boku N, et al. Phase II study of gemcitabine chemotherapy alone for locally advanced pancreatic carcinoma: JCOG0506. Jpn J Clin Oncol 2010; 40:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/44\">",
"      Sahora K, Kuehrer I, Eisenhut A, et al. NeoGemOx: Gemcitabine and oxaliplatin as neoadjuvant treatment for locally advanced, nonmetastasized pancreatic cancer. Surgery 2011; 149:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/45\">",
"      Conroy T, Gavoille C, Samalin E, et al. The Role of the FOLFIRINOX Regimen for Advanced Pancreatic Cancer. Curr Oncol Rep 2013; 15:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/46\">",
"      Klaassen DJ, MacIntyre JM, Catton GE, et al. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil--an Eastern Cooperative Oncology Group study. J Clin Oncol 1985; 3:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/47\">",
"      Hazel JJ, Thirlwell MP, Huggins M, et al. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial. J Can Assoc Radiol 1981; 32:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/48\">",
"      Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst 1988; 80:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/49\">",
"      Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000-01 FFCD/SFRO study. Ann Oncol 2008; 19:1592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/50\">",
"      Loehrer PJ Sr, Feng Y, Cardenes H, et al. Gemcitabine alone versus gemcitabine plus radiotherapy in patients with locally advanced pancreatic cancer: an Eastern Cooperative Oncology Group trial. J Clin Oncol 2011; 29:4105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/51\">",
"      Huguet F, Andr&eacute; T, Hammel P, et al. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies. J Clin Oncol 2007; 25:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/52\">",
"      Krishnan S, Rana V, Janjan NA, et al. Induction chemotherapy selects patients with locally advanced, unresectable pancreatic cancer for optimal benefit from consolidative chemoradiation therapy. Cancer 2007; 110:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/53\">",
"      Arvold ND, Ryan DP, Niemierko A, et al. Long-term outcomes of neoadjuvant chemotherapy before chemoradiation for locally advanced pancreatic cancer. Cancer 2012; 118:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/54\">",
"      Koong AC, Christofferson E, Le QT, et al. Phase II study to assess the efficacy of conventionally fractionated radiotherapy followed by a stereotactic radiosurgery boost in patients with locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2005; 63:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/55\">",
"      Hoyer M, Roed H, Sengelov L, et al. Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma. Radiother Oncol 2005; 76:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/56\">",
"      Chang DT, Schellenberg D, Shen J, et al. Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas. Cancer 2009; 115:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/57\">",
"      Schellenberg D, Goodman KA, Lee F, et al. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2008; 72:678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/58\">",
"      Crane CH, Willett CG. Stereotactic radiotherapy for pancreatic cancer? Cancer 2009; 115:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/59\">",
"      Mahadevan A, Jain S, Goldstein M, et al. Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 2010; 78:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/60\">",
"      Didolkar MS, Coleman CW, Brenner MJ, et al. Image-guided stereotactic radiosurgery for locally advanced pancreatic adenocarcinoma results of first 85 patients. J Gastrointest Surg 2010; 14:1547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/61\">",
"      Gillen S, Schuster T, Meyer Zum B&uuml;schenfelde C, et al. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010; 7:e1000267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/62\">",
"      Andriulli A, Festa V, Botteri E, et al. Neoadjuvant/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol 2012; 19:1644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/63\">",
"      Donahue TR, Isacoff WH, Hines OJ, et al. Downstaging chemotherapy and alteration in the classic computed tomography/magnetic resonance imaging signs of vascular involvement in patients with pancreaticobiliary malignant tumors: influence on patient selection for surgery. Arch Surg 2011; 146:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/64\">",
"      Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol 2006; 13:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/65\">",
"      Aristu J, Ca&ntilde;&oacute;n R, Pardo F, et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol 2003; 26:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/66\">",
"      Kim HJ, Czischke K, Brennan MF, Conlon KC. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg 2002; 6:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/67\">",
"      Bajetta E, Di Bartolomeo M, Stani SC, et al. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys 1999; 45:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/68\">",
"      Small W Jr, Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2008; 26:942.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/69\">",
"      Crane CH, Varadhachary GR, Yordy JS, et al. Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol 2011; 29:3037.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/70\">",
"      Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer 2013; 119:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/71\">",
"      Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant chemoradiation and pancreaticoduodenectomy for initially locally advanced head pancreatic adenocarcinoma. Eur J Surg Oncol 2009; 35:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/72\">",
"      Crane CH, Abbruzzese JL, Evans DB, et al. Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 2002; 52:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/73\">",
"      Wilkowski R, Thoma M, Schauer R, et al. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg 2004; 28:1011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/74\">",
"      White RR, Hurwitz HI, Morse MA, et al. Neoadjuvant chemoradiation for localized adenocarcinoma of the pancreas. Ann Surg Oncol 2001; 8:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/75\">",
"      Brown KM, Siripurapu V, Davidson M, et al. Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 2008; 195:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/76\">",
"      Takai S, Satoi S, Yanagimoto H, et al. Neoadjuvant chemoradiation in patients with potentially resectable pancreatic cancer. Pancreas 2008; 36:e26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/77\">",
"      Satoi S, Yanagimoto H, Toyokawa H, et al. Surgical results after preoperative chemoradiation therapy for patients with pancreatic cancer. Pancreas 2009; 38:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/78\">",
"      Yeung RS, Weese JL, Hoffman JP, et al. Neoadjuvant chemoradiation in pancreatic and duodenal carcinoma. A Phase II Study. Cancer 1993; 72:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/79\">",
"      Moutardier V, Giovannini M, Lelong B, et al. A phase II single institutional experience with preoperative radiochemotherapy in pancreatic adenocarcinoma. Eur J Surg Oncol 2002; 28:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/80\">",
"      Al-Sukhun S, Zalupski MM, Ben-Josef E, et al. Chemoradiotherapy in the treatment of regional pancreatic carcinoma: a phase II study. Am J Clin Oncol 2003; 26:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/81\">",
"      Lin LL, Picus J, Drebin JA, et al. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. Am J Clin Oncol 2005; 28:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/82\">",
"      Pipas JM, Barth RJ Jr, Zaki B, et al. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma. Ann Surg Oncol 2005; 12:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/83\">",
"      Palmer DH, Stocken DD, Hewitt H, et al. A randomized phase 2 trial of neoadjuvant chemotherapy in resectable pancreatic cancer: gemcitabine alone versus gemcitabine combined with cisplatin. Ann Surg Oncol 2007; 14:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/84\">",
"      Assifi MM, Lu X, Eibl G, et al. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery 2011; 150:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/85\">",
"      Shipley WU, Wood WC, Tepper JE, et al. Intraoperative electron beam irradiation for patients with unresectable pancreatic carcinoma. Ann Surg 1984; 200:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/86\">",
"      Willett CG, Del Castillo CF, Shih HA, et al. Long-term results of intraoperative electron beam irradiation (IOERT) for patients with unresectable pancreatic cancer. Ann Surg 2005; 241:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/87\">",
"      Mohiuddin M, Regine WF, Stevens J, et al. Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas. J Clin Oncol 1995; 13:2764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/88\">",
"      Garton GR, Gunderson LL, Nagorney DM, et al. High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 1993; 27:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/89\">",
"      Reni M, Panucci MG, Ferreri AJ, et al. Effect on local control and survival of electron beam intraoperative irradiation for resectable pancreatic adenocarcinoma. Int J Radiat Oncol Biol Phys 2001; 50:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/90\">",
"      Ruano-Ravina A, Almaz&aacute;n Ortega R, Guedea F. Intraoperative radiotherapy in pancreatic cancer: a systematic review. Radiother Oncol 2008; 87:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/91\">",
"      Moss AC, Morris E, Leyden J, MacMathuna P. Malignant distal biliary obstruction: a systematic review and meta-analysis of endoscopic and surgical bypass results. Cancer Treat Rev 2007; 33:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/92\">",
"      Speer AG, Cotton PB, Russell RC, et al. Randomised trial of endoscopic versus percutaneous stent insertion in malignant obstructive jaundice. Lancet 1987; 2:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/93\">",
"      Levy MJ, Baron TH, Gostout CJ, et al. Palliation of malignant extrahepatic biliary obstruction with plastic versus expandable metal stents: An evidence-based approach. Clin Gastroenterol Hepatol 2004; 2:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/94\">",
"      Chen VK, Arguedas MR, Baron TH. Expandable metal biliary stents before pancreaticoduodenectomy for pancreatic cancer: a Monte-Carlo decision analysis. Clin Gastroenterol Hepatol 2005; 3:1229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/95\">",
"      Mullen JT, Lee JH, Gomez HF, et al. Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2005; 9:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/96\">",
"      Kahaleh M, Brock A, Conaway MR, et al. Covered self-expandable metal stents in pancreatic malignancy regardless of resectability: a new concept validated by a decision analysis. Endoscopy 2007; 39:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?32/37/33370/abstract/97\">",
"      Shin HP, Kim MH, Jung SW, et al. Endoscopic removal of biliary self-expandable metallic stents: a prospective study. Endoscopy 2006; 38:1250.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2479 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33370=[""].join("\n");
var outline_f32_37_33370=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CRITERIA FOR UNRESECTABILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Borderline resectable",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20569101\">",
"      - Recommendations from expert groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EXTERNAL BEAM RT ALONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CONCOMITANT CHEMORADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      5-FU-based approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Early trials versus RT alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Medicare/SEER report",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Versus supportive care alone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Oral fluoropyrimidines as a substitute for infusional 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Gemcitabine-based chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Gemcitabine versus fluoropyrimidines",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Combining gemcitabine and 5-FU",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Paclitaxel plus EBRT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Role of surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CHEMOTHERAPY ALONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Trials comparing chemotherapy and chemoradiotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - 5-FU-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Gemcitabine-based chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Meta-analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      CHEMOTHERAPY FOLLOWED BY CHEMORADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      GERCOR series",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MD Anderson report",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      STEREOTACTIC BODY RADIOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      ROLE OF SURGERY AND MANAGEMENT OF BORDERLINE RESECTABLE DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606636893\">",
"      Initially unresectable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H606636900\">",
"      Borderline resectable disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Role of intraoperative RT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SYMPTOM PALLIATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Obstructive jaundice",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718238237\">",
"      - Percutaneous versus endoscopic stenting",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718238244\">",
"      - Plastic versus metal stents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H718238153\">",
"      - Covered versus uncovered stents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Gastric outlet obstruction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Palliation of pain",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8145733\">",
"      Locally advanced, unresectable",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8145744\">",
"      Borderline resectable",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2479\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2479|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?42/32/43532\" title=\"table 1\">",
"      TNM panc endo exo CA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/3/44094\" title=\"table 2\">",
"      FOLFIRINOX for metastatic pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?40/38/41580\" title=\"table 3\">",
"      CRT vs chemo LAPC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?35/56/36749\" title=\"table 4\">",
"      Gemcitabine for metastatic pancreatic and biliary tract cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/33/22042?source=related_link\">",
"      Adjuvant and neoadjuvant therapy for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/51/4922?source=related_link\">",
"      Adjuvant therapy for resected rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/38/21098?source=related_link\">",
"      Cancer pain management: Interventional therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/12/39114?source=related_link\">",
"      Chemotherapy for advanced exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/40/41610?source=related_link\">",
"      Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/63/8186?source=related_link\">",
"      Endoscopic stenting for malignant pancreaticobiliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/24/30088?source=related_link\">",
"      Endoscopic ultrasound-guided celiac plexus and ganglia interventions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/0/37895?source=related_link\">",
"      Enteral stents for the palliation of malignant gastroduodenal obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/13/27866?source=related_link\">",
"      Epidemiology and risk factors for exocrine pancreatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/20/17735?source=related_link\">",
"      Exocrine pancreatic cancer: Palliation of symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/22/42346?source=related_link\">",
"      Neoadjuvant chemoradiotherapy and radiotherapy for rectal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/27/44472?source=related_link\">",
"      Pathology of exocrine pancreatic neoplasms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?30/55/31603?source=related_link\">",
"      Patient information: Pancreatic cancer (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?11/21/11602?source=related_link\">",
"      Patient information: Pancreatic cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/39/37491?source=related_link\">",
"      Percutaneous transhepatic cholangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/21/43350?source=related_link\">",
"      Stereotactic body radiation therapy: Rationale and clinical experience",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/34/8746?source=related_link\">",
"      Surgery in the treatment of exocrine pancreatic cancer and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/42/32417?source=related_link\">",
"      Treatment protocols for pancreatic cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f32_37_33371="Further NHLBI dietary modifications for elevated LDL-C in childr";
var content_f32_37_33371=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53962&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    2011 NHLBI* expert committee recommended diet for elevated low-density lipoprotein cholesterol in children refractory to initial low-saturated fat diet",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Refer to a registered dietitian for family medical nutrition therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary components include: 25 to 30 percent of calories from fat, &le;7 percent from saturated fat, ~10 percent from monounsaturated fat; &lt;200 mg/d of cholesterol; avoid trans fats as much as possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Other supportive actions include:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <ul>",
"         <li>",
"          Plant sterol esters and/or plant stanol esters up to 2 g/d as replacement for usual fat sources can be used after age 2 years in children with familial hypercholesterolemia. Plant stanol esters as part of a regular diet are marketed directly to the public. Short term studies show no harmful effects in healthy children. These can be added to some foods, such as margarine.",
"         </li>",
"         <li>",
"          The water-soluble fiber psyllium can be added to a low fat, low saturated fat diet as cereal enriched with psyllium at a dose of 6 g/d for children 2-12 years, and 12 g/d for those &ge;12 years.",
"         </li>",
"         <li>",
"          As in all children, 1 h/d of moderate to vigorous physical activity and &lt;2 h/d of sedentary screen time are recommended.",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * NHLBI: National Heart, Lung, and Blood Institute.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Daniels SR, Benuck I, Christakis DA, et al. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: Full report, 2011. National Heart Lung and Blood Institute. Available at:",
"     <a href=\"file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf\" target=\"_blank\">",
"      file://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33371=[""].join("\n");
var outline_f32_37_33371=null;
var title_f32_37_33372="Randomized trials of novel agents in advanced NETs";
var content_f32_37_33372=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F68953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F68953&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Randomized trials of novel agents in advanced neuroendocrine tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of patients",
"       </td>",
"       <td class=\"subtitle1\">",
"        Tumor response rate",
"        <br/>",
"        (percent)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Median TTP or PFS",
"        <br/>",
"        (months)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Reference",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Carcinoid tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Everolimus + Octreotide LAR",
"       </td>",
"       <td>",
"        216",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        16.4",
"       </td>",
"       <td rowspan=\"3\">",
"        Pavel et al, 2011",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"4\">",
"        versus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Placebo + Octreotide LAR",
"       </td>",
"       <td>",
"        213",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        11.3",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Octreotide + Bevacizumab",
"       </td>",
"       <td colspan=\"4\" rowspan=\"3\">",
"        SWOG S0518/North American Intergroup, ongoing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        versus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Octreotide + Placebo",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Pancreatic neuroendocrine tumor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sunitinib",
"       </td>",
"       <td>",
"        86",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        11.4",
"       </td>",
"       <td rowspan=\"3\">",
"        Raymond et al, 2011",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"4\">",
"        versus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Placebo",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        5.5",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Everolimus",
"       </td>",
"       <td>",
"        207",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td rowspan=\"3\">",
"        Yao et al, 2011 (RADIANT-3)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"4\">",
"        versus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Placebo",
"       </td>",
"       <td>",
"        203",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4.6",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"indent1\">",
"        Everolimus",
"       </td>",
"       <td colspan=\"4\" rowspan=\"3\">",
"        CALGB 80701, ongoing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        versus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Everolimus + Bevacizumab",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     NR: not reported; PFS: progression-free survival; TTP: time to progression.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33372=[""].join("\n");
var outline_f32_37_33372=null;
var title_f32_37_33373="Obesity family hx and NIDDM";
var content_f32_37_33373=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F70645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F70645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Obesity decreases insulin sensitivity in susceptible subjects",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 430px; height: 216px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Responsiveness to insulin (as assessed from the intravenous glucose tolerance test) according to body weight in nondiabetic subjects with no family history of type 2 diabetes mellitus in first-degree relatives and in those with two parents with type 2 diabetes. Both groups had similar insulin responsiveness at near normal ideal body weight, but the degree of insulin resistance (decrease in insulin sensitivity) as body weight increased was more pronounced in the offspring of parents with type 2 diabetes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes.&nbsp;Diabetes 1994; 43:1066.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33373=[""].join("\n");
var outline_f32_37_33373=null;
var title_f32_37_33374="Symptoms in ZES";
var content_f32_37_33374=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F82168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F82168&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 515px\">",
"   <div class=\"ttl\">",
"    Presenting symptoms and signs in patients with Zollinger-Ellison syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 495px; height: 593px; background-image: url(data:image/gif;base64,R0lGODlh7wFRAsQAAP///wAz/4CAgAAZf0BAQMDAwAAAAPDw8DAwMKCgoODg4NDQ0FBQUGBgYCAgIHBwcLCwsJCQkBAQEAAMPwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADvAVECAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4hCChECCQcABA8ACQQLKJEumCQLDAQJiaChojUJBqYGBACoAAUCCiiNLqskDhICBS0CBrijvb6DCgYSuAsCqqmtCgoCEA8ExgCxk50PBwWdBBEisyKlDsYHAgQMECLOBA0LCgQGDQnLuPDRCcUA4ePlv/r7ZxEGkiRW6SpQwBQBCQY+CTTAQICDVg3EJTxG4oGwVAhsITBg6dsDCQ4WODCA4EFBYydV/yE0ACCjgI2W+Mmc2UUXtBELCRowBmEnRZAiDgiNwGCjMW7bUi1AJaCBzwLOEEbbxeqpT5Iilj5zepOm169SSqUS8SpnypSrkGaM4O/oWJzImAq41ZPcxqm4zl4dW/DZXF47CIIdTNjFyGedKA7U6xYAAwMRrhV8aLFxwLESJCQoECGBTQgjp95aaoudZQCZN3fuMbew69clFDw24ECbWauNDzRA6EBBKVR7S8ziZMoBhAMbHYRWMJIBAIsOuFLMOts4666ws2tP1Hq79++DuoMfTz6P+PLo0785r769+zLs38ufvyU+/fv4o9jPz7//kf3+BXhEK3MVaOCBCCao4P+CDDbo4IMQRihhgbwAKOCFQhA44YYcdujhhx1WiB2GJJZIg4UmpqiiCSiu6GKKLb4o44UxzmgjfzXeqON8Oe7oo3o9/ijkeEEOaaR24oCo5JJMNunkk1A+CNiR5k0wwJVYZqnlllx26eWXYIYp5phklmnmmWimOeYEI1JZhwADBCDnnHTWaeedeOap55589unnn4AGKuighPo5QJtuzgFnoYw26uijkEYqqaSHJmpenJNmqummnHbaaaWW2gPYAgCZ8EBML0ypwlsuKBPDop7GKuustM4KqqX+8FIAqyQQoCoLvKbAEgwJfAIDrLUmq+yyzPJ5a6LfNCBCAQiIY+z/NQw8BIACDXjSDQQMMHCPNtFs61k25hBAQD7DjpAAuOKy0kkDjwj2brivqIBss/z266+nz1K5AAIHSDBtbweEpAACCiCHy0MHMPBJJAdEgEABCZfFCsS9AVBOxqqUgAlRAKgDQATStkYxyivs++/LMMcsaMBHPqANOayMNVcEAPm6AF/O+ZqzCEKztCvReUWFS7tIb2MPUQikonJewZbgssxYZ611ADQb6UDU0Q0dTYFIHz200GYXLbavECBgidq98sISAhFYI7UxaFdNwtVb9+03s10LOXBQBpvtNgRjXYzaIwJok3fTRo/lqwCSOBxy3B47Z8AjlIwNCdUtY/r3/+ik0xr4jzaPQE4BEhBQrTkINKB427E/8vjnIaeNcdRFLS1y1JVM4gA6d+Nudgp8l6788o+eHuoTQvOQPPPUV/+n8883Ef0O01vv/fd1Yp+9Gt2Db7714o+PRvnnt698+uqbIYCVatZv//3456///vqzGb8cSYqSAAdIwAIaEES/+t8aiqTABhKCgQ6M4B8gKMEK6oGCFszgmxClwQ76AYMeDCEbQCjCEp6BhCZMoRhQqMIW1oSDLoxhGlgowxpSgYY2zOETcKjDHiqBhz4MYhECeMAiGvGISPxQAoU4hfnx74lQjKIUp8g//zERC+xznxZlBr8r/lB0Wwxj37roRf8kZFGMaAQcDMvIhDOm8Y2mW6MNF0AQVLECBqfSgRvhyMdPybGG6GiK24gGg+3dYI99TOSkyNjC6ImEcdvqFgMs4ZtWRGMZ6yAKA/KFuElGchx2PAEiFUlKRzFShdtrgG22ZQmRsEICDTmGK1YmLXAdgDm3bKUDQlfKXsrqlCncXmuGlYBuRQ4nI3gcAyLiEFwUkx289KU0NwVME6ayHCx5QAM0drx2PS4bBMGYNjWmLzBO85zN+6MMo5cABDhtXds6ptOadjQBOMce6yhHMKKJzn42qpoldJ3r6OU0kURCnpcz3lgeEDWGGdQi/PSnRGemTjb+x5wTzaizKmrRIWL/VKMgvRNAO+qDUYYUnSMlqfToR8WWuvSlMIWiFVW6Q78k8aY4zelNl0hTM3K0p0DFARCDSlQW/bSoSH3BUJNa1KUyNahOfWpPoypVlVK1qh29KlbZqNWterGrXmUiWMMaxLGStYdmPWsO06rWGhJRp3A1IE/bGgonxvSueOXSTOn6C5OeVKRH5Ssg/PrX8AVWsEE4AKoW8AgaFOsHhC3snFKKWB4cz5C5gMZQIytZrh22sj64LC5084xuqAsa9IjMaZfRgG5ZQjDluqQr7rXJiHaWoqCNQgG+MRdtKe4BKHmExCDxjQK0FmP2VKzBujMspqyjGiwr520LRdnc4oBa/+G8mEjm0q1tieMbuPOceCcHjeYmE3TSne6gqmtdG4gWu3VkTjmmJoLudIe88/QmepH3UfVutL1OEG3BYkJHdwIgIuGlXH3BYTCexXOeCrWtf/vEXgDPQLQla6gxZDcOvPFiYZVwiOs+NjyIJvR2/J1woCpsYTdwVrIsbvEI+6tiPMVYxuSjcY3tdGMcr0/HO6ZTj30sPyAHWU5DJjIZ7JrXJuN1r0qeoE3jSmUBzjXKeGArlhWo5S3Hr8teHh+Yw/y8MZPZUmY+s5vSrOYjsbnNQ3oznH8k5znvqM52vhGe8zyjPfP5RX7+84oCLWgYTbnKBLxyofnBZCfDFMqL/v/Ki0uX5EjvYdKkq7SlL5VITW8aCdZoLGPNaOT2efrTRmCdtMJrBEyP7tSoJsKuCPAKoVGitLEVDCdw3UlKSjKULCr1+WAd6wz5SlpoE65CFowaxmrDlrhUgC4ljEZiFxsIR6O10JZBAPAOqzUOMIlwmamtZzJNlMI2n7WvHVpkdKsA8vXct8FBFAkcAJwEOcA4EwqLdINv3ey2rOQeQi0RINjeB0aJCC5mz6Dk88Hp5SPAA64DsxUEFxyOZQSGF8uilAR2rpN2ic8d7E5/luJ9cPXfJo7yIpu85X319/dYDvMxqNxvNK95GBrtaJdCWueHeCuiB6hooA/25EY3EqH/k46epTOdPE5/OniiLnXvUL3qSEI61vWs9a33ueteBzTYwz7osZMdRmY/e4murnawsL3tXnk73Gci9KFLqOhz/yBLe16/n+c9PDLPWs7/Xp/AY23whA+KHfGu+BKM2gY3XxbiE784EYALBqQSbx4hb3gupp3yM3CHwT9BiW3WF3HVeLe5IPEM37yCGegIijgeYKwUz/zzoI/B5ReXAHHtdhufwJcrj3bcey8t+J8A7iT0NoLIK2vylLf35RnAi+DN22n1hAbcWoPw4/X737jPPQzcIfrobb+8Q7uv7+Q9LebXt/Mxg37i24ZwBydsnsxNf8/W35rZuT8a8Acz8pd4/2FjD7KDAOzCbLmTCiD2M/xnDAMTLv/nfMkygOL3A41VTNS2PBZ4gT2QAMNDAI1le97TgR64BBRYKyZ4gkmQgnHEghMUgC+zgjDYanvHd2nidzX4JodmdxHCeDvYBnIXhOERfkT4HUN4hEenhC6ShEyYckb4hLDhhFJ4QVFYhYVBhVh4B1q4hRvkhRjShWAIQFc4hjQhhma4Hj2oU0CYhgB0g46mg26YZTJIKWU4h1zggit2h3ioBXoIKDRIeIrVePYAbINoAo+1AomYA394PXwohQcwLBFgMCdTKiOQeUYlHJmoR3UYKYFIeIPUCZaAM722evdAe9GgTWizE7XnOf/c4i0eoy7lsGtr1IiG8ohS2DgtkQDaIH3igktHo3ydIw4iF08FYEfghjES80i+0WwVs4GSh4tPeA0LsE2TlArL1FsEkQrdVzyXQ3Jz8TPTskkSEBkiEG4YA43PJ41PWI6fgACeAQmRkW9HMyzZl19GZXEM+BKpUDEMgHAk6C+fSHjZ8gqygwsNh09H43/i1VwjyGwI1ziuEol31BJzZYsUxo5MuHHd0C4MFXJHE4GJkX/R8HHNxxMIUDsgBo+OkZKWiG4CqJF9GBTdsGpfFJMzyQQgqC4PSWo4mZOX1omQMpBACVlCmU5FeUFw6GRymJRqOHRt6JQnJJNSuYRVmR7/aHiVYJCVWukFXNmVeUiVYGmFY0kkYlmWXHiWaPmFa7kdX9mWVfCWcNlEajmXcCCXdgkFeJmXTlB3PsggUcmXRMBzOEgmTSmYN1k9RImWGJkpi0l2ChBO7tKKLJBHj1cDjblIdSl+SfIADsA4HCU0m4eZR7mOgql+nkNa0KCa45gtzvR6iLNqp0iZJaeYm5l7TVEAneM5v2UMvbkwDaM4RYN8z2EMuxmQHHiboBdACDg229UUlcBb3eJguHN+led9MGmbpwkNiDM28HWM31kM2ocL1mmPE1iaFaiclNcdLDMXA5YV71ky3WmRuHN9DBlxzPOYYSdiCBAvrTEwrgOB/xr2HLEjnA+YYRKojjinnlKZgTb5fdqJmEOwkyKooGPEoHyZmXYooU2EniqIoXmpoZ4IonZJmIUpJofJoa22hn+pIIGpoiVFojDqlTI6o2Fpo3RXoziaBXu5o0LQoz4KBEAapDFKpH2lo0ZKl0naC0O6pIyIpE66Q1AapU3QpFSKmSxKZS96pdyzlDiYolwaBCKakWFapR46lFPKoWP6X31IR/CGAltqDna0iC1gmT0pA2u6J/r5aYHEkibwf5d4CVPSI6IJbK9ypkjZh0JDkeeQD8bgG+JALn96Cfbkn+DQLauJqa1ZbrAZe/Ywe7RpNYhqSmnKp/FgMCTGTRyTL/8iQ6kn4xz9hwvK95sMYznD6RjJZ5znqTV7ummB5ACfABUH4Tu6QwIEwluUGT0sEY7SGZ3clQ37V58QWS+7Knil6quR8Qht8zbEKjlTEpnwFUrK6p0XU0fhiZrl2X4WqkYzKUyVozjyhFmEdAJCc3nuKQEEFp8LMJ8GejmxGovrGo3tChjIMQ7wujYJpDcCFTz/OaAA+joMdZDS6jkiWa2Hd60NWpMBa5plugMUeqeiyqsYm6Gj+k8jG6Ilyyi9eppeyndg2rGskaVxFacweyInW7NFirOBYKU62zI327N69LNAK1RCO7SQV7RGa7NJywc8u7R7g7ROeyxQG7Uu0LT/VGu1UYu1Tqu1S+uXLfq1OUWzW2eiJ1q2ZjsALzt3eRpkK0tka7tjbbsj1pBvI+AqLoCJSmC3SpWyR6YncasjuzUXJkmnK4CdMtAwM0C4LPC2Nfa3N3I8CGYvp9UNCzCPurkZz4AuBohrjQoLCURb9TIv9eJM8MKqENq3HCtVx6MAyxVcuEpctyAAEkB7u4UxHdObHmMPHcMiCSsJJGMy7Yk30PWg2Ym66YlV3resj/pdHqaAuvOc3SWsw0ACyyAOzCQycvM0RVE8KHa6xvuCVbW67jQX8UZf4qU74bmtrCYqxjWP2Os0dGM3ntO9xfu9tjK1K2I2yDFft2BgCBY9/92hO/qqYJbDu/SKC5e3Ocs3v/vlvfYbK45rI6yjLs3pORnXvOfrrRkWoAXbO6KUsMBjCTvZXfRluCH7wPcLdPJ6SHyLwkiGv2W0wpznwr8Ew5XFuCoWwRaGwxOmwwDGw/7lw+1FtmdbxD2XtnDntWC7xEcktljHtUkLxUYrxUNLxUBrxT2LxTqrxTjLxTXrxTALxh0rxmVKxmFqxlyqxEy8xmzcxgXkxGvWskY8x3Rcx4WJxF/WwjRsv0I8hXq8x8bbx68BxIBcWH08tzQLxzugtyeAeojYioqLn4U8ySo7tYHLUCCbCTQgwy8gr5FMFp95p+fRI4RMySDVx2YDXP+V9KjdYiygG6n1ZS6wXDKd4KixuS3RgR2lBw2dGw2gxBwIllqSSVrV0HzFdQ8CAJqfVFq0uLGm/MyGxQZmo0qsE0sQM1wrczEgYzSrCpzGpwrIhxzmOALQNiyp+rvHQTfkWVz99wkQgCrtBG8I1hS8iXHGgK/PKMnQvM96asnRQjBmI47yEmHSqjsR4BeldX2YhTOXI726CY8xYX4iMjgmYDaUiBrOaWDgJm7OzM/PjMrapa5ik23opTa6k5sEQU7me15Oo75o45kYDMC3UDVm0y7Kazat4Y8A6cAe3dPRvAbedzwR6Tgl3a1l85lZ4a94kw8joHwUScDapa2pAE//CZbMEvAKtzQCZoMz1zA2BfMIyscLioOcPl3WniXNrHI8tENQt2PSGtxOI6bUHhM1JHBvB2UPvHMxbeM6lrDXVT3X6sKqAa0uDGuc/dlxLtnRZr3HgmwFjcUcK/THi/1XjV0FBjVIOyfZkx1SlU0YpbzZpNTZg/HZoP1yJkTEdpzaqr3aU4TH6qPGbhzbsj3bG6LIbmbDVIs8uJ3borTbvG01vv3bJyncdIDGV2rcVIrcUarcTsrcS+rcSQrdRirdRErdQWrdPgrbFELcSybHWOLa3K2XpSbaWTzewf1pbgpbMQCoMfDJKnCZYmredhlIDERyhwRD9j2aLM098j2X/4bUzMtnepAKiwZwy8uHa694C/WFDqHL4OIVFN1CLyfxCa4wW6+waxEAzLPVDa9AEI9VivoMWPPNTPfsbNNgDbu0W4wVEuD8uuk4XIqDYMrXncCbMl3BAM+mDrtgCc7lK8zhbOK8jU0ju7QHbUhN1iLu35YLAOgoXNVHRzpzFMzGbd9A0dxXICzhj3R9Hg1ADvli0+dFnfSkwd2Rjc0U4jx23r46JTr9zZ+D01I+NuU708y2C5IZv/dIAsU0vWCONOfR1gipfZabye9Hpv49JWLNGZWT4onD4wtWcAn31cUpj0mtwMPYFbygfAp8YgSxSyUDCbPoTpZjX/eU1Uie5v/zDTzYmNi6kZLlMMGvI9cXPAn9WVoRk5LOMcLeWF/Awzgfp18lOQ6A3ZIeLB4fyTBo/tNEasIq0Fii53JsuuzsTQIH+JI219/hvZXYnu1eue3cnofe/u1+6N1XAt7i/kMyayC2fe5iqua/jd07Cu84Ku82Su8zau8wiu8qqu9q6u68ze8SCvCIKfBYBq6G+hwHX7emewPTPpmb7LPJjRjE2zQq4N4yYN/6clgYP9zLDQ0IeBPJjDbhwgvCLBjE/JDYUiGYpOfowBLNOAmv8IrG8oq4Zr31AgGq9xyyCGGwkO613ZXdERKKU3A+3hvMUWvs7JvujCpHf/SyxKrljLD/TK6M72jPk96dxOhKubvNLUPuZWLuWJgksaeB5ccZmkXUC0bRJcAI9bVKJcDQ8XqMQGPl94zlDTktSsNv9UuqQN8AbyoC+EqJ+MXAj1419hXnmLOAZcMXvhLlqhBOgd7SgwQ3p04o5M1n7OEQ40nRwSPTBYPVrMr5jl4CTs0Sg2M5Qy3pyqe5lpB/UL1+lb9e/t5m7BEMjSU0LxHrMg3YtLY3KYl+JWDXuiACReHBa805hw0OHger6NfBB5vssg+XGjhYpXn5lra7Mbih7N5G1T/799792z8D8D0DKmf9Vanf5A/+4Q3g1qsOv2YullThrhcNBj6biu233s+C+KwN/9oEAsACKYvoAIXECIBBCApRuAnA2E+bEID/AwGCQaBoPCKTykEr6HxCo9IptWq9YrPaLbfr/YLD4jEZ63gUDgCJ+pdoEAypnk/um7l8ghZ7Ph0qBQoeMZUZHiImKi4yNjo+Ph5EMLDZ+Tw0KOQV0OXd0djteXL+EQ2eJhVCrrK2ur7Cxspi0QAgcNqIEEAAKMiR1v3ghbbcAkB0QgGiMhepzkJHS09TV8cyICA86BLsLjgQPPx2Wg7rtSwgMDAkPwlMDMTLz9PX2080Wevv8/f7/yNq8+YPjD0GDyJMqFBALYAOH0KMKFFaAnAE2kQRNXEjx44ePwLUCHIkyZImT/+KEYlyJcuWLkGqfClzJs2as2LazKlzJ88vOHsCDSoU6M+hRo8iPVk0KdOmTkPmeyp1KlVpS6tizarV0NWtXr+CrdI1LNmmCjT5qNVQEbJtXR6YsNLjQFw3uXzQpZL3ytiyfo2KtNMu2BgFDg5g3ILHipwF2zSqdExFMt+ofy8zDawHwAE4DQ4UMCDARoF1tWIIgJBLQYQgPDIJccDwh4IEAgi0FsGOl5C2dyYx0FS7QIvSDGrJqQ2gG2pMeJSXJvBZN4xeNhaws+zk9sLu3r8bXIt5PD/ue+zIYdAawgJfBdo7OBvfBYwFfQS49ZGAAWgUCW6hlYIDacSnAAIKHDD/DC/qLfeAJA2ksEIMBc43DgANNJDGbSWgQEp7AEQAoQQLSOLHiCVK8Y49K7LYYj34kBdjeRkWEFowDTBAAmERNCFAa5Y0YMN8Pxx3xwLA/ADMDBEUVJ0dpOBBCjA86vGjH5A1YaEk2PRwRhp+eJmYO6Y0U6Ygz8iYplX5oKdfAxKAco6clnwDAQNBLDYDkmnRMYMANBagyZM9RNkDMFhu0gOiidoSAWhzTcIGKVv2kRGZZmJKiHZqcvqKZptc0oIBaqRjpCd3DBhEBNsc0GE7StZ4mA8m2PFAa4X6IQICplqIn5yMjgoADyn4cIuUxYoXxDKZMhsAmp1C28qncgiA/0A3alT7WDZZAvGfE51lw8ueueLxHwEI8PICAtPhimS1CHBLioEELKCRhRVJ1wM22vixb37KXNqsmc9GW/BEQSJiCUTLCjzwpgZD/I9hiSj8EMMNN0NwxBtz7MXFGKOicccjk0zFxyAPInLJK1eVwF1VzFWXWAGjnPLDLOP8VF8/NPavyTTXHIjKORMdkXGnKRADbQkQRx1vqUmXFjvTxYRMjsJKh1ZyudzWgMzbAR10KjcXXbbEFAoKQ4AqsGAggsPYgIMImoQoRFQQIHBAbfv1FwwpmIjAG8Bih0y22YfrQ6UQVgYxZZOiyrmltXYDcbUPRS5Hq4liDk64zYiDDv/VnE4cCqigciLgKCkqLbZcLeaQUrGlnn8euu37lJr5qUnSUYCsIngiSrDDqvTnrKtyhgKjBOTytbJh0+6s4bdT7+m2hAGBpLnoBr8DOHBQ/gO4MIDLPaMLdLNLivC42L778sBYvfyXmQee/fcnO7/+W+28v/8l9+9/AtxYAAdowGgV8IAKTFMCF+hAzDTwgRIkSwQnaEH+Te+CGgxLBTfoQad08IMiPEoIR2hComTwhCpESglX6MKZtPCF8yMRXkywl0Xc5mVZ6MwMnKcFymQkhTJc4GI85LNciWE/nOlCA1pTgCNqYVzbKcj9qmjFK2Ixi1rcIhe76MXZ+K+IPVD/DnaqIwDZ0OA1wmFaatQiOM5wRw3MCZAQpGMCNVrnNq0xTANiQJoCuKw2OcROcPQgHTUc4Dbs+AP73ufIR0IykpKcJCUraclLxm9/0tkD+Ehxotb8J1B8812EWICMO7yxj0KAEIa+dAkIjWCUHRpQqxCUuhopSgIPYBotZfMgAOjgGD0I5rBSBL3oITOZylxm9IYWOtzUiElgQoMagIE5eiGJQkGQwA+4GZNK3eB1R+oTDXClEViZyCBy6IMUn8fMd8IznvJ02P/E6AdKPeoTn0BSiGwVBEtQyzIKyxMu9WnOJqAzdjWq0SgG4855QjSiEl2mM0Fnz2PZoka7AhGr/1wlPgf8jkjiulNMmHe8jpKrnDRYHULJ6QfczCqjwizFRGtq05sKrKKIu6i+suGWbiSgfOJKRgOOiL5umCAmR92FUFPquiu1VJ+T2ted0sEA8BkTp1rdKleRoNMRDokkJ+sqWcsKz69+cCAmGatZ2+pWwqF1iBxh61vraldmxVWuE6HrXfvq1zMJUa9fOAsWXJaSY/41sYrNq2BpQQfDVuawip0sZTXVWCskwE78MeR0CgABOCQVjQzloYOWph9NiIK0iIFDExKwgAjk7wd8rSxtzcrYIYYDRHcK5ilvQxduhjJpxbABe3inT1EggLjpoEEwCYDGrNY2une9rQwXs/9OdYZPT3TYQ+4a51LubvQEnCRUbIEwW+mi16bUfaF1XbBQGmhEu+doJzr3gKQCGOs9T6VpevtL1vW6EA92Wk5uktqCA3ATv+dAsCb09oNSHcAYe2AwZ+wTFxO0LiONvCSHO+zhD4M4xJLM5GWlcC6kcoaqsTkXb4AqCrx1g47YwAZ8WwBjApTAWvDab4qo+MUfAznIQh4yke1X3hIL48gxJMOSkSzYDG8nsI5ospOr3A8qWznL1cCylrsMDS57OcyekrKYy7xlMps5zV9Gs5rbPGY3w/nKbI4znRkB5jrjmQt3zjOfI9vnP0trzoAe9Bb2TGiv0LDCirazSaEAWSf/OFQKN5xCpGXrY+8c+dCXsScQjTsGJXJOtg+T3RQ6LQVSm3fDLCKxpmVkTzJmJzazweNw2piWNyaSfMtRW5Kmhi0M0Us/0nmSafTQFh7SADqfXcwDusEbVMsWsc4QdKupssk/GaoHnxQWgGRZSqihEgiqNF4rMfKhugmAP/Y5Bn980Qu01eAGwfnGlXBM72Mk73TQPQWAqz0VaBZAmqQIU66uOc4faBMI3PSBNy0jOUU1YQaWk4PifNQ9v0GcME8kAJx2NyZm9NvfT+EpZyKVz/3K1wf9zA3PWh6T1OUzvpxATviE96tecQtvGI7TvmsncvKQvBbG2ijyWoXEVoX0/3IjDR/P1EC8A3MzmAdozEaDTQyMh49arDIGtPUgben9PEYk99cdmNfUPRXVCUs1sGu+pyhwcC9BMAjF9S7OKHtxxlo09jjYQE7tsEcrrCU5b8gBzym1KuXrhTd8mwn/d8Y3XvGPh7z+ysgFwnpM8pRXoQMSbQWNPFrPmt/8AD0LWh9YzQQ1clloRpNrAVQTkEzz9a5jwFAFwCEXmV0HHT9eONIP0LfrtpPeDiMAXSbAPQsYN4SOv8tzszJDiWwBLeUWjl/2HLDAF6DMr7qHAX1q4WsI38NrLgD0Se2p7TTv6Le/P5kDXENswl5Ai6W6jNsNGFBaaaX1oOoVsZr7Vf9PannTnXCGcLXcDSydvTidoriFKNzHrfAfQeCPAL4f3PHGA+gYAhLG2oUPvoDPvNSLjWUDu0xgikyeBZqNoTFZCqpg0bDgGMTgC2rZDNKgldngDTpZDupgifFgDzbWDwKhXgnhEA5R/RRZEirhEjJhEzrhE2ZRpjkQEnoRcwSZFf4YFmbhpVUhF3aRFn4RGH6hF47hFbpg6DQZlaXhGaohG7phC3KFCxYhx6xhGdQhHOKhDL6hHsZhHnrQHfJhIApiSuzhIIIBlgHiH8phIYZBG9ohIzbiIvahIWpQIkaiH14iJh4iJPrEGTJdJn6QJW6iJnbiI5oiKXYBIkqiCIn/YilSoiu+osdwoixOIiGOUCvSYiym4izmoi4Wmifi4gQFo56toi/+4ikaYxaoIioKYzHaYjIqIy/uIjKCIjT6WSg6YzWOIjMSIzVqIyxa4+d5IuIM4zGGozh64zaeo8kAYzZqEEONATzGoxTSAj3WYxnIoxjkYxjs4xf0Ixj8YxcEpBESZEEa5EEiZEIqpEccgG0E1TSwho+0QUO6XjQcCVpQ5ENGA0U2QUaGGitQpKPghUN+5CPo10hWJOr5SO8ZEAK8gAGEFzTEgQHAZLG8ZEzCgn2Ihk3GAU7mpAS8gPK4ZE/KQoS9ZB8MZU26Qr28wA8k5UaJAwJIgASw5P9A/4AB3AkDGMAbyQIEIIYDGIBnYeUNbOUsuOROXmVWluUsgGVdpCVZciUrhMauxIFYqmVcOsJM0sFbaqVXGgA3RYABQJH/CMBOFuY4ggFYJo1h7mQsOB9jtsBhzsICGABIjaVkSiYsGCUCOEDzQeYrhMZ2QWZopkBTKhBmNqY0BOZjfGZObiVqRmZqwsJc4pcB2EZrvkJnSABY5g1sgqZpwiZpkqYCrSYwGQDLQYM4QAiICKZxIqe00GR0+khzisNzLmVTHmZxVmcsBGYLaOV0bsN2usJwaudxUuauvKUC+cKAKKY0aKVsMMR6+o4BVCUkKECNNIABZIJ8tidbbqVLBv9KZc5nfT5CAsBkbSafgPYnK7zWgeqNgtInAIClndimA1VEZeqQLEQnTXoPhkZDZl6oA2ToK6TDX+oeWIroLDwAUMqGfqDoiOblhqbRi86KS+rSQuJojurojvJoj/rojwJpkArpkBJpkRrpke7Ee7kSkmbZhoYlULQekzYFTS4URbKGJvAATOmGesRA0iTbbOTa1RDHsvGGAjRbjkCA0thGqNkGJ0wH1sCUl6pGL5wpL+CeHQlLaqyDCeRndUgpUnCoKMQBUD6RYGplBCjAVN5GWEZplEpltRgAU0rATCKIoubeca6B8kCaforDbhnqcYYGUF6EpeKYBMDLVC5HZbr/JAqsav/9qU44aaq2wW6eB25UaGHWyE62HmXCQH6eB3OFZWCuBoKhC6Y+QRzYZKbWami4hbD6AGvo56Jygh24ZGki5qtyBE0CAbLWAXyOBq4KAaPqqmiEZniAK66C6w/kp0t+JLcia2UaBNM0ZrqGax/tgQwIxi/IJrYGhbYKgyV8JyAxBFZO63v85aLygQQwTQTcJnyF5XkC0p2Exlgy51rUZWCqJUO0aWNC7H6cJwQ8Efrka2laDr/260BZgm4erHGCw5OKQ2fuJHbQpAOk6ZOCK95wqA9M6OVo6h1U5gsg0pscbJSi3lmSIE0eiLvmq/iZrFfQaxhMnaYqLJ50MV3T4szTgkF3PqsBbmvVWu3Xgm3Yiu3Ykm3Zmu3Zom3aqu3asm3buu3bwm3cym2OhgAAOw==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The presence or absence of clinical symptoms or signs at the initial assessment in 261 patients with Zollinger-Ellison syndrome (ZES). Prominent gastric body folds, esophageal stricture, and pyloric or duodenal scarring were determined by upper gastrointestinal endoscopy; a confirmed peptic ulcer was assessed by upper gastrointestinal endoscopy or x-ray studies.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Roy PK, Venzon DJ, Shojamenesh H, et al, Medicine (Baltimore) 2000; 79:379.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33374=[""].join("\n");
var outline_f32_37_33374=null;
var title_f32_37_33375="Retracted end colostomy";
var content_f32_37_33375=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F81992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F81992&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Retracted end sigmoid colostomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 399px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A flush or retracted stoma is undesirable because it may require more specialized equipment or additional accessories to aid in the appliance fit and therefore facilitate drainage.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jeffrey B Matthews, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f32_37_33375=[""].join("\n");
var outline_f32_37_33375=null;
